{"meta":{"query_hash":"fdc8860e50c3","filters":{"venue":"Investigational New Drugs"},"cohort_total":191,"direct_labels_cover":1,"predictions_cover":191,"exported":191,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/fdc8860e50c3","api":"https://metacan.xera.ac/api/v1/cohort?venue=Investigational+New+Drugs"},"results":[{"id":"W137248159","doi":"10.1023/a:1026211620793","title":"A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University; Baker Hughes (Canada); Ottawa Regional Cancer Foundation; Hôpital Notre-Dame","funders":"McGill University","keywords":"Oligodendroglioma; Topotecan; Medicine; Oncology; Cancer research; Internal medicine; Chemotherapy; Glioma; Astrocytoma","score_opus":0.016566857196750384,"score_gpt":0.2629395205782845,"score_spread":0.24637266338153413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W137248159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985579,0.000025013474,0.000012535941,0.00015982028,0.000082890285,0.0009225003,0.000026935617,0.000027897087,0.00018445525],"genre_scores_gemma":[0.99796957,8.6371875e-7,0.0016235542,0.00010691457,0.000033190187,0.000077967976,0.000070298294,0.000027628377,0.000089989444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981147,0.00007291362,0.00048486088,0.00037136296,0.00067166344,0.00028446558],"domain_scores_gemma":[0.99885654,0.00018060804,0.00017553021,0.0002597436,0.0001608999,0.0003666927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008256003,0.00025294774,0.00043592977,0.0004134905,0.00008368619,0.000013892074,0.00008209919,0.000059783662,0.0001381639],"category_scores_gemma":[0.00027874263,0.00018753938,0.000047314574,0.00084382296,0.00010012474,0.00010825156,0.000029038407,0.000120679026,0.000011869989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009011907,0.04961398,0.92459434,0.00012900597,0.00077186537,0.0006957413,0.00474946,0.0014704879,0.00053277845,0.0025637394,0.0016940403,0.0041726492],"study_design_scores_gemma":[0.12833092,0.0790495,0.7766968,0.00053847843,0.0004896775,0.000080961196,0.0011814695,0.00035361596,0.012018158,0.00052056747,0.00028707905,0.00045279108],"about_ca_topic_score_codex":0.00016915014,"about_ca_topic_score_gemma":0.00074263086,"teacher_disagreement_score":0.14789756,"about_ca_system_score_codex":0.00013812319,"about_ca_system_score_gemma":0.00054033793,"threshold_uncertainty_score":0.7647634},"labels":[],"label_agreement":null},{"id":"W1419213143","doi":"10.1007/s10637-015-0275-x","title":"Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Cancer research; Clonogenic assay; Chloroquine; Cell growth; Cell cycle; Medicine; U87; Biology; Cell culture; Pathology; Glioma; Cancer; Internal medicine","score_opus":0.028273027919605703,"score_gpt":0.26436842016810513,"score_spread":0.23609539224849943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1419213143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97141993,0.0011757703,0.000029150297,0.025396906,0.00014357523,0.0003037655,0.000034486784,0.000037918082,0.0014584955],"genre_scores_gemma":[0.99669546,0.000008280601,0.0009301806,0.0014753939,0.00025513239,0.000024593883,0.0001003802,0.000022157988,0.0004884004],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852735,0.00004691958,0.00035689672,0.00022750998,0.0006304469,0.00021086857],"domain_scores_gemma":[0.99883395,0.00012856601,0.00016378587,0.00026586687,0.00021492664,0.00039289694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021442796,0.00016684695,0.0002483859,0.000059589645,0.000066126646,0.000028335258,0.000112088055,0.00006342815,0.00010263621],"category_scores_gemma":[0.00015337484,0.0001083693,0.00007915409,0.00024658573,0.00022134103,0.00010909739,0.000057135574,0.00009689882,0.00007674971],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074854033,0.0013017583,0.049808327,0.000121499994,0.000602892,0.00009583,0.006503267,0.00093072787,0.24469185,0.028489001,0.65729666,0.009409672],"study_design_scores_gemma":[0.004764282,0.00058415637,0.0123631675,0.00036627328,0.00026403138,0.0000757379,0.00023976192,0.0006450774,0.9417252,0.007543635,0.031204809,0.000223893],"about_ca_topic_score_codex":0.0002024778,"about_ca_topic_score_gemma":0.000024131516,"teacher_disagreement_score":0.69703335,"about_ca_system_score_codex":0.00006142372,"about_ca_system_score_gemma":0.00057268125,"threshold_uncertainty_score":0.44191718},"labels":[],"label_agreement":null},{"id":"W1539780911","doi":"10.1007/s10637-006-9022-7","title":"A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Adverse effect; Rash; Internal medicine; Multiple myeloma; Nausea; Vomiting; Clinical endpoint; Anemia; Gastroenterology; Phases of clinical research; Diarrhea; Pharmacokinetics; Pharmacology; Clinical trial; Oncology","score_opus":0.01286201718875107,"score_gpt":0.26738986107407725,"score_spread":0.2545278438853262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1539780911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977262,0.00009997521,0.0000071146637,0.0002399181,0.000023685167,0.0016318667,0.0000849953,0.000022004471,0.000164266],"genre_scores_gemma":[0.99737775,0.0000018354598,0.0018642619,0.00004889603,0.00006511096,0.00007274972,0.0002973583,0.00002983476,0.0002422132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978259,0.000098496996,0.00053169415,0.00039693483,0.0008563783,0.0002905873],"domain_scores_gemma":[0.99863774,0.00020991873,0.00025262352,0.00022744614,0.00038351744,0.0002887688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014853297,0.00024196816,0.0004628978,0.00038554682,0.00009187735,0.000010586527,0.0000745528,0.000082736995,0.000021766742],"category_scores_gemma":[0.00034921677,0.00019819879,0.000042032534,0.0006943088,0.00025492985,0.00019479197,0.00006794954,0.00022655587,0.0000031299096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005150647,0.012776423,0.9682695,0.000098073775,0.00018219372,0.00003989549,0.0025249247,0.00005629569,0.007539871,0.000081345555,0.00047473767,0.0028060896],"study_design_scores_gemma":[0.07189522,0.008838983,0.899248,0.0002726273,0.000080963335,0.00000444276,0.00026079416,0.00044934422,0.018398575,0.00036318076,0.00003055421,0.00015730136],"about_ca_topic_score_codex":0.0031326946,"about_ca_topic_score_gemma":0.00044081768,"teacher_disagreement_score":0.069021486,"about_ca_system_score_codex":0.00017202704,"about_ca_system_score_gemma":0.00055990816,"threshold_uncertainty_score":0.8082312},"labels":[],"label_agreement":null},{"id":"W1902804987","doi":"10.1007/s10637-015-0282-y","title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Adverse effect; Pharmacokinetics; Nausea; Vomiting; Dosing; Tyrosine-kinase inhibitor; Gastroenterology; Pharmacology; Internal medicine; Cancer","score_opus":0.035171827927367574,"score_gpt":0.31735924606254523,"score_spread":0.28218741813517767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1902804987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979054,0.000031261232,0.000021098087,0.00044708833,0.00006284426,0.001294834,0.000012175993,0.000025754221,0.0001995978],"genre_scores_gemma":[0.99700546,7.02232e-7,0.0017289683,0.00032694146,0.00013482122,0.000056634977,0.00028765487,0.000032552853,0.00042625426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730897,0.00013920116,0.0005538125,0.00039704007,0.0013536821,0.00024728247],"domain_scores_gemma":[0.9983844,0.000063950065,0.00017018523,0.00028611126,0.0005205198,0.00057478895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000292536,0.00019508631,0.00035384332,0.00035587893,0.00004224343,0.000017877834,0.00010699785,0.00007008254,0.00008702034],"category_scores_gemma":[0.000412082,0.00016690916,0.0000380257,0.00057780126,0.000117182964,0.0002164561,0.00007078644,0.0002550691,0.000028416574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019475676,0.035064008,0.5159275,0.00036402378,0.0002052739,0.00039822806,0.022490142,0.0042189206,0.34969544,0.00039809104,0.024488214,0.0272745],"study_design_scores_gemma":[0.21630354,0.05690389,0.39585504,0.0010272719,0.0001363477,0.00002539757,0.0036030556,0.010204204,0.3119786,0.0012639115,0.0016472895,0.001051437],"about_ca_topic_score_codex":0.00013964679,"about_ca_topic_score_gemma":0.0001496586,"teacher_disagreement_score":0.19682787,"about_ca_system_score_codex":0.00021759637,"about_ca_system_score_gemma":0.0013809365,"threshold_uncertainty_score":0.6806358},"labels":[],"label_agreement":null},{"id":"W1939928011","doi":"10.1023/a:1016253716438","title":"Preclinical Antitumor Activity and Pharmacokinetics of Methyl-2-Benzimidazolecarbamate (FB642)","year":2002,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Care Ontario; Procter and Gamble; Eli Lilly and Company","keywords":"Pharmacokinetics; In vivo; Pharmacology; Medicine; Melanoma; Toxicity; In vitro; Cancer; IC50; Apoptosis; Cancer research; Chemistry; Internal medicine; Biology","score_opus":0.03213157658821065,"score_gpt":0.2863443809432163,"score_spread":0.25421280435500565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1939928011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538493,0.00070539914,0.00023800391,0.0018048409,0.000116236,0.00013883202,0.000022954551,0.000013234457,0.0015755887],"genre_scores_gemma":[0.9947507,0.00024345385,0.00297411,0.0005945219,0.0002662117,0.00000655023,0.00003512934,0.0000126273235,0.0011167366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991654,0.000061769824,0.00022445116,0.00023981486,0.0001868975,0.0001216764],"domain_scores_gemma":[0.9994552,0.00003209455,0.0001263471,0.00015510713,0.00006925441,0.00016195832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013266991,0.00011521042,0.00012172663,0.000039383427,0.000042375257,0.00001517729,0.00010529829,0.00008863282,0.00010675667],"category_scores_gemma":[0.00018647374,0.00011467364,0.000052577474,0.00008524492,0.00020566351,0.000010448555,0.000074529045,0.000089655754,0.00001083465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022741136,0.000054350956,0.001638807,0.000020832389,0.000034159697,5.765765e-7,0.00006314613,0.00004185098,0.9772899,0.00069402147,0.013554163,0.006585461],"study_design_scores_gemma":[0.0006821031,0.000080437334,0.004927444,0.00001639986,0.000017469947,0.0000068416807,0.0000065796667,0.0013121024,0.9714518,0.0007485908,0.020606391,0.00014379613],"about_ca_topic_score_codex":0.000021344109,"about_ca_topic_score_gemma":0.0000022536208,"teacher_disagreement_score":0.007052227,"about_ca_system_score_codex":0.0000053286803,"about_ca_system_score_gemma":0.000060573522,"threshold_uncertainty_score":0.46762553},"labels":[],"label_agreement":null},{"id":"W1964185052","doi":"10.1007/s10637-010-9399-1","title":"A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Population; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Doxorubicin; Chemotherapy; Adenocarcinoma; Surgery; Esophagus; Progressive disease; Oncology; Cancer; Clinical trial","score_opus":0.007041558149605497,"score_gpt":0.25788050142822094,"score_spread":0.25083894327861544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964185052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99696624,0.0010865919,0.0000022847823,0.00034813257,0.000051212766,0.0015032211,0.000010859485,0.0000071653344,0.000024275174],"genre_scores_gemma":[0.9986595,0.000002365068,0.0011009569,0.000057626698,0.000041219482,0.000051381317,0.000026107331,0.000015852345,0.000045007895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983971,0.00006729565,0.0003926016,0.00027040223,0.0006577692,0.00021479258],"domain_scores_gemma":[0.9992583,0.00006305828,0.00018286872,0.00021548285,0.00011795332,0.00016238024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021413839,0.00014824657,0.00027394472,0.00021169231,0.0000392554,0.000006897221,0.00009643167,0.000044638153,0.000026344836],"category_scores_gemma":[0.00015985261,0.00010160732,0.000029095489,0.0004667338,0.00018908472,0.0001220488,0.000055264416,0.00036436718,7.875475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001289699,0.001630354,0.99212164,0.000055961045,0.000029698362,0.000019531157,0.001319771,0.00009823494,0.0006088818,0.00013171465,0.000016896469,0.0026776355],"study_design_scores_gemma":[0.027469827,0.0033867897,0.95813483,0.00012021298,0.000027087128,0.0000030495905,0.00025021491,0.00008891109,0.0101316655,0.00032716268,0.0000019455676,0.000058313544],"about_ca_topic_score_codex":0.0009519833,"about_ca_topic_score_gemma":0.0005174655,"teacher_disagreement_score":0.0339868,"about_ca_system_score_codex":0.00009109238,"about_ca_system_score_gemma":0.0004503657,"threshold_uncertainty_score":0.4143426},"labels":[],"label_agreement":null},{"id":"W1966040155","doi":"10.1007/s10637-007-9044-9","title":"Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Hamilton Health Sciences; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Nausea; Adverse effect; Internal medicine; Neutropenia; Urology; Vomiting; Clinical trial; Gastroenterology; Oncology; Surgery; Toxicity","score_opus":0.05282090444412633,"score_gpt":0.3459315138132732,"score_spread":0.29311060936914685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966040155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979506,0.00008742953,0.00004323073,0.00012146501,0.00045256413,0.0009279153,0.0003216102,7.7650276e-7,0.00009440499],"genre_scores_gemma":[0.9989206,0.0000059063427,0.0003824404,0.00020525395,0.0002726134,0.000023288827,0.00011819759,0.00001021635,0.00006146987],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975419,0.00019484913,0.0012739059,0.00023684588,0.0006110919,0.00014142516],"domain_scores_gemma":[0.99823046,0.00027678013,0.00087888376,0.00017263982,0.0003306527,0.000110605804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017040042,0.00013422794,0.00041609065,0.00007003818,0.00004337076,0.0000036087997,0.00020639894,0.00006302748,0.000009933545],"category_scores_gemma":[0.0013541316,0.00010036905,0.000095405805,0.00024179665,0.00017365465,0.000007216369,0.00008359074,0.000108110864,4.689382e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22536269,0.045640312,0.56724995,0.0003871221,0.0021514304,0.000012923861,0.003873694,0.025823908,0.069653146,0.0033869739,0.044511773,0.011946067],"study_design_scores_gemma":[0.55630803,0.017573444,0.3311962,0.00013327913,0.00047268273,0.0000011491746,0.000330974,0.00011570564,0.08563818,0.0012020834,0.0064386483,0.00058966764],"about_ca_topic_score_codex":0.038116414,"about_ca_topic_score_gemma":0.11542359,"teacher_disagreement_score":0.3309453,"about_ca_system_score_codex":0.000077664874,"about_ca_system_score_gemma":0.0048166327,"threshold_uncertainty_score":0.96828884},"labels":[],"label_agreement":null},{"id":"W1967210005","doi":"10.1007/s10637-010-9396-4","title":"Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Cetuximab; Toxicity; Medicine; Internal medicine; Pharmacology; Cancer; Colorectal cancer","score_opus":0.015400231313834022,"score_gpt":0.291901193244463,"score_spread":0.276500961930629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967210005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961024,0.00006418509,0.00004404836,0.0014966503,0.000056504614,0.00041392894,0.000010318912,0.00002260589,0.0017893859],"genre_scores_gemma":[0.9962411,0.0000024408075,0.0029750643,0.00014540211,0.00011352809,0.000020833993,0.000018222498,0.0000094234765,0.00047400693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992668,0.000013658442,0.00018508162,0.00017402024,0.00027181502,0.00008862057],"domain_scores_gemma":[0.9994858,0.000111456175,0.00009876291,0.0000902309,0.00009982276,0.00011393827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080429985,0.00010658009,0.00020295537,0.00006136064,0.0000858681,0.000012262216,0.000023827477,0.000030609623,0.000042509182],"category_scores_gemma":[0.000097376695,0.00007766428,0.000022092403,0.00014757324,0.00015091212,0.00008327111,0.000022854985,0.00012184403,0.0000018822573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011034117,0.0018995685,0.9060064,0.00007181346,0.0004632487,0.000025392828,0.017257055,0.00003588854,0.019090772,0.0023298224,0.000886418,0.0508302],"study_design_scores_gemma":[0.019852253,0.004773857,0.9571612,0.00016313572,0.00042555042,0.000074076095,0.004162418,0.0017114255,0.008401827,0.0024649377,0.0005657998,0.00024353915],"about_ca_topic_score_codex":0.00028405018,"about_ca_topic_score_gemma":0.00021972125,"teacher_disagreement_score":0.05115477,"about_ca_system_score_codex":0.000021076174,"about_ca_system_score_gemma":0.00019280022,"threshold_uncertainty_score":0.31670573},"labels":[],"label_agreement":null},{"id":"W1968618374","doi":"10.1007/s10637-015-0230-x","title":"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Pharmaceuticals International; Takeda Oncology","keywords":"Ixazomib; Medicine; Rash; Pharmacodynamics; Multiple myeloma; Pharmacokinetics; Adverse effect; Internal medicine; Proteasome inhibitor; Pharmacology; Gastroenterology; Oncology; Carfilzomib","score_opus":0.07539078866375962,"score_gpt":0.36400187646837306,"score_spread":0.2886110878046134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968618374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634075,0.000077951954,0.00001794298,0.001150928,0.00006966718,0.0018682645,0.00002657443,0.00004716993,0.00040074362],"genre_scores_gemma":[0.9897766,0.0000018663908,0.008850298,0.00024516077,0.00012861095,0.00027374917,0.0002868918,0.000023775196,0.00041304366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974112,0.00013507158,0.00059374294,0.00042807686,0.0011064222,0.00032550996],"domain_scores_gemma":[0.99805677,0.00010940169,0.00018796588,0.0003226822,0.00037224576,0.0009509204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003904837,0.00023490808,0.0004410842,0.00033779355,0.000055950084,0.000023540164,0.0001609097,0.00009237502,0.000044552868],"category_scores_gemma":[0.0009327977,0.00020223764,0.000051145165,0.0005589144,0.00025173524,0.0004639695,0.00006846458,0.00019278158,0.000039027607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020479474,0.014187469,0.9074607,0.00020506176,0.0002061347,0.0003862795,0.013745108,0.0008258672,0.05223007,0.0029619718,0.0024432524,0.0033001595],"study_design_scores_gemma":[0.15922022,0.015568794,0.63144964,0.0010183188,0.00014082709,0.00022896737,0.0109708505,0.008607889,0.11045126,0.060792122,0.00060678885,0.0009443527],"about_ca_topic_score_codex":0.0005677428,"about_ca_topic_score_gemma":0.00009423977,"teacher_disagreement_score":0.27601105,"about_ca_system_score_codex":0.00019303625,"about_ca_system_score_gemma":0.0022484313,"threshold_uncertainty_score":0.8247012},"labels":[],"label_agreement":null},{"id":"W1972337517","doi":"10.1007/s10637-013-0033-x","title":"Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Spleen; Virology; Biology; Virus; Oncolytic virus; Reverse transcriptase; Cancer; Pharmacology; Virotherapy; Immunology; Medicine; RNA; Internal medicine","score_opus":0.03682878076399858,"score_gpt":0.297222366403331,"score_spread":0.2603935856393324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972337517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916685,0.00009804281,0.00022153073,0.0065316926,0.00007727761,0.0008890657,0.000018743409,0.000032165906,0.00046297963],"genre_scores_gemma":[0.9963772,0.000024633024,0.0020199993,0.0007418272,0.00016689954,0.000051207513,0.00042158863,0.000014091657,0.00018251104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795365,0.00024296614,0.0006612571,0.00032247033,0.0004484487,0.00037119206],"domain_scores_gemma":[0.9989977,0.000076807046,0.00016390777,0.00024812852,0.00023854536,0.00027495265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033841585,0.00015904414,0.0004094649,0.00012815658,0.000048738617,0.000018086119,0.00012222114,0.0001050141,0.00026027617],"category_scores_gemma":[0.0011539595,0.00014295739,0.00006306751,0.00042664836,0.00023362553,0.00025541816,0.00009111811,0.0002894341,0.00009284469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084904494,0.0048584207,0.53947216,0.00022253401,0.00020537182,0.0001697267,0.007668832,0.0003836111,0.35390416,0.0023122143,0.0656542,0.024299746],"study_design_scores_gemma":[0.00738234,0.0069395965,0.9374182,0.00061364495,0.000054481396,0.00015503677,0.0026154504,0.0013111429,0.012667723,0.028143797,0.0023839278,0.00031463924],"about_ca_topic_score_codex":0.0062792636,"about_ca_topic_score_gemma":0.00027205324,"teacher_disagreement_score":0.39794606,"about_ca_system_score_codex":0.00016829952,"about_ca_system_score_gemma":0.00026685445,"threshold_uncertainty_score":0.949241},"labels":[],"label_agreement":null},{"id":"W1974638172","doi":"10.1007/s10637-012-9865-z","title":"REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Baker Hughes (Canada); Oncolytics Biotech (Canada); Alberta Cancer Foundation","funders":"Oncolytics Biotech","keywords":"Medicine; Oncolytic virus; Tolerability; Gastroenterology; Toxicity; Internal medicine; Adverse effect; Clinical trial; Cancer; Progressive disease; Surgery; Disease","score_opus":0.017600910885360137,"score_gpt":0.3095962140356946,"score_spread":0.29199530315033445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974638172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924207,0.00011714122,0.000011743115,0.00007446622,0.000061067694,0.0003535235,0.00003251813,0.0000045207144,0.00010294565],"genre_scores_gemma":[0.9974694,0.000011500213,0.0016705455,0.000074439406,0.00015879406,0.000009734536,0.00048370255,0.000019293266,0.00010255528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986925,0.00008584756,0.0003718791,0.00020148134,0.0004244979,0.00022380617],"domain_scores_gemma":[0.99922085,0.000034864293,0.00018272012,0.00020209329,0.00019861822,0.00016086214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023143917,0.00012920462,0.00018097805,0.00009208065,0.000029956685,0.000005707725,0.00012731962,0.000083479485,0.00004880265],"category_scores_gemma":[0.00018215716,0.00012171665,0.000038752863,0.00014871468,0.00016197568,0.000018437293,0.000035711913,0.00010231594,0.00000442562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16331047,0.0012739999,0.008060938,0.000037452945,0.00007270841,0.0000036795373,0.0002971177,0.0006061375,0.82049304,0.0001895826,0.00018371915,0.005471154],"study_design_scores_gemma":[0.042027302,0.016262136,0.012242195,0.00010675464,0.000025414367,0.000018807881,0.000047995534,0.00009519814,0.927928,0.00051082665,0.00039134672,0.00034402107],"about_ca_topic_score_codex":0.000026102916,"about_ca_topic_score_gemma":0.000037234102,"teacher_disagreement_score":0.12128317,"about_ca_system_score_codex":0.00003139569,"about_ca_system_score_gemma":0.00072569476,"threshold_uncertainty_score":0.4963461},"labels":[],"label_agreement":null},{"id":"W1975767948","doi":"10.1007/s10637-011-9668-7","title":"A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Chemical synthesis and alkaloids","field":"Chemistry","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Brock University; University of Windsor","funders":"Canadian Institutes of Health Research","keywords":"Apoptosis; Autophagy; Mitochondrion; Reactive oxygen species; Cell culture; Cytochrome c; Biology; Cancer cell; Programmed cell death; Cancer research; Molecular biology; Chemistry; Cell biology; Biochemistry; Cancer","score_opus":0.015427867166089843,"score_gpt":0.23300123272907783,"score_spread":0.21757336556298798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975767948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997747,0.00015588859,0.00007351866,0.00032337988,0.000023990855,0.00014779714,0.00066094,0.000007364865,0.0008601015],"genre_scores_gemma":[0.99794227,0.000022430306,0.0016658,0.000062236904,0.0000404753,0.00006898767,0.00005702685,0.00001559999,0.0001251552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870914,0.0000515353,0.00041796427,0.0003170607,0.00030659774,0.00019770596],"domain_scores_gemma":[0.9987002,0.0005870789,0.00041783406,0.00010288376,0.00008268838,0.00010931956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013297822,0.00019697228,0.00031388603,0.000030601463,0.00008072786,0.000014141886,0.00018569102,0.000106465915,0.00035424498],"category_scores_gemma":[0.00015014184,0.00016184464,0.000056297533,0.00016285932,0.0004968946,0.00011253489,0.000073036965,0.00020930801,7.7504484e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041914733,0.0001991376,0.0008974193,0.000051372903,0.00007045349,1.2433033e-7,0.004010375,0.0000023080836,0.9924571,0.00015970622,0.0014471209,0.00066299026],"study_design_scores_gemma":[0.0004487123,0.000025551477,0.0011575464,0.00022255222,0.00003480589,3.3661834e-7,0.0004432385,0.00007423375,0.99592376,0.0014786049,0.000022741826,0.00016789028],"about_ca_topic_score_codex":0.009948746,"about_ca_topic_score_gemma":0.00010711522,"teacher_disagreement_score":0.009841631,"about_ca_system_score_codex":0.00008640856,"about_ca_system_score_gemma":0.000112994676,"threshold_uncertainty_score":0.9966441},"labels":[],"label_agreement":null},{"id":"W1976371429","doi":"10.1007/s10637-013-9965-4","title":"A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Gemcitabine; Pharmacokinetics; Medicine; Tolerability; Neutropenia; Pharmacology; Internal medicine; Rash; Gastroenterology; Toxicity; Adverse effect; Chemotherapy","score_opus":0.00475852084442618,"score_gpt":0.22247079158488545,"score_spread":0.21771227074045926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976371429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998644,0.000017166522,0.000016425705,0.00029698116,0.000042590407,0.0009171356,0.00001016799,0.000004858249,0.00005067722],"genre_scores_gemma":[0.9984676,7.9802504e-7,0.00062028493,0.00016876172,0.000021839092,0.0000768411,0.0005152766,0.00001172495,0.000116839976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989573,0.0000952065,0.00030274867,0.00026806814,0.00022254752,0.00015415183],"domain_scores_gemma":[0.9994557,0.000012944584,0.00016985676,0.00016418973,0.00013234971,0.000064994034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010718767,0.00014939373,0.00015225385,0.000075901116,0.000045533096,0.000009530535,0.00012187169,0.0000697393,0.000013712422],"category_scores_gemma":[0.000042672087,0.00010348592,0.000018345509,0.0002757828,0.00014117814,0.000025971356,0.000055850196,0.00008736972,0.0000033839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065391953,0.001816286,0.9539271,0.00001512912,0.000046584795,0.0000012563835,0.0007244833,0.0012346973,0.037416935,0.00009093314,0.0002419115,0.003830764],"study_design_scores_gemma":[0.013644231,0.0016969654,0.93179125,0.00006303101,0.000008541519,0.0000016492197,0.0002473985,0.00011319411,0.051694676,0.00048030415,0.00007983811,0.00017893036],"about_ca_topic_score_codex":0.00012267687,"about_ca_topic_score_gemma":0.00033853078,"teacher_disagreement_score":0.022135861,"about_ca_system_score_codex":0.00003334489,"about_ca_system_score_gemma":0.0002402307,"threshold_uncertainty_score":0.42200336},"labels":[],"label_agreement":null},{"id":"W1976444729","doi":"10.1007/s10637-006-5730-2","title":"SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; St. Boniface Hospital","funders":"University Health Network","keywords":"Medicine; Colorectal cancer; Chemotherapy; Internal medicine; Neutropenia; Toxicity; Progressive disease; Phases of clinical research; Performance status; Gastroenterology; Cancer; Surgery; Oncology","score_opus":0.1546958686457002,"score_gpt":0.4449759926281748,"score_spread":0.2902801239824746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976444729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922396,0.00079417287,0.0000010413863,0.004190527,0.0007810628,0.0012759813,0.00035409624,0.0000061664427,0.000357377],"genre_scores_gemma":[0.99811083,0.000058976293,0.00017842687,0.00036405816,0.00033032248,0.00028912083,0.000035466317,0.00000928988,0.00062349706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971618,0.00025041075,0.0012535915,0.00025698898,0.0009141205,0.000163056],"domain_scores_gemma":[0.99843806,0.00055467343,0.00053951883,0.00008691126,0.00027554628,0.00010527185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008597044,0.0001665333,0.0007464013,0.00008425951,0.00011109637,0.0000046840314,0.0001108843,0.000033343662,0.00014316948],"category_scores_gemma":[0.0010659151,0.00010023437,0.00012110707,0.0005111837,0.00023675368,0.00006584375,0.00006750045,0.00016009182,1.7564096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01621214,0.020720027,0.7078283,0.00040666858,0.0040287254,0.00007458783,0.008089792,0.0045761866,0.0027451168,0.0048007383,0.16733168,0.06318608],"study_design_scores_gemma":[0.04406324,0.0050860797,0.9237622,0.00071088993,0.00094075326,0.000011690339,0.0008836379,0.00091137947,0.001954513,0.0031150382,0.018228868,0.00033173006],"about_ca_topic_score_codex":0.5218482,"about_ca_topic_score_gemma":0.8801669,"teacher_disagreement_score":0.35831875,"about_ca_system_score_codex":0.00058740267,"about_ca_system_score_gemma":0.008126889,"threshold_uncertainty_score":0.9974961},"labels":[],"label_agreement":null},{"id":"W1977529605","doi":"10.1007/s10637-014-0066-9","title":"Phase II trial of vorinostat in advanced melanoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Vorinostat; Clinical endpoint; Medicine; Melanoma; Adverse effect; Nausea; Internal medicine; Oncology; Progressive disease; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy; Randomized controlled trial; Cancer research; Histone deacetylase; Histone; Biology","score_opus":0.013002947923047731,"score_gpt":0.2994760520324806,"score_spread":0.2864731041094329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977529605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968157,0.00006515478,0.00013357679,0.00064535125,0.00014627949,0.00023325073,0.000020385743,0.0000062026584,0.0019340958],"genre_scores_gemma":[0.9950412,0.000008320842,0.002278451,0.00015711327,0.00040004958,0.000023133181,0.00022468182,0.000014809467,0.0018522762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890137,0.000090412024,0.00029346492,0.00025448852,0.00028491215,0.00017534771],"domain_scores_gemma":[0.9994175,0.000041747906,0.000085287014,0.00023324956,0.00007768713,0.000144568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027201918,0.00010269146,0.00013856201,0.00008720784,0.00004325915,0.000005560644,0.00016136479,0.00009162404,0.00002574477],"category_scores_gemma":[0.00054424437,0.00010834142,0.000057255507,0.00014308607,0.00014879962,0.000006189319,0.00008255655,0.000094269635,0.000011761586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049303314,0.0005958447,0.00024487116,0.00001978073,0.000019044985,0.0000019564213,0.00031734112,0.00029829532,0.9630648,0.002430566,0.008904379,0.019172812],"study_design_scores_gemma":[0.058161616,0.0029631301,0.00017218397,0.000029925486,0.0000041309254,0.0000032877845,0.000020923393,0.00030550617,0.8603813,0.0018797242,0.07589846,0.00017983322],"about_ca_topic_score_codex":0.00006564074,"about_ca_topic_score_gemma":0.000036100515,"teacher_disagreement_score":0.1026835,"about_ca_system_score_codex":0.000018984032,"about_ca_system_score_gemma":0.000362727,"threshold_uncertainty_score":0.4418035},"labels":[],"label_agreement":null},{"id":"W1981746443","doi":"10.1007/s10637-011-9678-5","title":"Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Luitpold Pharmaceuticals; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Doxorubicin; Cytotoxicity; Cisplatin; Comet assay; DNA damage; DNA fragmentation; Molecular biology; Cancer research; DNA; Chemistry; Cancer cell; Biology; Pharmacology; In vitro; Cancer; Biochemistry; Apoptosis; Programmed cell death; Chemotherapy; Genetics","score_opus":0.012550214348946445,"score_gpt":0.22081646188326232,"score_spread":0.20826624753431588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981746443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562293,0.00006723899,0.00005527074,0.0033606796,0.00012161331,0.00062103494,0.00006545652,0.0000032516598,0.00008253007],"genre_scores_gemma":[0.996416,0.000008221572,0.00030692184,0.0026353018,0.00009804785,0.00009508508,0.0000036706126,0.000017002221,0.00041977598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991196,0.00010376922,0.00017311933,0.00024688285,0.00020536047,0.00015126332],"domain_scores_gemma":[0.9994757,0.000052250434,0.00008694958,0.00023689594,0.00004601067,0.00010218342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027789126,0.00013631993,0.000098508965,0.000039955823,0.00005809934,0.000012761289,0.00018950984,0.000078633595,0.000016562602],"category_scores_gemma":[0.000045793407,0.00009172792,0.000039435174,0.0001227457,0.00009884672,0.000004022836,0.00011684522,0.0000991635,0.0000022576596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005047524,0.000056003504,0.000089111454,0.000016179814,0.000019737836,0.0000010635068,0.0005969291,0.000033047174,0.9961134,0.0020091236,0.0002193799,0.00034123962],"study_design_scores_gemma":[0.0007411543,0.00011363813,0.0155314505,0.00014025284,0.000011417643,0.000002404087,0.000045878805,0.00002023167,0.9812333,0.0012637773,0.000782027,0.000114487375],"about_ca_topic_score_codex":0.00046535768,"about_ca_topic_score_gemma":0.00018105177,"teacher_disagreement_score":0.015442339,"about_ca_system_score_codex":0.00003103373,"about_ca_system_score_gemma":0.00028169792,"threshold_uncertainty_score":0.3740556},"labels":[],"label_agreement":null},{"id":"W1982150095","doi":"10.1007/s10637-010-9548-6","title":"A novel aminosteroid of the 5α-androstane-3α,17β-diol family induces cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Plant biochemistry and biosynthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Propidium iodide; Apoptosis; Acute promyelocytic leukemia; Cytotoxic T cell; Programmed cell death; Leukemia; Molecular biology; Cell cycle; Flow cytometry; Cell culture; Annexin; Chemistry; Cancer research; Caspase; Cytotoxicity; Biology; Immunology; Biochemistry; Genetics; In vitro; Retinoic acid","score_opus":0.009195888427141058,"score_gpt":0.2070571217329161,"score_spread":0.19786123330577504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982150095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982522,0.00007577371,0.00000506899,0.00029992734,0.00013514861,0.00021057783,0.00014081305,0.0000074281797,0.0008730223],"genre_scores_gemma":[0.99814755,0.000013712433,0.000610895,0.0003494932,0.00020154509,0.000013526345,0.00011163288,0.000015333891,0.000536291],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882317,0.00003382176,0.00031675454,0.00038349416,0.0002228257,0.00021993651],"domain_scores_gemma":[0.99927336,0.000049556693,0.00017883602,0.00030397694,0.000051983072,0.00014227409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016238057,0.00020791937,0.00017527553,0.000040039944,0.00010219544,0.000031754415,0.0003291794,0.0002628366,0.000008263489],"category_scores_gemma":[0.00008259326,0.0001698671,0.000069126756,0.00013449632,0.0003601064,0.000010686572,0.0001488856,0.00024132659,0.000002524768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020168738,0.000046530662,0.0014407556,0.000050471386,0.000014580949,7.708623e-7,0.00015454709,0.00004802025,0.99756277,0.000032284996,0.00049556664,0.00013356554],"study_design_scores_gemma":[0.00058148656,0.000036662845,0.017450817,0.000058079164,0.000015863508,0.00001114587,0.00008886915,0.00005214407,0.98071843,0.00020790385,0.0005676111,0.0002109662],"about_ca_topic_score_codex":0.00035573024,"about_ca_topic_score_gemma":0.00012145627,"teacher_disagreement_score":0.016844288,"about_ca_system_score_codex":0.000022071647,"about_ca_system_score_gemma":0.00040430497,"threshold_uncertainty_score":0.6926979},"labels":[],"label_agreement":null},{"id":"W1983086187","doi":"10.1007/s10637-005-2905-1","title":"Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Camptothecin; Lethargy; Vomiting; Toxicity; Nausea; Pharmacokinetics; Diarrhea; Pharmacology; Gastroenterology; Anesthesia; Internal medicine; Chemistry","score_opus":0.01063012803762387,"score_gpt":0.27958224717583585,"score_spread":0.268952119138212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983086187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820095,0.0001771193,0.00015650415,0.00019009187,0.000058538837,0.0010152112,0.00012814399,0.000006527963,0.00006689889],"genre_scores_gemma":[0.99651843,0.000034754066,0.001651364,0.0007679438,0.00010377861,0.00013013538,0.00021373351,0.000026560307,0.00055329246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998886,0.000032798995,0.00031890976,0.0003571474,0.00020951215,0.00019561441],"domain_scores_gemma":[0.9993357,0.000027004173,0.00017904586,0.00017653924,0.0001475195,0.0001342001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009618339,0.00019236628,0.00020828437,0.000073338146,0.000054833705,0.000017736746,0.00011769389,0.000068250316,0.000025168178],"category_scores_gemma":[0.000027982102,0.00017692543,0.000034290126,0.00009053191,0.000077373305,0.000016838701,0.000064171065,0.000053152187,0.0000011746297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046813386,0.0021432585,0.0037612375,0.000072055016,0.00021208286,0.0000029383782,0.005121009,0.0012162501,0.95821595,0.00022313239,0.00079413614,0.02355658],"study_design_scores_gemma":[0.0895059,0.019208211,0.013948921,0.00032160294,0.00019339916,0.000010158715,0.0016388029,0.00117969,0.83762914,0.002184597,0.033148598,0.0010309832],"about_ca_topic_score_codex":0.00003675266,"about_ca_topic_score_gemma":0.00010663405,"teacher_disagreement_score":0.12058685,"about_ca_system_score_codex":0.000026321055,"about_ca_system_score_gemma":0.00027206755,"threshold_uncertainty_score":0.72148097},"labels":[],"label_agreement":null},{"id":"W1983180167","doi":"10.1007/s10637-009-9367-9","title":"Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Pharmaceuticals Bayer","keywords":"Sorafenib; Medicine; Discontinuation; Rash; Adverse effect; Placebo; Randomized controlled trial; Internal medicine; Soft tissue sarcoma; Nausea; Surgery; Sarcoma; Tolerability; Oncology; Soft tissue; Pathology; Hepatocellular carcinoma","score_opus":0.011751264357806945,"score_gpt":0.278792244268608,"score_spread":0.26704097991080106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983180167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954077,0.00039961014,0.00006982665,0.0020107357,0.000027967762,0.0019147279,0.00010592025,0.000010551809,0.000052984644],"genre_scores_gemma":[0.99407905,0.00002192161,0.004682433,0.00017117293,0.000048047834,0.00003928086,0.0009268559,0.00000866432,0.000022581755],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99867064,0.000084057974,0.0005638788,0.00021493091,0.00035994354,0.00010656329],"domain_scores_gemma":[0.9987995,0.0005506658,0.00029319903,0.00013913524,0.00009559431,0.00012188849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015685947,0.00014447598,0.00063229725,0.000107785534,0.000029133982,0.000005182789,0.000040371015,0.000048363585,0.000043870252],"category_scores_gemma":[0.00037824694,0.00010541772,0.00005593772,0.00016887097,0.00015451538,0.00010881809,0.000012737583,0.00006402095,8.62974e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8544557,0.0064797616,0.022467261,0.000015324998,0.0001808078,0.0000074823943,0.0027336997,0.000058959133,0.0014057088,0.0013380821,0.00012474926,0.11073244],"study_design_scores_gemma":[0.7874567,0.0017629161,0.20283796,0.00028264726,0.00016512358,5.053938e-7,0.000022194483,0.00009344079,0.004350295,0.002845542,0.000095905416,0.0000867827],"about_ca_topic_score_codex":0.0001732551,"about_ca_topic_score_gemma":0.000020835003,"teacher_disagreement_score":0.1803707,"about_ca_system_score_codex":0.000034672536,"about_ca_system_score_gemma":0.0001757139,"threshold_uncertainty_score":0.429881},"labels":[],"label_agreement":null},{"id":"W1984395407","doi":"10.1023/b:drug.0000006171.54078.3d","title":"The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"","keywords":"Plasmin; Plasminogen activator; Urokinase; Angiogenesis; Tissue plasminogen activator; Chemistry; In vitro; Stimulation; T-plasminogen activator; Fibrinolysis; Activator (genetics); Pharmacology; Biochemistry; Enzyme; Biology; Receptor; Endocrinology; Cancer research; Internal medicine; Medicine","score_opus":0.0133581378657629,"score_gpt":0.24500450344369587,"score_spread":0.23164636557793297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984395407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944221,0.00084774406,0.001913849,0.0011768484,0.00039354968,0.0003257124,0.000027325315,0.000024711973,0.0008681899],"genre_scores_gemma":[0.9942223,0.00004318353,0.0018886044,0.00058116496,0.00045869403,0.000028758132,0.00006762193,0.000027308106,0.0026823534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885327,0.00010575523,0.00016743522,0.0003292483,0.0002591914,0.00028511175],"domain_scores_gemma":[0.9992593,0.00004891541,0.000096929834,0.0003067616,0.000063153384,0.0002249566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019192144,0.00018335054,0.00010271999,0.000025692685,0.00028934868,0.000058736416,0.00019117683,0.000121109544,0.000057613688],"category_scores_gemma":[0.00021426583,0.00014792131,0.00009844399,0.00010583676,0.00011703268,0.000013046019,0.00006273691,0.00009695008,0.00008092975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037650552,0.000025106752,0.00012843368,0.000003909844,0.00006881573,0.0000023515997,0.000046820416,0.00010376859,0.9766948,0.0031933978,0.017537378,0.0021575536],"study_design_scores_gemma":[0.00033238003,0.00007786409,0.00019249634,0.0000075831726,0.0000134639995,0.000013244878,0.00001697465,0.000041094103,0.8251932,0.0070380117,0.16691162,0.0001620728],"about_ca_topic_score_codex":0.000035799196,"about_ca_topic_score_gemma":0.000008611295,"teacher_disagreement_score":0.15150161,"about_ca_system_score_codex":0.000025505164,"about_ca_system_score_gemma":0.00044655518,"threshold_uncertainty_score":0.6032056},"labels":[],"label_agreement":null},{"id":"W1985731766","doi":"10.1007/s10637-009-9375-9","title":"Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Cancer Research Society","keywords":"Sphingosine; Sphingosine kinase 1; Sphingosine-1-phosphate; Docetaxel; Sphingosine kinase; Breast cancer; Apoptosis; Pharmacology; Cancer research; Cancer; Cytotoxicity; Medicine; Systemic administration; Cancer cell; Kinase; Internal medicine; Chemistry; Biology; Cell biology; In vitro; Receptor; Biochemistry; In vivo","score_opus":0.011669850574289218,"score_gpt":0.2609885731992294,"score_spread":0.2493187226249402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985731766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084586,0.0029845666,0.00061845896,0.0044205016,0.0003474557,0.00015393549,0.00003825412,0.000038881568,0.00055207795],"genre_scores_gemma":[0.9853847,0.00018598771,0.00057497347,0.010371612,0.0021413313,0.00001043334,0.00026094273,0.000022848164,0.0010471673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987764,0.00003580322,0.00025697763,0.00036659464,0.00028443002,0.00027984515],"domain_scores_gemma":[0.999329,0.000004711979,0.000108350774,0.00022344539,0.00009606501,0.0002384853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012545256,0.00020397826,0.00014899216,0.000048490983,0.00018905307,0.00006713346,0.000227736,0.00011706313,0.00009924145],"category_scores_gemma":[0.000013976587,0.00019731717,0.000115188304,0.00012592072,0.00008979546,0.000012696797,0.00003858095,0.000110916335,0.00001696645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035656696,0.000046162724,0.0007154507,0.000004869725,0.000051629042,0.0000035537562,0.00015242033,0.0018200739,0.9771316,0.0022723477,0.006527572,0.011238661],"study_design_scores_gemma":[0.0045801527,0.00018570067,0.19820918,0.00014829484,0.00015239243,0.00010453869,0.00013913354,0.0010942996,0.66393274,0.019222993,0.110762075,0.0014685234],"about_ca_topic_score_codex":0.00012501774,"about_ca_topic_score_gemma":0.0000067708147,"teacher_disagreement_score":0.3131989,"about_ca_system_score_codex":0.000022343891,"about_ca_system_score_gemma":0.0002835158,"threshold_uncertainty_score":0.8046361},"labels":[],"label_agreement":null},{"id":"W1986001121","doi":"10.1007/s10637-012-9899-2","title":"Clinical trial design in biosimilar drug development","year":2012,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biosimilar; Clinical trial; Drug development; Immunogenicity; Medicine; Drug; Risk analysis (engineering); Pharmacology; Intensive care medicine; Drug approval; Immune system; Immunology; Internal medicine","score_opus":0.2911499705476818,"score_gpt":0.4276049626942675,"score_spread":0.13645499214658569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986001121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000127620815,0.9948462,0.00026828135,0.00050708035,0.0024627168,0.0013178047,0.000027290145,0.0000567716,0.0005010569],"genre_scores_gemma":[0.0000054942197,0.9451759,0.044303857,0.0010155808,0.00080761,0.00013840427,0.00036614412,0.000059616166,0.008127391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936763,0.002637643,0.002197897,0.0007165468,0.0001360424,0.0006355863],"domain_scores_gemma":[0.99611276,0.0026504733,0.0005861329,0.00037952908,0.000054725777,0.00021640013],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004074731,0.0005934998,0.0020223167,0.00031824358,0.00011755749,0.00003061293,0.0006063663,0.0013851915,0.0010740043],"category_scores_gemma":[0.00063482113,0.00044987182,0.00056575413,0.00048085023,0.0005224441,0.00009366431,0.000201636,0.0013520176,0.0013370386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043337492,0.00024108888,0.000017268543,0.000557891,0.00034696207,0.0000041473018,0.00009222729,2.0619046e-7,0.0000017307553,0.00085637067,0.030259239,0.9671895],"study_design_scores_gemma":[0.006260193,0.00006973541,0.000022360467,0.0019956147,0.0004827426,0.000018682806,0.0000064511405,5.030798e-7,0.000050990766,0.00095367397,0.9896124,0.0005266602],"about_ca_topic_score_codex":0.00001743463,"about_ca_topic_score_gemma":0.0000070057854,"teacher_disagreement_score":0.9666628,"about_ca_system_score_codex":0.00017124062,"about_ca_system_score_gemma":0.0029954533,"threshold_uncertainty_score":0.99991125},"labels":[],"label_agreement":null},{"id":"W1987291688","doi":"10.1007/s10637-010-9431-5","title":"Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research; Cancer Research UK","keywords":"Carbamate; Potency; Chemistry; Epidermal growth factor; Biochemistry; DNA; Intracellular; Molecular biology; Stereochemistry; In vitro; Biology; Receptor","score_opus":0.008599591222095335,"score_gpt":0.21366069975280813,"score_spread":0.2050611085307128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987291688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99267226,0.000016617909,0.000031969397,0.005603231,0.00007159279,0.00019125931,0.00031723335,0.000016905651,0.0010789196],"genre_scores_gemma":[0.9987765,0.0000032867997,0.00009755916,0.00020206196,0.00013904882,0.00003303225,0.00024373516,0.000016415579,0.0004883672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866694,0.00005961181,0.0005737004,0.00019160453,0.00036609234,0.00014205994],"domain_scores_gemma":[0.99819213,0.00033107662,0.0008390983,0.00038774186,0.00018762621,0.00006231547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020590238,0.00014718827,0.00019352691,0.000015613605,0.0002425825,0.00001273911,0.00040635752,0.0001159072,0.00019382624],"category_scores_gemma":[0.00045623953,0.000093599476,0.00015359586,0.000222777,0.00043665315,0.00007618667,0.00014967244,0.00025520843,0.0000015809131],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017468032,0.00003825718,0.005893383,0.00007740297,0.000024852205,6.6954705e-8,0.0009095755,0.000043601678,0.98852575,0.0042999038,0.00006630223,0.00010342048],"study_design_scores_gemma":[0.00041434262,0.0000051965917,0.012959594,0.00009422987,0.000034925364,0.000005406332,0.000094139854,0.0006780046,0.9821291,0.0032363897,0.0002564988,0.000092190116],"about_ca_topic_score_codex":0.00017066752,"about_ca_topic_score_gemma":0.000013481959,"teacher_disagreement_score":0.007066211,"about_ca_system_score_codex":0.00003514281,"about_ca_system_score_gemma":0.00021759035,"threshold_uncertainty_score":0.38168758},"labels":[],"label_agreement":null},{"id":"W1987338076","doi":"10.1007/s10637-012-9901-z","title":"Characterization of a membrane-active anti-tumor agent, UA8967","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"National Cancer Institute; National Institutes of Health; University of Arizona Cancer Center","keywords":"Medicine","score_opus":0.02169782672767152,"score_gpt":0.23911225117782303,"score_spread":0.21741442445015152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987338076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761295,0.000031722517,0.00029462582,0.0006951838,0.00055157417,0.0002268172,0.00012100969,0.00007942653,0.00038668685],"genre_scores_gemma":[0.9964701,0.0000029965647,0.0018248992,0.0008965942,0.0003958512,0.00001876207,0.00010506079,0.000022131528,0.00026361432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984227,0.00011200244,0.0003982234,0.00022824592,0.0005051803,0.0003336655],"domain_scores_gemma":[0.998895,0.000117129595,0.00030668694,0.00022843549,0.00013828215,0.00031444838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003355708,0.00015796511,0.00021159681,0.00010346113,0.000093870454,0.00003279125,0.00019783022,0.000048776,0.00086062733],"category_scores_gemma":[0.00015787341,0.00015695956,0.000058577054,0.00030226982,0.00020613571,0.00097363186,0.00006244575,0.00007310445,0.0006846573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026315443,0.00009367409,0.0022282982,0.000024691286,0.000008572022,0.0000013105719,0.0013006654,0.00006272489,0.99213237,0.0036630188,0.00028325012,0.00017508728],"study_design_scores_gemma":[0.00039020018,0.000018432804,0.028669043,0.000038375147,0.000022176398,0.00000860169,0.000058405294,0.00015796335,0.9684266,0.00056224037,0.0014827731,0.00016519998],"about_ca_topic_score_codex":0.00012122588,"about_ca_topic_score_gemma":0.0000018103101,"teacher_disagreement_score":0.026440745,"about_ca_system_score_codex":0.000069427675,"about_ca_system_score_gemma":0.00031361714,"threshold_uncertainty_score":0.94232655},"labels":[],"label_agreement":null},{"id":"W1988476175","doi":"10.1007/s10637-014-0113-6","title":"Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Posterior reversible encephalopathy syndrome; Sunitinib; Bevacizumab; Colorectal cancer; Peripheral edema; Pathology; Adverse effect; Magnetic resonance imaging; Radiology; Internal medicine; Cancer; Chemotherapy","score_opus":0.024869257835693874,"score_gpt":0.26272831302886096,"score_spread":0.23785905519316708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988476175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98870337,0.00009264997,0.000068522175,0.01001363,0.000059455957,0.00043553725,0.000020976975,0.000049725008,0.0005561557],"genre_scores_gemma":[0.9914835,0.0000051823577,0.003251434,0.0047294796,0.000034248238,0.000095099414,0.00006717653,0.00001977211,0.00031409707],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984541,0.00010510648,0.00034686236,0.000402081,0.00043596845,0.00025589054],"domain_scores_gemma":[0.9990849,0.0001636188,0.000109551656,0.0002224813,0.00008552023,0.00033392795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012755221,0.00018565678,0.00033721866,0.0001241536,0.00006918158,0.000024023151,0.000116935145,0.00006238177,0.00025019565],"category_scores_gemma":[0.0001494606,0.00014171514,0.00005133399,0.00044207243,0.00012696377,0.0001255819,0.000040912757,0.00027402764,0.000043241063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005955929,0.0040071397,0.31226584,0.0009944824,0.00081368623,0.002574863,0.009545496,0.001072823,0.48622558,0.025729042,0.05548622,0.09532889],"study_design_scores_gemma":[0.010011266,0.007139729,0.9275539,0.0010111408,0.0003078216,0.0062894304,0.00035852674,0.0029153267,0.008203576,0.018676504,0.016286027,0.0012467721],"about_ca_topic_score_codex":0.00025220812,"about_ca_topic_score_gemma":0.000031078613,"teacher_disagreement_score":0.615288,"about_ca_system_score_codex":0.00009516551,"about_ca_system_score_gemma":0.00032404662,"threshold_uncertainty_score":0.57789755},"labels":[],"label_agreement":null},{"id":"W1988711151","doi":"10.1007/s10637-015-0245-3","title":"Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Pharmacokinetics; Cmax; Feeding tube; Tyrosine-kinase inhibitor; Pharmacology; Internal medicine; Oncology; Gastroenterology; Cancer; Surgery","score_opus":0.01691844029429995,"score_gpt":0.28355555763398604,"score_spread":0.2666371173396861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988711151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952017,0.00012587423,0.00024118129,0.0014045433,0.00013860362,0.0007373098,0.0000101197475,0.000029581646,0.0021110806],"genre_scores_gemma":[0.98299867,0.000002095967,0.015785156,0.00061150506,0.00012348086,0.00003198203,0.00016059344,0.000029080848,0.00025740787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819076,0.00004540402,0.00045933292,0.00033732908,0.00071693637,0.00025021567],"domain_scores_gemma":[0.9991686,0.00008813362,0.00019718414,0.00014446428,0.00014929238,0.00025232913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018795548,0.00023404139,0.00033927677,0.00014640321,0.000041618794,0.000036430534,0.000076625736,0.00005570776,0.000013604005],"category_scores_gemma":[0.00006787804,0.00021542399,0.000054091375,0.00036443432,0.000112962225,0.00035949473,0.00005862222,0.00018741626,0.0000014709437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005377836,0.0002877185,0.9938521,0.00014752465,0.00002103782,0.000032045074,0.0006104186,0.00032292033,0.0017788468,0.00028311618,0.0010716673,0.0010548506],"study_design_scores_gemma":[0.027640715,0.0012973828,0.9655518,0.00032490276,0.00013980942,0.0000054776324,0.00025605195,0.00060466595,0.003057177,0.00019062088,0.0007209758,0.0002104019],"about_ca_topic_score_codex":0.00016018769,"about_ca_topic_score_gemma":0.000029025377,"teacher_disagreement_score":0.028300252,"about_ca_system_score_codex":0.00019579509,"about_ca_system_score_gemma":0.0007937933,"threshold_uncertainty_score":0.8784735},"labels":[],"label_agreement":null},{"id":"W1989987919","doi":"10.1007/s10637-006-5938-1","title":"Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pyrogenesis (Canada); Queen's University; London Health Sciences Centre; Hôpital Notre-Dame; Princess Margaret Cancer Centre; University Health Network; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Medical Research Council; University Health Network","keywords":"Clinical trial; Medicine; Renal cell carcinoma; Cancer; Phases of clinical research; Drug; Oncology; Cancer drugs; Internal medicine; Pharmacology","score_opus":0.03687109437820722,"score_gpt":0.32023486744838175,"score_spread":0.2833637730701745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989987919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607205,0.00015023342,0.0005168872,0.001270731,0.00017213543,0.0013962173,0.00035040712,0.0000046530063,0.00006667056],"genre_scores_gemma":[0.9957299,0.00000786487,0.0021854262,0.00021976646,0.0004721833,0.00006199135,0.0011628944,0.000024517673,0.00013543108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961763,0.0006963005,0.0013492658,0.00044695192,0.0011172013,0.00021399742],"domain_scores_gemma":[0.9980666,0.0002891591,0.0007331775,0.00022039958,0.0004935536,0.0001970927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019998988,0.00026305224,0.0005093298,0.00012891616,0.00013343302,0.000019720504,0.00015626299,0.00007466273,0.000016838361],"category_scores_gemma":[0.0005543831,0.00019060128,0.00010498517,0.00040705825,0.00036833767,0.000036899142,0.000041571308,0.00017475041,2.110804e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09238487,0.022132007,0.39716324,0.00023584296,0.0029811196,0.000044943135,0.003030738,0.11529396,0.30343798,0.011833836,0.043749012,0.0077124443],"study_design_scores_gemma":[0.3365597,0.010225121,0.3880836,0.00025539566,0.00083329075,0.0000032090072,0.00027229593,0.0006133196,0.25000414,0.008932951,0.0031172975,0.0010996506],"about_ca_topic_score_codex":0.0730341,"about_ca_topic_score_gemma":0.17388852,"teacher_disagreement_score":0.24417484,"about_ca_system_score_codex":0.00007713508,"about_ca_system_score_gemma":0.0057757106,"threshold_uncertainty_score":0.99986064},"labels":[],"label_agreement":null},{"id":"W1991064094","doi":"10.1007/s10637-010-9408-4","title":"A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Sorafenib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Clinical endpoint; Internal medicine; Oncology; Surgery; Phases of clinical research; Clinical trial; Chemotherapy; Hepatocellular carcinoma","score_opus":0.04450204486330388,"score_gpt":0.35368284050258053,"score_spread":0.30918079563927664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991064094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167126,0.00008820234,0.000007797281,0.0046091718,0.0006034026,0.0024612816,0.00028706656,0.000018356825,0.0002534576],"genre_scores_gemma":[0.9975341,0.000011793361,0.00034009866,0.0004917294,0.00039882175,0.0002405837,0.00003071304,0.0000256488,0.0009265093],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979746,0.000085597094,0.00076586386,0.00029817826,0.0006693095,0.00020649067],"domain_scores_gemma":[0.9987739,0.00014110256,0.0003512115,0.00036565022,0.00016534804,0.00020279572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025069807,0.00021911428,0.0005312125,0.00014445983,0.00014009976,0.000006745116,0.00019664818,0.000063531945,0.0004282535],"category_scores_gemma":[0.00031039794,0.00015568882,0.00014039001,0.0004538572,0.0003135396,0.00008999289,0.00008162531,0.00030641697,0.0000029818932],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21542081,0.25830486,0.025237737,0.0007695388,0.003967792,0.00014447316,0.10063451,0.0010467721,0.3162251,0.0056765648,0.012551556,0.060020264],"study_design_scores_gemma":[0.87671846,0.027040599,0.002101446,0.00030520925,0.0013071755,0.000023786653,0.00064163125,0.00069493114,0.07976052,0.0060784006,0.004984427,0.00034343931],"about_ca_topic_score_codex":0.0044785333,"about_ca_topic_score_gemma":0.0022849746,"teacher_disagreement_score":0.6612976,"about_ca_system_score_codex":0.00005389652,"about_ca_system_score_gemma":0.0019639325,"threshold_uncertainty_score":0.67702323},"labels":[],"label_agreement":null},{"id":"W1991265164","doi":"10.1007/s10637-010-9456-9","title":"A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; St. Joseph’s Healthcare Hamilton; St Joseph's Health Care; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Causality (physics); Clinical trial; Attribution; Thematic analysis; Objectivity (philosophy); Medicine; Psychology; Qualitative research; Medical education; Internal medicine; Social psychology; Epistemology","score_opus":0.8588413857350846,"score_gpt":0.7504655684450426,"score_spread":0.10837581729004198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991265164","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94100523,0.0000035068763,0.049976584,0.0016396054,0.0021898514,0.004443353,0.0005481172,0.00013224441,0.00006153907],"genre_scores_gemma":[0.42539862,8.518499e-7,0.5718613,0.00021179336,0.0017425237,0.00043234555,0.000032756474,0.00004104629,0.00027871784],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97449315,0.018033437,0.0049225627,0.0009272141,0.0011132935,0.000510332],"domain_scores_gemma":[0.6404143,0.3527565,0.0035056253,0.00088397966,0.0012966444,0.0011429649],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09192492,0.0003501179,0.0017211775,0.00010833229,0.00032246174,0.00002932265,0.00037551875,0.00048058314,0.0003010666],"category_scores_gemma":[0.59387445,0.00031631766,0.0005040406,0.0002983514,0.00042385253,0.00021107201,0.00014869378,0.0010157161,0.00006157787],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01706636,0.020651009,0.015458524,0.00077937415,0.0041905707,0.00006994497,0.11855894,0.000053676737,0.051958907,0.6317368,0.0068215793,0.13265432],"study_design_scores_gemma":[0.022082303,0.0022959108,0.009058708,0.0000635197,0.0005579119,0.000004854734,0.0023237497,0.0005121591,0.0008012675,0.9617441,0.0002019103,0.00035354806],"about_ca_topic_score_codex":0.00009306557,"about_ca_topic_score_gemma":0.00005164716,"teacher_disagreement_score":0.52188474,"about_ca_system_score_codex":0.0001823188,"about_ca_system_score_gemma":0.0013366302,"threshold_uncertainty_score":0.9999289},"labels":[],"label_agreement":null},{"id":"W1991823030","doi":"10.1007/s10637-007-9066-3","title":"A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Pancreatic carcinoma; Medicine; Internal medicine; Phases of clinical research; Oncology; Deoxycytidine; Chemotherapy; Pancreatic cancer; Cancer","score_opus":0.025480800549538923,"score_gpt":0.338689633946706,"score_spread":0.31320883339716704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991823030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385464,0.00025069044,0.000016608896,0.0018012606,0.00014055536,0.003052397,0.000031917167,0.000019197072,0.00083271763],"genre_scores_gemma":[0.99810034,0.000023281185,0.0008655711,0.00015053786,0.00017299443,0.00008745143,0.000034297685,0.000022318827,0.0005432349],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99709225,0.00016413574,0.0010683911,0.00041409562,0.00087492215,0.00038619892],"domain_scores_gemma":[0.9978845,0.00064939715,0.0004391326,0.0004492072,0.0002542407,0.00032351693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010817584,0.00025154123,0.0009037169,0.0002622622,0.0001448555,0.0000060093425,0.00023707598,0.00013927548,0.000044869295],"category_scores_gemma":[0.0013286775,0.00018907529,0.00009035806,0.00064079755,0.00072942616,0.0001130061,0.00024326408,0.00038697934,8.078944e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05188814,0.030706834,0.80725396,0.00037332755,0.00057367835,0.00013273307,0.027837513,0.000014115976,0.073249474,0.0022353993,0.00060768035,0.0051271445],"study_design_scores_gemma":[0.51812,0.046593044,0.40877095,0.000538849,0.00080434687,0.000046033012,0.0050517647,0.0012099076,0.016115801,0.0021527866,0.00019770379,0.00039880708],"about_ca_topic_score_codex":0.00063427404,"about_ca_topic_score_gemma":0.000102826874,"teacher_disagreement_score":0.46623185,"about_ca_system_score_codex":0.00011971191,"about_ca_system_score_gemma":0.001331732,"threshold_uncertainty_score":0.7710266},"labels":[],"label_agreement":null},{"id":"W1995930791","doi":"10.1007/s10637-014-0171-9","title":"A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Norris Cotton Cancer Center; Bristol-Myers Squibb","keywords":"Medicine; Pharmacokinetics; Mucositis; Neutropenia; Pharmacology; Toxicity; Epothilone; Folate receptor; Cancer; Dosing; Internal medicine; Oncology; Cancer cell; Chemistry","score_opus":0.016924110530593332,"score_gpt":0.3168864988068077,"score_spread":0.29996238827621435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995930791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955881,0.00060141593,0.00020103416,0.002561544,0.000055996028,0.0005264548,0.00005001387,0.000036146623,0.0003792779],"genre_scores_gemma":[0.9941177,0.0001654976,0.0025477207,0.0019652084,0.00009586975,0.000046164863,0.00034991396,0.000028700064,0.0006832507],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99850374,0.00008375151,0.000493868,0.00037621637,0.0002884362,0.00025398436],"domain_scores_gemma":[0.99908143,0.00014211415,0.00023896614,0.0001622596,0.00009017242,0.0002850285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019299121,0.00023675498,0.0006319083,0.00042621192,0.000053685977,0.000008600945,0.000071554496,0.000059391477,0.0006961337],"category_scores_gemma":[0.000025892126,0.00020407567,0.00010299781,0.0007636847,0.00020797041,0.00009253755,0.000020246882,0.00016780628,0.000006885693],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010388962,0.0027189695,0.05086626,0.00035729926,0.0075085065,0.000045468998,0.012653838,0.004936619,0.8490097,0.0012366168,0.0012005384,0.05907723],"study_design_scores_gemma":[0.2158765,0.014802492,0.30844447,0.0014202794,0.019960687,0.00007849049,0.00039494806,0.09018638,0.30551693,0.00870997,0.03242083,0.002188022],"about_ca_topic_score_codex":0.00018766806,"about_ca_topic_score_gemma":0.000085334446,"teacher_disagreement_score":0.5434928,"about_ca_system_score_codex":0.00011650553,"about_ca_system_score_gemma":0.00024653206,"threshold_uncertainty_score":0.8321964},"labels":[],"label_agreement":null},{"id":"W1996453449","doi":"10.1007/s10637-010-9554-8","title":"Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Topoisomerase; K562 cells; Apoptosis; Molecular biology; Biology; Etoposide; DNA fragmentation; Leukemia; DNA; Biochemistry; Programmed cell death; Immunology; Genetics","score_opus":0.010398452731451124,"score_gpt":0.24502683942644496,"score_spread":0.23462838669499383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996453449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812037,0.00019998658,0.00021125643,0.00040271474,0.00030264413,0.00013931762,0.00012611349,0.000014015326,0.00048356954],"genre_scores_gemma":[0.994194,0.00003138143,0.0030634338,0.0008741859,0.00048500704,0.000019044244,0.00038472548,0.00003017842,0.0009180598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885505,0.000017553664,0.00031148532,0.00034403498,0.00024282986,0.0002290711],"domain_scores_gemma":[0.9992696,0.000015745174,0.00018887603,0.00023521172,0.000093635055,0.00019695425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015459667,0.00018686382,0.00017277928,0.000060896276,0.00017559639,0.000025631558,0.00024563578,0.00019175427,0.00006168873],"category_scores_gemma":[0.000027790751,0.00019491359,0.00011264203,0.0001350834,0.00013370792,0.000009238708,0.00012244484,0.0001798227,0.0000046881246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000109636285,0.0000408203,0.00004442999,0.000009881528,0.00005176416,8.986413e-8,0.00018409586,0.00002444363,0.9890616,0.0021284174,0.0077763284,0.000667158],"study_design_scores_gemma":[0.0005932198,0.00009401533,0.00004996751,0.00001076551,0.00002163416,0.0000018927948,0.00006977194,0.000028262593,0.9444477,0.0022518386,0.052216083,0.00021486348],"about_ca_topic_score_codex":0.00032916068,"about_ca_topic_score_gemma":0.000023244665,"teacher_disagreement_score":0.044613924,"about_ca_system_score_codex":0.000020728068,"about_ca_system_score_gemma":0.00030500063,"threshold_uncertainty_score":0.79483455},"labels":[],"label_agreement":null},{"id":"W1996463727","doi":"10.1007/s10637-012-9832-8","title":"Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development; BC Cancer Agency; University of British Columbia","funders":"University of British Columbia; British Columbia Innovation Council","keywords":"Topotecan; Pharmacokinetics; Pharmacology; Liposome; Camptothecin; In vivo; Ovarian cancer; Irinotecan; Bioavailability; Drug; Chemistry; Medicine; Doxorubicin; Pharmacodynamics; Chemotherapy; Cancer; Internal medicine; Biochemistry; Biology","score_opus":0.046230400316462986,"score_gpt":0.32016301409947817,"score_spread":0.2739326137830152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996463727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251086,0.00097627967,0.00008444284,0.005135467,0.00016220106,0.00062044675,0.000082628874,0.000013276255,0.00041438208],"genre_scores_gemma":[0.9912241,0.000042297397,0.007490996,0.00016293982,0.00042841234,0.00016285166,0.000069677,0.0000134604115,0.000405278],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992179,0.000010966819,0.0002847425,0.00012272462,0.00019447437,0.00016918675],"domain_scores_gemma":[0.9993213,0.00008417373,0.0001404661,0.00013989164,0.00010952559,0.00020465258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056541416,0.00010388164,0.00024086694,0.000053870106,0.000033807064,0.0000036523822,0.000027416581,0.000049258266,0.00015075007],"category_scores_gemma":[0.000026528662,0.00008578679,0.00010943154,0.0001231795,0.000045708075,0.00010060131,0.000006686289,0.00001371572,0.0000029533307],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007301545,0.0022168488,0.715907,0.00027302132,0.0007543269,0.0000018153656,0.009027082,0.0003045997,0.077962294,0.114975,0.00201802,0.07582988],"study_design_scores_gemma":[0.006135793,0.0009506316,0.3584128,0.00014680014,0.0004085656,0.0000100692905,0.00009377348,0.0004342309,0.62080055,0.00491541,0.00756733,0.00012403275],"about_ca_topic_score_codex":0.0008966507,"about_ca_topic_score_gemma":0.00002588156,"teacher_disagreement_score":0.5428383,"about_ca_system_score_codex":0.00018858947,"about_ca_system_score_gemma":0.00039712715,"threshold_uncertainty_score":0.3498284},"labels":[],"label_agreement":null},{"id":"W1997853067","doi":"10.1007/s10637-007-9097-9","title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Queen's University; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Melanoma; Neutropenia; Adverse effect; Toxicity; Clinical trial; Internal medicine; Phases of clinical research; Cancer; Pharmacokinetics; Chemotherapy; Surgery; Oncology; Gastroenterology; Cancer research","score_opus":0.08669226906530368,"score_gpt":0.38267614061835153,"score_spread":0.29598387155304784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997853067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995746,0.00073768554,0.000039453953,0.00022244417,0.0014793059,0.0015424754,0.00019107577,0.000008240471,0.000033331362],"genre_scores_gemma":[0.9984869,0.000019131912,0.00026492507,0.0002072271,0.00007216056,0.00006998241,0.00022554825,0.000014904427,0.00063922384],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99595976,0.0009986,0.0021267787,0.00030961295,0.0003224086,0.00028282776],"domain_scores_gemma":[0.9970725,0.0013225882,0.0010369672,0.00018172484,0.0003306508,0.00005553877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003680908,0.00022950588,0.0008824651,0.0002545761,0.00012040536,0.000005403379,0.00023670547,0.00010887153,0.00028831253],"category_scores_gemma":[0.0018805295,0.00015943786,0.0001015269,0.00043249904,0.00031622546,0.0001617238,0.000050173752,0.00024951706,0.0000018433765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85736483,0.03491444,0.02498228,0.000114677816,0.0042187385,0.000028993267,0.006271905,0.00017599377,0.01293991,0.0030438493,0.011034554,0.044909846],"study_design_scores_gemma":[0.7597958,0.041608963,0.15946451,0.00061414164,0.00042832107,0.000011933745,0.0011215416,0.000013788582,0.0117735015,0.00059810065,0.023811692,0.00075770356],"about_ca_topic_score_codex":0.057044327,"about_ca_topic_score_gemma":0.09794987,"teacher_disagreement_score":0.13448223,"about_ca_system_score_codex":0.00015848615,"about_ca_system_score_gemma":0.0052586067,"threshold_uncertainty_score":0.9492349},"labels":[],"label_agreement":null},{"id":"W2000023204","doi":"10.1007/s10637-010-9570-8","title":"A phase I study of temsirolimus and metformin in advanced solid tumours","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Temsirolimus; Metformin; Medicine; Internal medicine; Maximum tolerated dose; Toxicity; Cancer; Limiting; Gastroenterology; Discovery and development of mTOR inhibitors","score_opus":0.012043021149741137,"score_gpt":0.30803073724029995,"score_spread":0.2959877160905588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000023204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990134,0.00016841479,0.000024243387,0.00015423572,0.00013849058,0.00023300199,0.0000147125775,0.00000670324,0.00024680176],"genre_scores_gemma":[0.99714243,0.000008189826,0.0021938009,0.0001843756,0.00018071597,0.000029053703,0.000035642795,0.000015080323,0.00021068123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913585,0.000028064109,0.00025502013,0.00026413563,0.00017560346,0.00014131237],"domain_scores_gemma":[0.99948055,0.000030313107,0.0001108104,0.00019115588,0.0000635884,0.00012360113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018531682,0.000117479954,0.00014349383,0.00006818808,0.000028330956,0.000009698315,0.00013339796,0.000079500525,0.000014845342],"category_scores_gemma":[0.00017250836,0.00011915919,0.000025062487,0.00011076408,0.00012379498,0.000008596813,0.000057341233,0.00013353986,0.0000015670794],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008733035,0.00029969643,0.008949162,0.00000845322,0.000021410751,0.000002920409,0.0005885533,0.00021207845,0.9859861,0.00023540965,0.00033745417,0.0032714298],"study_design_scores_gemma":[0.010240478,0.0016012604,0.013770513,0.000037364436,0.000031164156,0.000029656541,0.00059437804,0.00045488935,0.9633265,0.004617534,0.0049259705,0.00037027145],"about_ca_topic_score_codex":0.0001272899,"about_ca_topic_score_gemma":0.000179875,"teacher_disagreement_score":0.022659581,"about_ca_system_score_codex":0.000008762888,"about_ca_system_score_gemma":0.0002490486,"threshold_uncertainty_score":0.48591706},"labels":[],"label_agreement":null},{"id":"W2000123112","doi":"10.1023/b:drug.0000026258.02846.1c","title":"Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University","funders":"National Cancer Institute; McGill University","keywords":"Nausea; Medicine; Gastroenterology; Internal medicine; Vomiting; Diarrhea; Melanoma; Progressive disease; Anorexia; Toxicity; Regimen; Phases of clinical research; Surgery; Chemotherapy; Cancer research","score_opus":0.021077545427093294,"score_gpt":0.2726131858557945,"score_spread":0.25153564042870125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000123112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976671,0.00022878306,0.0002571511,0.00056462426,0.0002302335,0.00045548528,0.00008918453,0.000012147487,0.00049532304],"genre_scores_gemma":[0.995729,0.000020941936,0.002568599,0.00030345737,0.00032257393,0.000042535576,0.00053858705,0.000020501822,0.0004538001],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848354,0.000083382736,0.000533783,0.0003672424,0.00029616253,0.00023588845],"domain_scores_gemma":[0.9992597,0.000023703695,0.00017951369,0.00026216038,0.00007018764,0.0002047053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023943538,0.00020012238,0.00024988333,0.00011944024,0.00005688105,0.00001277003,0.00016969997,0.00011465022,0.000029303459],"category_scores_gemma":[0.00018719211,0.00018984359,0.000101910366,0.0001717239,0.000117347234,0.00001035861,0.00008966221,0.000094399846,0.00001529574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003463191,0.0013602732,0.00013219789,0.000030600826,0.00007115663,0.000052860956,0.00040026905,0.00062931946,0.9872986,0.0039609927,0.00065396103,0.0019465942],"study_design_scores_gemma":[0.0747743,0.002993667,0.000103741964,0.00007408797,0.000036833448,0.000021531352,0.00006191953,0.000032512136,0.9106226,0.008556578,0.0024799393,0.00024226925],"about_ca_topic_score_codex":0.00046744116,"about_ca_topic_score_gemma":0.00018827379,"teacher_disagreement_score":0.07667597,"about_ca_system_score_codex":0.000039208528,"about_ca_system_score_gemma":0.00096676743,"threshold_uncertainty_score":0.77415967},"labels":[],"label_agreement":null},{"id":"W2000249294","doi":"10.1007/s10637-007-9056-5","title":"Silencing of endo-exonuclease expression sensitizes mouse B16F10 melanoma cells to DNA damaging agents","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada); McGill University; Montreal General Hospital","funders":"National Cancer Institute; Cancer Research Society","keywords":"Exonuclease; Molecular biology; Transfection; Nuclease; Chemistry; Gene silencing; DNA damage; DNA; DNA repair; Cisplatin; Biology; Cancer research; Biochemistry; Gene; DNA polymerase; Genetics","score_opus":0.011602185164888488,"score_gpt":0.2417345264299355,"score_spread":0.23013234126504703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000249294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958178,0.00003594627,0.0025956358,0.00019332538,0.00016591455,0.00019334345,0.000023924864,0.000030452897,0.000943663],"genre_scores_gemma":[0.9691445,0.0000037176058,0.027781012,0.0013588015,0.0002710652,0.0000036774197,0.00010254842,0.000032352305,0.0013023098],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986726,0.00004670244,0.00032049514,0.00036000562,0.00033678452,0.000263382],"domain_scores_gemma":[0.9990385,0.00004114261,0.00013291766,0.00031589824,0.000109244735,0.00036229574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031188122,0.00016892362,0.00014154187,0.000097399585,0.000068922374,0.000020643805,0.00018782937,0.00010558323,0.00004201183],"category_scores_gemma":[0.00015418883,0.00017985264,0.00008059116,0.00011716182,0.00006324145,0.000012938997,0.0001708917,0.00007354021,0.00003706532],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042934178,0.000025066249,0.00021858375,0.000015704501,0.000016662925,0.0000099536555,0.00042183173,0.00040104138,0.9933804,0.00021590773,0.0046043536,0.0006475489],"study_design_scores_gemma":[0.0003956388,0.0000692938,0.0005726587,0.000053558448,0.000010437557,0.000009539738,0.00029231593,0.00012192485,0.995445,0.00047419444,0.0023677053,0.00018769027],"about_ca_topic_score_codex":0.00006923915,"about_ca_topic_score_gemma":0.000010312108,"teacher_disagreement_score":0.026673278,"about_ca_system_score_codex":0.000028275344,"about_ca_system_score_gemma":0.00015884376,"threshold_uncertainty_score":0.73341775},"labels":[],"label_agreement":null},{"id":"W2004766935","doi":"10.1007/s10637-010-9391-9","title":"LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Calgary Laboratory Services; University of Calgary","keywords":"Western blot; Molecular biology; Cell growth; Growth inhibition; Cell culture; Chemistry; Inhibitory postsynaptic potential; Flow cytometry; Trypan blue; Cell; Biology; Biochemistry; Endocrinology","score_opus":0.013771277549352775,"score_gpt":0.2527174040191496,"score_spread":0.23894612646979682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004766935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98865825,0.000011188644,0.00026983678,0.008477779,0.00003645698,0.00034982056,0.00018097853,0.000056727582,0.0019589593],"genre_scores_gemma":[0.98585594,0.0000029452476,0.010998984,0.0016503716,0.00019798138,0.000031450363,0.0003798307,0.000040343875,0.0008421613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797904,0.00007169699,0.00045225734,0.0005690358,0.0005650601,0.00036291758],"domain_scores_gemma":[0.9985404,0.0002211023,0.00022444829,0.0002564027,0.00017229284,0.00058535364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019831766,0.000331692,0.00040654035,0.00040196665,0.00018491996,0.00008000453,0.00012261696,0.00017538769,0.0001682774],"category_scores_gemma":[0.00020557374,0.00032760107,0.00010481715,0.00056488696,0.00045244498,0.00035777286,0.0000899866,0.000629772,0.000017204931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004248908,0.0007367869,0.026933284,0.00014218155,0.00002531882,0.000041587562,0.0027766542,0.000012603491,0.9664639,0.0018493737,0.0007886467,0.00018714587],"study_design_scores_gemma":[0.0059302,0.00009597817,0.21600237,0.00025541298,0.000065012944,0.00003959933,0.0005596424,0.0009838128,0.77305585,0.0025420894,0.00010710814,0.0003629041],"about_ca_topic_score_codex":0.0032038318,"about_ca_topic_score_gemma":0.0004610426,"teacher_disagreement_score":0.19340807,"about_ca_system_score_codex":0.000046552672,"about_ca_system_score_gemma":0.00048109118,"threshold_uncertainty_score":0.9999176},"labels":[],"label_agreement":null},{"id":"W2006721545","doi":"10.1007/s10637-005-1439-x","title":"A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pharmacokinetics; Paclitaxel; Medicine; Neutropenia; Pharmacology; Toxicity; P-glycoprotein; Chemotherapy; Febrile neutropenia; Internal medicine; Multiple drug resistance; Antibiotics; Chemistry","score_opus":0.008409667718402071,"score_gpt":0.2599263105277969,"score_spread":0.25151664280939484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006721545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955471,0.000078086276,0.000018019993,0.0022359807,0.000057735888,0.0019006111,0.0000125403085,0.000015826206,0.000134088],"genre_scores_gemma":[0.9980072,0.0000036674526,0.000986625,0.00036962176,0.000050614846,0.00014821813,0.00003343796,0.000022321825,0.00037832255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984408,0.000043738375,0.0003761806,0.00025235245,0.0007043703,0.00018256072],"domain_scores_gemma":[0.9993896,0.000023270975,0.00016945733,0.00017294836,0.0001371583,0.000107571934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116302945,0.0001666624,0.0002515196,0.0001471142,0.00003625788,0.000005879819,0.00009722937,0.000040697665,0.00004142007],"category_scores_gemma":[0.000014562647,0.00010511185,0.000025405669,0.00050491455,0.00009899262,0.0001583289,0.000011145525,0.00021523984,0.000001512061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005141397,0.013774352,0.9316981,0.00015874996,0.00010017277,0.000018062687,0.012597642,0.0056328876,0.007444307,0.00052339974,0.00015973201,0.022751242],"study_design_scores_gemma":[0.09567591,0.0022786334,0.8798086,0.0012663681,0.00009700803,0.0000012009547,0.0008077495,0.0003726663,0.018507868,0.00051148137,0.0004198129,0.00025269168],"about_ca_topic_score_codex":0.00042592818,"about_ca_topic_score_gemma":0.0027746062,"teacher_disagreement_score":0.090534516,"about_ca_system_score_codex":0.00015893439,"about_ca_system_score_gemma":0.00040352505,"threshold_uncertainty_score":0.42863372},"labels":[],"label_agreement":null},{"id":"W2007480962","doi":"10.1007/s10637-013-9974-3","title":"Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research; University of Texas at El Paso; Canada Research Chairs; University Health Network","keywords":"Docetaxel; Cyclophosphamide; Medicine; Chemotherapy; Pharmacology; Oncology; Drug resistance; Bevacizumab; Nitrogen mustard; Internal medicine; Biology","score_opus":0.014270792231690093,"score_gpt":0.29993228244452186,"score_spread":0.28566149021283177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007480962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556804,0.001314477,0.0005599153,0.001757498,0.000043424385,0.00016375756,0.000042580807,0.0000061099768,0.00054417254],"genre_scores_gemma":[0.9818531,0.00009247924,0.0078469645,0.0019409145,0.00018320927,0.000035023037,0.00008181821,0.000015793912,0.007950689],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989746,0.000029528075,0.0003259624,0.00036675707,0.0001525724,0.00015054595],"domain_scores_gemma":[0.9992185,0.00004824155,0.00012740845,0.0002714228,0.00013565712,0.00019871903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014873623,0.00012633245,0.00021056135,0.00007974509,0.000046940873,0.00003333829,0.00016373889,0.00009444197,0.00015177578],"category_scores_gemma":[0.00009633432,0.00012301368,0.00013800338,0.00027147512,0.00019408672,0.000009355061,0.000050129158,0.00003683914,0.000012971835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051734137,0.00015103605,0.28047583,0.00009079854,0.0023503583,6.0387947e-7,0.0005619238,0.002573941,0.60102475,0.003768237,0.10416979,0.004315421],"study_design_scores_gemma":[0.00084081205,0.000054517106,0.836198,0.00003471819,0.00013731878,2.8244665e-7,0.000032511136,0.00017008152,0.12189814,0.0017501212,0.03856853,0.00031501483],"about_ca_topic_score_codex":0.000071475544,"about_ca_topic_score_gemma":0.0001366602,"teacher_disagreement_score":0.5557221,"about_ca_system_score_codex":0.000018908304,"about_ca_system_score_gemma":0.00016312051,"threshold_uncertainty_score":0.50163525},"labels":[],"label_agreement":null},{"id":"W2007695631","doi":"10.1007/s10637-013-9990-3","title":"Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"National Institutes of Health; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust; GlaxoSmithKline; Amgen","keywords":"Medicine; Irinotecan; Oxaliplatin; Colorectal cancer; Toxicity; Internal medicine; Gastroenterology; Phases of clinical research; Surgery; Cancer; Progression-free survival; Dexamethasone; Chemotherapy","score_opus":0.01849474570922308,"score_gpt":0.27944620998014535,"score_spread":0.26095146427092225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007695631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925952,0.00019299812,0.0000011842399,0.003909135,0.00019657372,0.0021516234,0.00020147467,0.000017487722,0.00073430844],"genre_scores_gemma":[0.9983852,0.00001880562,0.0004130814,0.00020097342,0.0000708293,0.00026503776,0.00013845717,0.000013910937,0.0004936958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844503,0.000065954955,0.00046081972,0.00026586626,0.00056557887,0.0001967437],"domain_scores_gemma":[0.9990568,0.000103201106,0.0002348524,0.00014899223,0.00030988106,0.00014626142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093231596,0.00018787148,0.00035515788,0.00007848522,0.00009836766,0.000010634558,0.00008764054,0.00003810668,0.00010558584],"category_scores_gemma":[0.00019148256,0.00010788314,0.00007126875,0.0004445422,0.00021739655,0.000102188504,0.000054388605,0.00015031068,0.0000036236536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37983325,0.013853873,0.38294017,0.00023945482,0.0023935055,0.00001847839,0.018332995,0.00029763757,0.0013023244,0.0009756385,0.042109914,0.15770273],"study_design_scores_gemma":[0.25294298,0.011701677,0.72925067,0.00047169393,0.00027355689,0.0000016087894,0.0001240649,0.00020866432,0.0032043601,0.0010262615,0.00058795186,0.00020652446],"about_ca_topic_score_codex":0.0025929783,"about_ca_topic_score_gemma":0.0005049887,"teacher_disagreement_score":0.34631047,"about_ca_system_score_codex":0.00021281285,"about_ca_system_score_gemma":0.0007393004,"threshold_uncertainty_score":0.43993467},"labels":[],"label_agreement":null},{"id":"W2011261264","doi":"10.1007/s10637-013-9979-y","title":"Ring-substituted analogs of 3,3′-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and –independent prostate cancer cells","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Synthesis of Indole Derivatives","field":"Chemistry","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Armand Frappier Museum; Institut National de la Recherche Scientifique","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Propidium iodide; Apoptosis; Programmed cell death; Cancer research; Prostate cancer; Caspase; Cell growth; Biology; Chemistry; Internal medicine; Molecular biology; Cancer; Biochemistry; Medicine","score_opus":0.015218121862387147,"score_gpt":0.23283804644190056,"score_spread":0.21761992457951343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011261264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691355,0.00075430574,0.000004300979,0.0012406005,0.000060246086,0.00028101038,0.0000770647,0.00003682158,0.00063209457],"genre_scores_gemma":[0.9972956,0.00024002002,0.0015408427,0.00018273975,0.00006852309,0.0001456254,0.00002676295,0.000033187236,0.00046670227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980026,0.000048526243,0.0005668827,0.0005325006,0.0005144384,0.00033504286],"domain_scores_gemma":[0.9986482,0.0003245225,0.00030933588,0.00024200947,0.0001467436,0.00032916237],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020367808,0.0002983802,0.00039803894,0.00020285652,0.00007115909,0.00008707641,0.00021654161,0.00018290705,0.0004952715],"category_scores_gemma":[0.00020382839,0.0003024155,0.00004817016,0.00024916008,0.00038891548,0.00043349457,0.00015029991,0.00026183797,0.000012598073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033273143,0.000073392235,0.07062547,0.00016231718,0.000098674594,0.0000023976038,0.0023290284,0.0001532189,0.91852397,0.00025292844,0.00021309468,0.0075322124],"study_design_scores_gemma":[0.0013934157,0.000010834611,0.047965504,0.0002914012,0.000028412931,0.0000063881525,0.00055194495,0.0002893114,0.94564474,0.0034514058,0.000059816553,0.00030681744],"about_ca_topic_score_codex":0.0061081774,"about_ca_topic_score_gemma":0.00015046717,"teacher_disagreement_score":0.027120754,"about_ca_system_score_codex":0.0000964315,"about_ca_system_score_gemma":0.00028953303,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W2013709636","doi":"10.1007/s10637-013-0001-5","title":"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Internal medicine; Pharmacokinetics; Pharmacology; Neutropenia; Rash; Gastroenterology; Oncology; Toxicity","score_opus":0.014508266352405094,"score_gpt":0.29920246697569053,"score_spread":0.28469420062328543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013709636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599606,0.000094612216,0.0000030986646,0.0012905181,0.00005801461,0.0024355748,0.000017075683,0.00002594345,0.00007911129],"genre_scores_gemma":[0.9976983,0.0000032490875,0.0013302623,0.00047970863,0.000046516274,0.00021211457,0.00012775781,0.000022531756,0.000079553356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983549,0.0000550941,0.0005081844,0.00029985557,0.00055695814,0.00022502408],"domain_scores_gemma":[0.9988939,0.000075752156,0.00023334668,0.00018760827,0.00023409235,0.00037529875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106946354,0.00018017,0.00034460027,0.00019630922,0.000046599656,0.0000117894815,0.000046488967,0.000046301007,0.00004019659],"category_scores_gemma":[0.00006853943,0.00014851318,0.000017975113,0.00030921653,0.00011726392,0.000250875,0.00002658414,0.00014039608,0.000010412012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088442577,0.007212808,0.96893084,0.00020519692,0.00006213302,0.000014527969,0.0043626213,0.00009620615,0.00036756435,0.00016793612,0.0005152908,0.017180441],"study_design_scores_gemma":[0.055913992,0.009598765,0.92972636,0.00045444042,0.000054540622,0.0000045022543,0.0006647162,0.00045312982,0.0013215054,0.001585115,0.000051845294,0.00017107622],"about_ca_topic_score_codex":0.0010431111,"about_ca_topic_score_gemma":0.00007208271,"teacher_disagreement_score":0.055029567,"about_ca_system_score_codex":0.00023450865,"about_ca_system_score_gemma":0.00046820246,"threshold_uncertainty_score":0.6056192},"labels":[],"label_agreement":null},{"id":"W2014271351","doi":"10.1007/s10637-006-9021-8","title":"A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Irinotecan; Medicine; Pharmacology; Pharmacokinetics; Tolerability; Active metabolite; SN-38; Chemotherapy; Oral administration; Internal medicine; Cancer; Adverse effect; Colorectal cancer","score_opus":0.007061497655436181,"score_gpt":0.23943923806344042,"score_spread":0.23237774040800424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014271351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992067,0.000012275238,0.00003531743,0.00015411997,0.00002185013,0.0004529162,0.000013163477,0.000007666553,0.000095990785],"genre_scores_gemma":[0.99883455,4.8100867e-7,0.0006068118,0.00006363877,0.000028729824,0.00003178979,0.00036270652,0.000020489428,0.000050821527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889016,0.00007707227,0.000274483,0.00028595305,0.00030140276,0.00017095452],"domain_scores_gemma":[0.9995093,0.000009765446,0.0001482157,0.00014107204,0.00012131569,0.000070329996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095222735,0.00015347319,0.00016733026,0.00015155095,0.000028051885,0.00001314303,0.00011912167,0.00006998335,0.0000059620766],"category_scores_gemma":[0.000025395893,0.00013411893,0.000015016209,0.00031393842,0.00010096895,0.00001935062,0.00003293358,0.00010932054,0.0000012015552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064426125,0.003912312,0.9502208,0.0000092731625,0.000030330984,0.0000027318501,0.0004622681,0.0027947235,0.041219275,0.00005637399,0.000254918,0.00039271012],"study_design_scores_gemma":[0.03105598,0.0059246975,0.685314,0.00008203804,0.000018991985,0.0000019778333,0.0003841491,0.00016064287,0.27606806,0.00045274792,0.00015847193,0.00037823772],"about_ca_topic_score_codex":0.00079154014,"about_ca_topic_score_gemma":0.00061688625,"teacher_disagreement_score":0.2649068,"about_ca_system_score_codex":0.000053624113,"about_ca_system_score_gemma":0.00027106708,"threshold_uncertainty_score":0.54692113},"labels":[],"label_agreement":null},{"id":"W2014952173","doi":"10.1007/s10637-007-9098-8","title":"Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Neutropenia; Leukopenia; Chemotherapy; Internal medicine; Gastroenterology; Head and neck squamous-cell carcinoma; Adverse effect; Phases of clinical research; Oncology; Surgery; Head and neck cancer; Radiation therapy","score_opus":0.020606124122446463,"score_gpt":0.2880066215949376,"score_spread":0.26740049747249117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014952173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990324,0.00032127355,0.000054159133,0.00009957136,0.00005835833,0.00032430768,0.000019334218,0.0000013408777,0.00008926641],"genre_scores_gemma":[0.998744,0.000007465935,0.0007647497,0.00014382775,0.000039124025,0.0000051987026,0.000028352068,0.000008263204,0.0002590176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922407,0.00003974715,0.00031858106,0.00017254964,0.00013437077,0.00011068945],"domain_scores_gemma":[0.9995424,0.000025269368,0.00013585153,0.00017605393,0.00005677816,0.00006361669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016627215,0.0000971511,0.000128844,0.00004578087,0.000038106118,0.0000031870993,0.00012120547,0.000039407027,0.0000054745915],"category_scores_gemma":[0.000069063455,0.00007114889,0.000033665423,0.00014178875,0.000093197166,0.0000033428655,0.00009674988,0.00005958027,2.4742153e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044852775,0.003503898,0.046415396,0.00012952062,0.0000292503,0.0000047366552,0.0034798284,0.00015605899,0.9408886,0.00024420884,0.001090381,0.0036096177],"study_design_scores_gemma":[0.015490507,0.0072185323,0.10157877,0.0000637133,0.00008742405,0.000018856912,0.001655006,0.00040624663,0.8708983,0.00062116707,0.0016478208,0.00031367273],"about_ca_topic_score_codex":0.00025408895,"about_ca_topic_score_gemma":0.0007660672,"teacher_disagreement_score":0.06999029,"about_ca_system_score_codex":0.000008911001,"about_ca_system_score_gemma":0.00020163419,"threshold_uncertainty_score":0.29013675},"labels":[],"label_agreement":null},{"id":"W2015395716","doi":"10.1007/s10637-013-0024-y","title":"Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; University of California, Davis; Celgene; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Paclitaxel; Progressive disease; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Cisplatin","score_opus":0.01173629540340306,"score_gpt":0.31101612161331627,"score_spread":0.2992798262099132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015395716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393785,0.00010830779,0.000030855324,0.0018930527,0.0001944268,0.0022833652,0.000106682695,0.000023227107,0.0014222352],"genre_scores_gemma":[0.9925596,0.000009617072,0.003710683,0.0011644827,0.00014382915,0.0005422651,0.0002842053,0.000033382465,0.0015519343],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99852175,0.00002256387,0.00042135984,0.00032345494,0.0004665033,0.00024436842],"domain_scores_gemma":[0.9989093,0.000083494,0.00024491097,0.00021190722,0.00026835775,0.000282027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005029884,0.00021784488,0.00035972358,0.0002104747,0.000078402256,0.00001427651,0.000084069565,0.0000510788,0.00022925035],"category_scores_gemma":[0.0000671923,0.00016985304,0.00007297858,0.00036049503,0.000091807684,0.00018438818,0.000022612301,0.0001304519,0.000015850997],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15456094,0.08407237,0.37571278,0.0035686807,0.0044055087,0.00018993884,0.091647446,0.05145025,0.033849802,0.0038841139,0.0723802,0.124277964],"study_design_scores_gemma":[0.8576228,0.012604273,0.09753645,0.0020517437,0.00072879565,0.0000025259728,0.00064245355,0.001721243,0.023672957,0.001422346,0.001312381,0.0006820297],"about_ca_topic_score_codex":0.002747319,"about_ca_topic_score_gemma":0.00012028539,"teacher_disagreement_score":0.7030619,"about_ca_system_score_codex":0.0005517197,"about_ca_system_score_gemma":0.0021399516,"threshold_uncertainty_score":0.6926406},"labels":[],"label_agreement":null},{"id":"W2015941325","doi":"10.1007/s10637-010-9494-3","title":"Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Oxaliplatin; Cisplatin; Cytoplasm; Liposome; Chemistry; DNA; Cancer cell; Intracellular; Cytotoxicity; Cancer research; Pharmacology; Molecular biology; Biochemistry; Biology; Colorectal cancer; Cancer; Chemotherapy; In vitro","score_opus":0.02019884188833627,"score_gpt":0.24187397622232024,"score_spread":0.22167513433398398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015941325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982363,0.00048472543,0.000022183232,0.00046376523,0.00004582607,0.00024717447,0.000055893808,0.000011611979,0.0004324962],"genre_scores_gemma":[0.99873334,0.000027494747,0.0007443586,0.00006080232,0.00010295907,0.0000122849815,0.00014443579,0.000010981768,0.00016334925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991887,0.0000314457,0.00030767705,0.00019910479,0.00015412837,0.00011893358],"domain_scores_gemma":[0.99949867,0.00011926232,0.00011640284,0.000074565716,0.00005576004,0.00013531672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020114776,0.00013465657,0.00023052651,0.00004510815,0.00008577827,0.00002210954,0.000030234316,0.000095327436,0.0000671372],"category_scores_gemma":[0.00007743539,0.00010619944,0.00002380249,0.000071724746,0.00017759542,0.00014826853,0.000037320533,0.0001465527,5.652364e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006216355,0.000022236594,0.057843216,0.00009002427,0.000010765139,5.293976e-7,0.0010529506,0.0000038634407,0.9337219,0.005434594,0.000050934952,0.0017068032],"study_design_scores_gemma":[0.0009440659,0.00010775382,0.45031455,0.00010102536,0.000026254125,0.0000134477805,0.00011395962,0.0031819986,0.53974295,0.0047728405,0.00056281366,0.00011836769],"about_ca_topic_score_codex":0.0006926689,"about_ca_topic_score_gemma":0.0004605994,"teacher_disagreement_score":0.39397898,"about_ca_system_score_codex":0.000019897128,"about_ca_system_score_gemma":0.00009295631,"threshold_uncertainty_score":0.43306875},"labels":[],"label_agreement":null},{"id":"W2016664719","doi":"10.1007/s10637-008-9193-5","title":"Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Paclitaxel; Neutropenia; Pharmacokinetics; Febrile neutropenia; Mesothelioma; Pharmacology; Toxicity; Internal medicine; Chemotherapy; Oncology; Cisplatin; Pathology","score_opus":0.11158738678637896,"score_gpt":0.3833905561850204,"score_spread":0.2718031693986414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016664719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480695,0.00014715528,0.000012018286,0.0028868865,0.00008706106,0.0010656279,0.0000044951944,0.000072541465,0.0009172933],"genre_scores_gemma":[0.993434,0.0000049961045,0.0047037397,0.0006928964,0.00023517212,0.00013018891,0.00006701876,0.000029112603,0.0007028486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832207,0.000086251835,0.0003800204,0.00034773417,0.00058022153,0.00028370548],"domain_scores_gemma":[0.9990903,0.00024288207,0.00014084275,0.00016584822,0.00011006296,0.00025006328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030208347,0.00021246006,0.00038590253,0.00026222935,0.0001566024,0.000013451102,0.000088170156,0.00004892176,0.0002559149],"category_scores_gemma":[0.00014746426,0.0001760969,0.000051834646,0.00057079317,0.00018976077,0.0001290565,0.000035261495,0.00024638642,0.000040480678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010208545,0.00074094656,0.98841,0.00002477751,0.0001880022,0.00023820088,0.0044299862,0.000341088,0.0024818871,0.00069951196,0.00064983603,0.0007749069],"study_design_scores_gemma":[0.019886594,0.0035676737,0.9683311,0.00020057199,0.00017180292,0.00010305159,0.00086223497,0.001749078,0.00133672,0.0035076889,0.000045550296,0.00023790664],"about_ca_topic_score_codex":0.00073252636,"about_ca_topic_score_gemma":0.0005584456,"teacher_disagreement_score":0.020078877,"about_ca_system_score_codex":0.0002211689,"about_ca_system_score_gemma":0.0012434205,"threshold_uncertainty_score":0.7181023},"labels":[],"label_agreement":null},{"id":"W2019711560","doi":"10.1007/s10637-006-9002-y","title":"A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada); Royal Victoria Hospital; BC Cancer Agency; CancerCare Manitoba; University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Tolerability; Nausea; Vomiting; Chemotherapy; Doxorubicin; Melanoma; Internal medicine; Phases of clinical research; Oncology; Gastroenterology; Surgery; Adverse effect","score_opus":0.02426473383952529,"score_gpt":0.27331842390370087,"score_spread":0.24905369006417558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019711560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980259,0.000037371785,0.000025351406,0.000345927,0.00007019831,0.0013019571,0.00007220342,0.00003146622,0.00008962966],"genre_scores_gemma":[0.99344504,3.1204306e-7,0.00586053,0.00028771668,0.00003912067,0.00007997617,0.0000487839,0.000027774578,0.00021071997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976806,0.00020615828,0.0006586904,0.00043726788,0.0007128069,0.00030444286],"domain_scores_gemma":[0.9989303,0.00013461019,0.0003116458,0.00032927896,0.00015398745,0.00014022145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040376105,0.00022033135,0.00036345606,0.00016832123,0.00010784106,0.00008783082,0.00049776566,0.000030977888,0.00019292884],"category_scores_gemma":[0.000033174834,0.00018039624,0.000018708626,0.0005035078,0.00014837812,0.00058166677,0.00014352985,0.00007699657,0.000037705977],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031555064,0.034944687,0.15803136,0.00003956423,0.00008726558,0.00005957428,0.0060314448,0.005760163,0.78392833,0.0043566027,0.0022810479,0.0013244833],"study_design_scores_gemma":[0.11423967,0.013697183,0.09059591,0.00027150274,0.00013836172,0.000004906702,0.0006282038,0.0013223202,0.76706445,0.010922991,0.00021417107,0.000900307],"about_ca_topic_score_codex":0.00527905,"about_ca_topic_score_gemma":0.00054484996,"teacher_disagreement_score":0.11108416,"about_ca_system_score_codex":0.00008665666,"about_ca_system_score_gemma":0.00042535746,"threshold_uncertainty_score":0.798038},"labels":[],"label_agreement":null},{"id":"W2019787838","doi":"10.1007/s10637-011-9769-3","title":"Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Imatinib; Imatinib mesylate; Renal function; Creatinine; Discontinuation; Urology; Pharmacology; Internal medicine; Dosing; Gastroenterology","score_opus":0.03023631602534122,"score_gpt":0.2436660946716437,"score_spread":0.2134297786463025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019787838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996471,0.00007053856,0.000084999665,0.00084242213,0.00001536253,0.00043355112,0.00002502775,0.00003978025,0.0020173513],"genre_scores_gemma":[0.9911579,0.000011314421,0.008107402,0.00014176943,0.00004615217,0.000047364163,0.00022712548,0.000014950209,0.0002460085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987993,0.000036598994,0.00026211853,0.00027167992,0.00038500002,0.00024528627],"domain_scores_gemma":[0.99924725,0.0000471942,0.000072704395,0.00010688135,0.00008210971,0.0004438609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008041157,0.00017068085,0.00019915978,0.0001461436,0.00004304532,0.000011378775,0.000033334567,0.000027040394,0.00015617885],"category_scores_gemma":[0.000039365073,0.00012241173,0.000031131618,0.00020735516,0.00017183498,0.00010024351,0.000012019867,0.00018261177,0.000019072257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041327695,0.0007587919,0.9666073,0.000093055736,0.00016425407,0.002056778,0.003724896,0.000023855817,0.0069464864,0.0029416115,0.0007724208,0.011777784],"study_design_scores_gemma":[0.010683275,0.004358233,0.95699584,0.0011743726,0.0001213569,0.002563479,0.00014246361,0.0004867514,0.020686083,0.002182777,0.00036707043,0.0002383191],"about_ca_topic_score_codex":0.0009957306,"about_ca_topic_score_gemma":0.000098136166,"teacher_disagreement_score":0.013739596,"about_ca_system_score_codex":0.00007954994,"about_ca_system_score_gemma":0.0002904697,"threshold_uncertainty_score":0.49918056},"labels":[],"label_agreement":null},{"id":"W2019837162","doi":"10.1007/s10637-014-0169-3","title":"A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Bevacizumab; Mucositis; Discontinuation; Internal medicine; Interim analysis; Gastroenterology; Sorafenib; Hepatocellular carcinoma; Phases of clinical research; Clinical endpoint; Progression-free survival; Surgery; Toxicity; Clinical trial; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.0276207536430723,"score_gpt":0.24154964911411808,"score_spread":0.21392889547104577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019837162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669445,0.0000913575,0.00004842033,0.0007386092,0.000093599025,0.0014947217,0.000021712654,0.000036961635,0.00078020076],"genre_scores_gemma":[0.9962184,0.000002305428,0.0024389485,0.00024104216,0.00016793549,0.00008736914,0.0005033292,0.00003529199,0.00030539502],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809444,0.00008416642,0.0005161559,0.00036568215,0.00066289544,0.00027663133],"domain_scores_gemma":[0.9988712,0.000100337944,0.00020604752,0.0003214132,0.00016250303,0.00033851495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018688705,0.00025248688,0.00050417276,0.00023268162,0.00007238749,0.000009698931,0.00010508439,0.000110727284,0.00006317124],"category_scores_gemma":[0.00012841068,0.00020988673,0.000114984985,0.00037769973,0.00014300173,0.00014161672,0.000039726394,0.00016269357,0.000015722213],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03379832,0.0023174027,0.95013195,0.000086182175,0.000083141895,0.000024531477,0.001167352,0.000017722461,0.0006441148,0.0009113421,0.00022805002,0.010589896],"study_design_scores_gemma":[0.81747484,0.026298635,0.12032626,0.00039000085,0.00036135138,0.0000093749995,0.00005613058,0.013182047,0.015427443,0.0022547103,0.0036257966,0.00059342175],"about_ca_topic_score_codex":0.00020918043,"about_ca_topic_score_gemma":0.000008596011,"teacher_disagreement_score":0.8298057,"about_ca_system_score_codex":0.00014829068,"about_ca_system_score_gemma":0.00070565206,"threshold_uncertainty_score":0.85589325},"labels":[],"label_agreement":null},{"id":"W2020555572","doi":"10.1007/s10637-013-0055-4","title":"Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"U.S. Food and Drug Administration; GlaxoSmithKline","keywords":"Lapatinib; Pharmacokinetics; Cmax; Medicine; Meal; Tolerability; Pharmacology; Internal medicine; Gastroenterology; Adverse effect; Cancer; Breast cancer; Trastuzumab","score_opus":0.0052637587914176305,"score_gpt":0.2631291230371833,"score_spread":0.25786536424576567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020555572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979241,0.00006894345,0.0000115395815,0.00065073074,0.00006108776,0.00093241327,0.000034864992,0.0000115650655,0.00030475928],"genre_scores_gemma":[0.99680156,0.000014879464,0.0021566907,0.00048905436,0.00003131623,0.00005656583,0.00010542317,0.000018210942,0.00032631285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990535,0.00002744965,0.00027306814,0.00017435268,0.00033867225,0.00013300077],"domain_scores_gemma":[0.9991973,0.00017154079,0.00017930462,0.00009740559,0.00019119921,0.0001632695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000025163976,0.00013433804,0.00025742725,0.00011377134,0.000019875648,0.0000057488774,0.000039557508,0.00002785,0.000037731217],"category_scores_gemma":[0.0000555253,0.00010203848,0.000021213877,0.00015966845,0.00012674276,0.000112909656,0.0000140123775,0.00007558187,0.000008064832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019667414,0.0031378046,0.83964086,0.0026223725,0.0008887839,0.000022832432,0.013345599,0.009634717,0.073339865,0.0039699636,0.0071566263,0.04427384],"study_design_scores_gemma":[0.013508864,0.00091433496,0.8480159,0.00092010846,0.0001324183,5.6549567e-7,0.00004953848,0.00013581636,0.1337522,0.0024107029,0.00003284818,0.00012673615],"about_ca_topic_score_codex":0.00026487018,"about_ca_topic_score_gemma":0.000007886572,"teacher_disagreement_score":0.060412325,"about_ca_system_score_codex":0.00005539643,"about_ca_system_score_gemma":0.00013611375,"threshold_uncertainty_score":0.41610086},"labels":[],"label_agreement":null},{"id":"W2021908659","doi":"10.1007/s10637-005-2903-3","title":"An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Ontario Institute for Cancer Research; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Pharmacokinetics; Medicine; Doxorubicin; Tolerability; Dosing; Pharmacology; Toxicity; Chemotherapy; Stomatitis; Internal medicine; Adverse effect","score_opus":0.011232256567179634,"score_gpt":0.27975450958306297,"score_spread":0.26852225301588334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021908659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975907,0.00009117818,0.00035183638,0.0007054188,0.000076034805,0.0010704072,0.000011839308,0.000013704319,0.00008884964],"genre_scores_gemma":[0.99765,0.000003314893,0.001231569,0.00030976304,0.0003342039,0.00008011091,0.00013066795,0.000022727165,0.00023762311],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853504,0.00017905101,0.00036467868,0.00033692876,0.00041678443,0.00016753847],"domain_scores_gemma":[0.9992375,0.000012217005,0.00020043204,0.00031249598,0.000107327454,0.00013005287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002805621,0.0001817183,0.00014822719,0.00008757183,0.00007722536,0.000023005749,0.00021367136,0.00008890065,0.00003212305],"category_scores_gemma":[0.000047043897,0.00014049248,0.000046804264,0.00022994899,0.00007830551,0.00004128448,0.00005427388,0.00013078519,0.0000051329976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026346344,0.0012553054,0.0010820051,0.000011197713,0.000028757793,0.0000016641213,0.0004975807,0.0023045414,0.99209297,0.00043178533,0.0002532646,0.0017774687],"study_design_scores_gemma":[0.007701386,0.0012944211,0.003021779,0.000041024814,0.00004494577,0.000005773344,0.00017738245,0.0023919162,0.98324233,0.0010092974,0.0008700608,0.0001996594],"about_ca_topic_score_codex":0.00012285363,"about_ca_topic_score_gemma":0.00022877195,"teacher_disagreement_score":0.008850613,"about_ca_system_score_codex":0.000038995233,"about_ca_system_score_gemma":0.0002438166,"threshold_uncertainty_score":0.57291174},"labels":[],"label_agreement":null},{"id":"W2024080866","doi":"10.1007/s10637-007-9045-8","title":"Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of California, Davis","keywords":"Vinorelbine; Erlotinib; Medicine; Internal medicine; Vinca alkaloid; Neutropenia; Febrile neutropenia; Oncology; Lung cancer; Mucositis; Epidermal growth factor receptor; Combination therapy; Pharmacology; Chemotherapy; Gastroenterology; Cancer; Vincristine; Cisplatin","score_opus":0.01803718802920216,"score_gpt":0.3682471109087651,"score_spread":0.35020992287956293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024080866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949812,0.00022987669,0.000081109596,0.0022218877,0.000067238885,0.0008385699,0.00001371624,0.00003988037,0.0015264824],"genre_scores_gemma":[0.99397874,0.0000060515968,0.0033596554,0.00097937,0.00014426826,0.00003847176,0.00007864486,0.000016639093,0.0013981339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989213,0.00001590869,0.00033817248,0.00026097996,0.00026192606,0.00020176035],"domain_scores_gemma":[0.9993567,0.00008539589,0.00007479016,0.00012810984,0.000063156476,0.0002918492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019431653,0.0001318896,0.00020777747,0.00016055326,0.000057348127,0.000014494992,0.000037600563,0.0000308122,0.000054838772],"category_scores_gemma":[0.0000884152,0.00011175622,0.000026001326,0.0002597463,0.000072920906,0.00011641736,0.000020216146,0.000099282275,0.000015405376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018168164,0.00793179,0.7901825,0.00017442196,0.0005842685,0.0016086777,0.045997497,0.00032977914,0.030541325,0.01276678,0.004001641,0.10406455],"study_design_scores_gemma":[0.042453885,0.0024197195,0.92896396,0.000511535,0.00027143804,0.00017126834,0.0066172895,0.00038030566,0.0071273344,0.007569523,0.003111666,0.0004020646],"about_ca_topic_score_codex":0.00033521044,"about_ca_topic_score_gemma":0.00013538281,"teacher_disagreement_score":0.13878152,"about_ca_system_score_codex":0.000117163545,"about_ca_system_score_gemma":0.000416456,"threshold_uncertainty_score":0.45572865},"labels":[],"label_agreement":null},{"id":"W2024677994","doi":"10.1007/s10637-009-9222-z","title":"N-4-iodophenyl-N′-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"","keywords":"In vivo; Biodistribution; Pharmacology; Potency; Chemistry; Colorectal cancer; Pharmacokinetics; Medicine; In vitro; Cancer; Biochemistry; Internal medicine; Biology","score_opus":0.08898249194808416,"score_gpt":0.3413369859002879,"score_spread":0.2523544939522037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024677994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738637,0.00025199738,0.0049378397,0.018847054,0.00003247537,0.00072568643,0.00008456923,0.000060836224,0.0011958119],"genre_scores_gemma":[0.99108535,0.00003879269,0.0072172787,0.0006980592,0.00027396984,0.000046024423,0.00034962187,0.000006288725,0.0002846095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987555,0.000020292733,0.00030194828,0.0003573671,0.00036928515,0.00019562073],"domain_scores_gemma":[0.9992713,0.000065380955,0.00010899124,0.0001346863,0.00014077323,0.00027891647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011414774,0.00017961883,0.00023411715,0.00007618968,0.00012976339,0.000048539965,0.00006215581,0.000092388116,0.000114316375],"category_scores_gemma":[0.000023957562,0.00016291435,0.000034392375,0.00042318655,0.0002731421,0.00018997205,0.000010641232,0.00020961474,0.000009070064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012662631,0.0008482676,0.009728285,0.00009765328,0.000097291326,0.000027882046,0.0016777162,0.0029366484,0.8866994,0.0840184,0.009032566,0.0035696428],"study_design_scores_gemma":[0.01144681,0.00041054876,0.38790888,0.00039716196,0.00017157155,0.0003436141,0.00035241275,0.019061854,0.537021,0.007860682,0.034320474,0.00070498587],"about_ca_topic_score_codex":0.00001682876,"about_ca_topic_score_gemma":0.0000016499773,"teacher_disagreement_score":0.3781806,"about_ca_system_score_codex":0.0001769394,"about_ca_system_score_gemma":0.00024107781,"threshold_uncertainty_score":0.66434544},"labels":[],"label_agreement":null},{"id":"W2025486703","doi":"10.1007/s10637-005-1157-4","title":"Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Hôpital Notre-Dame; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Nausea; Toxicity; Gastroenterology; Internal medicine; Chemotherapy; Surgery; Progressive disease","score_opus":0.011628574128180441,"score_gpt":0.265100812633515,"score_spread":0.2534722385053345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025486703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891174,0.00021537878,0.000037242266,0.0001989625,0.000028758657,0.00043159715,0.000031102525,0.000008568661,0.00013663496],"genre_scores_gemma":[0.99698293,0.0000033052097,0.0020070046,0.00024569503,0.00009635731,0.000035392848,0.0002838779,0.00002081034,0.0003246546],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988939,0.00006428919,0.00030999337,0.00028726546,0.00028045705,0.00016405049],"domain_scores_gemma":[0.9993787,0.000017644878,0.00014700099,0.00021363863,0.00013427534,0.000108759166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010556159,0.00015394976,0.00017403308,0.00006972648,0.0000426606,0.0000088844145,0.00014709748,0.000043174554,0.000055557495],"category_scores_gemma":[0.00006446166,0.0001345058,0.000027388722,0.00018847991,0.00008664232,0.000010473877,0.00004893775,0.000067154426,0.0000039862794],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040719593,0.02703854,0.5959895,0.00017614049,0.00157098,0.000026179392,0.018106867,0.027798368,0.27201232,0.0007038617,0.015539399,0.03696586],"study_design_scores_gemma":[0.14704448,0.060080063,0.15025982,0.00057943113,0.0006617953,0.000027211783,0.0012288174,0.0026063656,0.6030514,0.00108794,0.030936984,0.0024356851],"about_ca_topic_score_codex":0.00015666791,"about_ca_topic_score_gemma":0.00020522843,"teacher_disagreement_score":0.4457297,"about_ca_system_score_codex":0.000039159517,"about_ca_system_score_gemma":0.000299007,"threshold_uncertainty_score":0.54849875},"labels":[],"label_agreement":null},{"id":"W2025697283","doi":"10.1007/s10637-015-0216-8","title":"The oncolytic virus, pelareorep, as a novel anticancer agent: a review","year":2015,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Oncolytic virus; Virus; Virology; Medicine","score_opus":0.0784854877160039,"score_gpt":0.3969353303191214,"score_spread":0.31844984260311754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025697283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029155572,0.9946277,0.000014090943,0.0015318928,0.00022589555,0.0014403575,0.00016100396,0.000021211754,0.0019486865],"genre_scores_gemma":[0.000002906106,0.9838077,0.0002259503,0.003225015,0.0011776702,0.0003462132,0.0011099012,0.0001074416,0.00999724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966372,0.00035329364,0.0007582789,0.000743,0.0010059506,0.00050226384],"domain_scores_gemma":[0.9974876,0.00014525701,0.00042690797,0.0010413394,0.00034575537,0.00055312534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013921729,0.0005267636,0.0008837678,0.00007455956,0.00022571367,0.00010336026,0.0010719006,0.00032969084,0.00012994991],"category_scores_gemma":[0.000802878,0.00037153278,0.00052118633,0.0004674614,0.00045882285,0.000006914894,0.00031233573,0.00047557833,0.0007299729],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010464257,0.00006662483,5.954327e-7,0.005815764,0.00056805596,0.000008586281,0.000035778772,0.0000041718954,0.00037948342,0.0009943758,0.25515875,0.7368632],"study_design_scores_gemma":[0.00031513802,0.00038095686,3.1913223e-7,0.0077243336,0.0002866104,0.00007758089,0.000003868929,0.0000038809785,0.00017463446,0.0010486954,0.9895688,0.00041514362],"about_ca_topic_score_codex":0.000075174656,"about_ca_topic_score_gemma":0.00009216208,"teacher_disagreement_score":0.73644805,"about_ca_system_score_codex":0.00020216509,"about_ca_system_score_gemma":0.009960625,"threshold_uncertainty_score":0.99987364},"labels":[],"label_agreement":null},{"id":"W2026940417","doi":"10.1007/s10637-014-0139-9","title":"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Oncology; Maximum tolerated dose; Internal medicine; Pharmacology; Chemotherapy; Cisplatin; Cancer; Gefitinib","score_opus":0.008347684921314954,"score_gpt":0.287026971593901,"score_spread":0.27867928667258607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026940417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967986,0.000016724118,0.000108319146,0.00087711576,0.000052886633,0.0013086699,0.000023800556,0.000025643287,0.00078825495],"genre_scores_gemma":[0.99498236,0.0000018266035,0.0038495513,0.00026446997,0.00006324477,0.00007253327,0.0004912412,0.000021606169,0.00025318752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879026,0.000043803277,0.00035929636,0.0002501177,0.00040514919,0.00015134006],"domain_scores_gemma":[0.9990942,0.00012515877,0.00024296362,0.00015035862,0.00019405154,0.00019325627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010328247,0.00016294986,0.00035457735,0.00014797608,0.000045787932,0.000013051252,0.000038142414,0.00004148117,0.000024736219],"category_scores_gemma":[0.00013965224,0.00011854089,0.000026371332,0.00029414342,0.00015484157,0.00017725676,0.000010670977,0.000089609304,0.0000019914798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23266467,0.009815691,0.61908597,0.00032747112,0.0007427132,0.000017637278,0.007818139,0.001481861,0.0021206671,0.0062449137,0.000883728,0.11879651],"study_design_scores_gemma":[0.46235976,0.012823208,0.5202831,0.0004723674,0.00022144085,0.0000023255882,0.0001218243,0.0010464207,0.00097407727,0.0013182241,0.00017064725,0.00020659855],"about_ca_topic_score_codex":0.0001013081,"about_ca_topic_score_gemma":0.000039749593,"teacher_disagreement_score":0.22969508,"about_ca_system_score_codex":0.00006668798,"about_ca_system_score_gemma":0.0003916533,"threshold_uncertainty_score":0.48339573},"labels":[],"label_agreement":null},{"id":"W2027376895","doi":"10.1007/s10637-005-2904-2","title":"A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Hôpital Notre-Dame; BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Cmax; Cardiotoxicity; Toxicity; Refractory (planetary science); Cancer; Internal medicine; Lethargy; Neutropenia; Gastroenterology","score_opus":0.07668926564023175,"score_gpt":0.42262326365263103,"score_spread":0.34593399801239927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027376895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957367,0.00028944353,0.0000035833941,0.0017089781,0.00048689367,0.0011480906,0.00021830427,0.000009583825,0.0003984087],"genre_scores_gemma":[0.9967948,0.00003427455,0.0006495861,0.0012498769,0.0005278363,0.00011207347,0.00021250886,0.000017271312,0.00040176345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708927,0.00022466166,0.0011857905,0.00034871488,0.00094201573,0.00020952366],"domain_scores_gemma":[0.99791026,0.0005437589,0.0007305128,0.00014382126,0.00040324213,0.000268392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006954065,0.00020162915,0.0007493304,0.00016106118,0.000045096236,0.0000037094865,0.0001172532,0.00008555208,0.00025092362],"category_scores_gemma":[0.0004304099,0.00017246221,0.000069718284,0.00035618068,0.00020373655,0.00026948666,0.000028217964,0.00027457406,0.0000011176601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015476694,0.010197279,0.88637465,0.00012626454,0.0012688763,0.000027595537,0.0028458266,0.008920537,0.0009401907,0.0002070781,0.03057843,0.04303659],"study_design_scores_gemma":[0.11129668,0.005199694,0.85046417,0.00047980167,0.00042033373,0.0000020051523,0.00026890542,0.00027181007,0.0010655792,0.0002320999,0.029945249,0.0003536616],"about_ca_topic_score_codex":0.13910761,"about_ca_topic_score_gemma":0.32032427,"teacher_disagreement_score":0.18121666,"about_ca_system_score_codex":0.0013705174,"about_ca_system_score_gemma":0.011562888,"threshold_uncertainty_score":0.9940406},"labels":[],"label_agreement":null},{"id":"W2028540870","doi":"10.1007/s10637-009-9332-7","title":"Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"Louisiana Board of Regents; Ohio Board of Regents","keywords":"Resveratrol; Cardiotoxicity; Medicine; Pharmacology; Hepatocellular carcinoma; Carcinogen; Liver cancer; Carcinogenesis; Cancer; Internal medicine; Toxicity; Chemistry; Biochemistry","score_opus":0.0273199683245389,"score_gpt":0.2657664345778118,"score_spread":0.2384464662532729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028540870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290574,0.0008219368,0.00018804135,0.0044680517,0.00006517365,0.0006321397,0.000021202402,0.000016415876,0.0008812891],"genre_scores_gemma":[0.99389756,0.000040887506,0.0041216575,0.00093373994,0.00027805066,0.000011758605,0.000036474536,0.000014681819,0.00066521455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978641,0.00005770695,0.00066310196,0.00035930268,0.00083553616,0.00022021112],"domain_scores_gemma":[0.9988518,0.000064240405,0.00022238081,0.00036677063,0.00026896666,0.00022588937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043538868,0.00019691962,0.00060207484,0.00023014712,0.000028852437,0.0000057271336,0.00013902194,0.00011993774,0.000028459204],"category_scores_gemma":[0.0003080855,0.00016623465,0.00016750924,0.00037254422,0.00021470834,0.00008904312,0.00003065257,0.00026368836,0.00000240145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006309526,0.00043013925,0.14998475,0.00021624714,0.00008676434,0.000039899853,0.0032079911,0.007231058,0.8314653,0.0032659937,0.002081887,0.0013590314],"study_design_scores_gemma":[0.0046182796,0.00048173653,0.16520399,0.00064987334,0.00015279578,0.000031416104,0.00021051224,0.045375273,0.77403504,0.00893294,0.00008369201,0.00022446248],"about_ca_topic_score_codex":0.00029364767,"about_ca_topic_score_gemma":0.0000036165095,"teacher_disagreement_score":0.05743025,"about_ca_system_score_codex":0.00009945027,"about_ca_system_score_gemma":0.00087942864,"threshold_uncertainty_score":0.67788523},"labels":[],"label_agreement":null},{"id":"W2028577286","doi":"10.1007/s10637-009-9279-8","title":"Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute","keywords":"Viral shedding; Medicine; Viral load; Neutralizing antibody; Virology; Antibody; Virus; Viral replication; Chemotherapy; Oncolytic virus; Immunology; Internal medicine","score_opus":0.01033617842663142,"score_gpt":0.2731821496401648,"score_spread":0.26284597121353337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028577286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980139,0.00009153695,0.00007788435,0.0011331147,0.000014903904,0.0003893256,0.000036794623,0.000007644964,0.00023486109],"genre_scores_gemma":[0.9961183,0.000025676429,0.0020000166,0.001029318,0.00006474605,0.000016763212,0.000603847,0.000014173626,0.0001271603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986335,0.000062340114,0.0003503884,0.00038963012,0.0003780204,0.00018612198],"domain_scores_gemma":[0.9990211,0.000014229549,0.00019975626,0.0004076894,0.00022626617,0.00013092361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001580831,0.00014282177,0.00015892548,0.00008283729,0.000044769044,0.00001323882,0.00017347893,0.000076677265,0.000030752435],"category_scores_gemma":[0.00007708716,0.00014001362,0.000040128965,0.00019534047,0.00011332491,0.000013067149,0.000020538433,0.00010036699,0.000010149133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063252407,0.0005493256,0.0050181574,0.000019311174,0.000057481146,0.0000029368,0.0008071093,0.0013636838,0.95715773,0.0003398225,0.0006718562,0.027687332],"study_design_scores_gemma":[0.0017359416,0.005606478,0.11217026,0.000060832284,0.000007833864,0.0000024865358,0.00003681834,0.00012556082,0.8778436,0.0019927518,0.00022190911,0.00019548816],"about_ca_topic_score_codex":0.000037458944,"about_ca_topic_score_gemma":0.00008433563,"teacher_disagreement_score":0.1071521,"about_ca_system_score_codex":0.00004896632,"about_ca_system_score_gemma":0.00060239824,"threshold_uncertainty_score":0.57095903},"labels":[],"label_agreement":null},{"id":"W2031256158","doi":"10.1007/s10637-014-0187-1","title":"In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Centre Hospitalier Universitaire de Québec","keywords":"Selective estrogen receptor modulator; Steroid sulfatase; Estrogen receptor; Chemistry; Estrogen; Pharmacology; Raloxifene; Cell growth; Antiestrogen; Alkaline phosphatase; Estrogen receptor alpha; Steroid; Endocrinology; Internal medicine; Biochemistry; Hormone; Biology; Medicine; Cancer; Breast cancer; Enzyme","score_opus":0.007794038978604045,"score_gpt":0.2511937937726388,"score_spread":0.24339975479403475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031256158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982241,0.00059116684,0.00006971834,0.00052256003,0.00006215639,0.00036798965,0.00003134911,0.0000069736916,0.00012401154],"genre_scores_gemma":[0.9971059,0.000016361482,0.001974912,0.00025222913,0.00016482949,0.000037146125,0.00036468692,0.000018041834,0.00006590977],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987047,0.00021917677,0.000266681,0.00032499997,0.0003214653,0.00016297617],"domain_scores_gemma":[0.9993423,0.000043461536,0.00013740113,0.00014415562,0.00017794837,0.00015473766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004486395,0.00015670437,0.00016800029,0.000094159615,0.000037742902,0.000011363735,0.00007970316,0.00016432774,0.0000072658445],"category_scores_gemma":[0.000550741,0.00015401776,0.000044690234,0.00018523286,0.00012725274,0.000016319003,0.00005184015,0.00012066321,0.0000086228665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019391174,0.000051490504,0.0007847213,0.000014270847,0.00005596836,3.247593e-7,0.0003753681,0.00036445388,0.99541086,0.00038000618,0.00082564325,0.0015430014],"study_design_scores_gemma":[0.0020681585,0.0002611702,0.00092048757,0.000037128524,0.00003620725,0.000015565573,0.00005478402,0.003811007,0.9885274,0.0036990554,0.00040193126,0.00016706566],"about_ca_topic_score_codex":0.0001166516,"about_ca_topic_score_gemma":0.0000039190063,"teacher_disagreement_score":0.0068834005,"about_ca_system_score_codex":0.000040152805,"about_ca_system_score_gemma":0.00040924223,"threshold_uncertainty_score":0.62806624},"labels":[],"label_agreement":null},{"id":"W2033997665","doi":"10.1007/s10637-011-9650-4","title":"A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Cancer; Gastroenterology; Clinical endpoint; Adenocarcinoma; Oncology; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","score_opus":0.03554854809381155,"score_gpt":0.2814283974656747,"score_spread":0.24587984937186316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033997665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937251,0.000039397444,0.00012204383,0.00091132714,0.00076417375,0.0042064968,0.00007113472,0.000024929235,0.00013534725],"genre_scores_gemma":[0.99417526,0.0000033206506,0.0029482895,0.00052813056,0.00029117364,0.00016341193,0.00007176193,0.000032460324,0.0017862142],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967324,0.00019667647,0.0011493887,0.00041109018,0.0011658187,0.00034459383],"domain_scores_gemma":[0.9978394,0.0001870415,0.0009596641,0.0005210151,0.00027498457,0.00021788968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003922274,0.00033303848,0.0006423654,0.00027492558,0.00017207408,0.000011619102,0.0003136339,0.00006786926,0.0002561592],"category_scores_gemma":[0.00090636575,0.00017836934,0.00021338496,0.0013149282,0.00048254855,0.00024572187,0.00017662848,0.00030521315,0.0000025971674],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94896406,0.012713397,0.018044887,0.0002275367,0.00033744154,0.000026381975,0.0028454196,0.00007627487,0.00040654134,0.00047016446,0.004282854,0.011605041],"study_design_scores_gemma":[0.9144779,0.0331317,0.04712744,0.0004250826,0.00084498536,0.00001123596,0.00034319007,0.00017603903,0.0025249494,0.00033872394,0.00037096723,0.00022779194],"about_ca_topic_score_codex":0.00018926241,"about_ca_topic_score_gemma":0.00007314075,"teacher_disagreement_score":0.034486163,"about_ca_system_score_codex":0.00015563231,"about_ca_system_score_gemma":0.0018759813,"threshold_uncertainty_score":0.7273691},"labels":[],"label_agreement":null},{"id":"W2035105453","doi":"10.1007/s10637-009-9230-z","title":"A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint-Vincent Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Lung cancer; Overall survival; Oncology; Gastroenterology; Surgery; Chemotherapy","score_opus":0.022813625574936238,"score_gpt":0.3220910436634508,"score_spread":0.2992774180885146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035105453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509114,0.0023845471,0.00009989388,0.00046356593,0.00014244749,0.0013572332,0.00010222556,0.000007830037,0.00035109455],"genre_scores_gemma":[0.99602073,0.00024216803,0.0012726415,0.00023903594,0.00041779547,0.00010544458,0.00014968416,0.000016407188,0.001536077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985618,0.00011161162,0.00054937234,0.000419346,0.0001681051,0.00018978491],"domain_scores_gemma":[0.99904186,0.00006764376,0.0003168256,0.00019921962,0.00021597605,0.00015848277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001580816,0.0002564621,0.00051269995,0.00007273249,0.000091638416,0.000007443037,0.00011388159,0.00011427578,0.000023767878],"category_scores_gemma":[0.00008938875,0.00022768312,0.000087643566,0.00012948056,0.0001577332,0.000008495106,0.00005799194,0.000065029504,9.095806e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011805954,0.0062332507,0.0006034591,0.000040595554,0.0004193639,0.000009080252,0.008072913,0.000570282,0.9547031,0.00005547956,0.0004057814,0.017080754],"study_design_scores_gemma":[0.20645863,0.11259071,0.0004675574,0.00006837594,0.00026355026,0.0000049267883,0.0014291148,0.00043389323,0.6718812,0.00023741405,0.0057677007,0.00039696266],"about_ca_topic_score_codex":0.00011594983,"about_ca_topic_score_gemma":0.00017930468,"teacher_disagreement_score":0.28282192,"about_ca_system_score_codex":0.00005129069,"about_ca_system_score_gemma":0.000775368,"threshold_uncertainty_score":0.92846483},"labels":[],"label_agreement":null},{"id":"W2036144482","doi":"10.1007/s10637-014-0070-0","title":"Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Cancer Institute; National Institutes of Health","keywords":"Irinotecan; Bortezomib; Medicine; Adenocarcinoma; Internal medicine; Gastroenterology; Oncology; Stomach; Population; Cancer; Multiple myeloma; Colorectal cancer","score_opus":0.01462400329320097,"score_gpt":0.24959230195326385,"score_spread":0.23496829866006289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036144482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970567,0.000005781658,0.00014344938,0.0015977002,0.000092411865,0.0009714347,0.000005158959,0.000010082043,0.000117276024],"genre_scores_gemma":[0.9980999,7.4361714e-7,0.0009026164,0.0002884786,0.000072183386,0.000023700428,0.00006806526,0.00001281613,0.0005314822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998586,0.00006480726,0.0004116407,0.00018275107,0.0006159292,0.00013889013],"domain_scores_gemma":[0.99926656,0.00007495315,0.00028961417,0.00018815388,0.00010850323,0.00007219269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021941432,0.0001266107,0.00029528057,0.00022544233,0.000032905613,0.0000052544324,0.00009369782,0.00003905901,0.000043402488],"category_scores_gemma":[0.00013428209,0.00007143678,0.000032422187,0.00063472765,0.00014419844,0.00011594746,0.00003449449,0.00012780032,5.9854176e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06682014,0.0022709223,0.92172927,0.00010406668,0.000054817512,0.0000038729972,0.0006727939,0.00026210962,0.000055027238,0.0005601527,0.0005925402,0.0068743075],"study_design_scores_gemma":[0.18183611,0.009004563,0.80771285,0.00016956433,0.00007066613,0.0000016344958,0.00004836135,0.00043055613,0.00042804124,0.00017524307,0.000060565566,0.000061827835],"about_ca_topic_score_codex":0.00043607163,"about_ca_topic_score_gemma":0.00042280048,"teacher_disagreement_score":0.115015976,"about_ca_system_score_codex":0.00010678185,"about_ca_system_score_gemma":0.00039365835,"threshold_uncertainty_score":0.2913107},"labels":[],"label_agreement":null},{"id":"W2036546477","doi":"10.1007/s10637-009-9341-6","title":"A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Cancer Care Ontario; Regional Municipality of Durham; Lakeridge Health","funders":"","keywords":"Cetuximab; Medicine; Immunostaining; Colorectal cancer; Epidermal growth factor receptor; Immunohistochemistry; Internal medicine; Oncology; Cancer; Pathology","score_opus":0.01860524585751648,"score_gpt":0.28023986716293553,"score_spread":0.26163462130541904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036546477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732304,0.00015037187,0.0000060734005,0.00082004844,0.000040581694,0.0014663357,0.000046262274,0.00002522894,0.00012207773],"genre_scores_gemma":[0.99774814,0.000005467837,0.0015809695,0.00036390833,0.000040012204,0.00006187956,0.0000967005,0.000023834054,0.00007909668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830306,0.00006714183,0.0004411378,0.00034820838,0.00058070564,0.00025977023],"domain_scores_gemma":[0.9990734,0.000104981904,0.0002411551,0.00015126506,0.0002627048,0.0001664834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067849054,0.0002812747,0.0005259254,0.00017997118,0.000110050474,0.000013804203,0.000074055024,0.00003081573,0.000055674667],"category_scores_gemma":[0.000052455798,0.00019131214,0.000049882798,0.0002985079,0.00011108425,0.00018062485,0.000021992772,0.00016430639,0.0000018476936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016624013,0.01399032,0.9290045,0.000028572558,0.0005733696,0.000038416758,0.030207992,0.000022898006,0.0007081376,0.00003890478,0.00015334906,0.008609524],"study_design_scores_gemma":[0.061580747,0.036690883,0.8977671,0.00014090558,0.00012762196,0.0000020817638,0.0019869846,0.000066751745,0.0013255123,0.000046679106,0.00005824306,0.00020646428],"about_ca_topic_score_codex":0.00070462207,"about_ca_topic_score_gemma":0.00010776326,"teacher_disagreement_score":0.044956733,"about_ca_system_score_codex":0.00026746932,"about_ca_system_score_gemma":0.00033714614,"threshold_uncertainty_score":0.78014827},"labels":[],"label_agreement":null},{"id":"W2037125902","doi":"10.1023/b:drug.0000047105.38511.2a","title":"Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; CancerCare Manitoba; Ontario Institute for Cancer Research; AstraZeneca (Canada); Hôpital Notre-Dame; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Doxorubicin; Bolus (digestion); Toxicity; Cancer; Internal medicine; Chemotherapy; Gastroenterology; Surgery","score_opus":0.023312347774086896,"score_gpt":0.33420681025171406,"score_spread":0.31089446247762714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037125902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744356,0.00022014507,0.000010036457,0.0010846183,0.000051137074,0.001030358,0.00001966059,0.000012174709,0.0001282976],"genre_scores_gemma":[0.9967252,0.000022728815,0.0015060976,0.0009837609,0.00003623132,0.00009074796,0.000043120996,0.000014465615,0.0005776377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990452,0.000027327142,0.0002665184,0.00022446389,0.00028558032,0.00015089531],"domain_scores_gemma":[0.9994884,0.00005489356,0.00009170359,0.00009346982,0.00010097747,0.00017052038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057438978,0.0001405926,0.00029824665,0.0001198538,0.000032238975,0.00000602899,0.000042933756,0.000023873561,0.00021230483],"category_scores_gemma":[0.00002080925,0.000098817814,0.00001433722,0.00030109606,0.00010460616,0.00013263023,0.000017655188,0.00010547343,0.0000031554177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018794585,0.02066269,0.8935609,0.0003065514,0.0009742591,0.00016721086,0.020933611,0.013069506,0.004507099,0.00062427873,0.0011659442,0.025233384],"study_design_scores_gemma":[0.35935158,0.024755955,0.59314346,0.0008607078,0.0009130781,0.000017794466,0.001702355,0.00015645432,0.015003303,0.002285921,0.001290344,0.0005190796],"about_ca_topic_score_codex":0.0025833996,"about_ca_topic_score_gemma":0.0014524347,"teacher_disagreement_score":0.34055698,"about_ca_system_score_codex":0.00015105704,"about_ca_system_score_gemma":0.0008652645,"threshold_uncertainty_score":0.40296733},"labels":[],"label_agreement":null},{"id":"W2037598471","doi":"10.1007/s10637-014-0166-6","title":"A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; National Center for Research Resources; Institute of Clinical and Translational Sciences","keywords":"Capecitabine; Refractory (planetary science); Medicine; Internal medicine; Solid tumor; Oncology; Pharmacology; Cancer; Materials science; Colorectal cancer; Metallurgy","score_opus":0.00805643969638922,"score_gpt":0.25682505050062404,"score_spread":0.24876861080423482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037598471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99916965,0.000032969238,0.000089534806,0.00019278785,0.000048030546,0.00031380347,0.0000052548858,0.0000044135218,0.0001435825],"genre_scores_gemma":[0.99839723,0.0000022045824,0.00074450695,0.00016057273,0.000058342826,0.000026234973,0.00047012005,0.000009407643,0.00013138086],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99904996,0.00011144898,0.00032246794,0.000249922,0.0001449259,0.000121280464],"domain_scores_gemma":[0.9996009,0.000023133507,0.00012933106,0.00012386349,0.00005724062,0.00006552593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022805663,0.00011586413,0.00014414646,0.00011681071,0.000023947014,0.000005184312,0.00007879725,0.00007852508,0.000010979489],"category_scores_gemma":[0.00008499757,0.00010659168,0.000016920616,0.00014715343,0.000085197826,0.0000122365045,0.00003425212,0.0000757494,0.0000034679226],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016671899,0.0032513386,0.3382707,0.000040681658,0.0000629763,0.000007659603,0.0025469523,0.0013985916,0.64263797,0.00028735344,0.0005242078,0.009304386],"study_design_scores_gemma":[0.028051367,0.0042892024,0.6407168,0.00015879916,0.00001883735,0.000009162627,0.0011551406,0.0017994219,0.3206834,0.00096751,0.0016713939,0.0004789906],"about_ca_topic_score_codex":0.00008563016,"about_ca_topic_score_gemma":0.00043249372,"teacher_disagreement_score":0.32195458,"about_ca_system_score_codex":0.000027639135,"about_ca_system_score_gemma":0.00013145378,"threshold_uncertainty_score":0.43466824},"labels":[],"label_agreement":null},{"id":"W2037647430","doi":"10.1007/s10637-005-2907-z","title":"A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Pharmacokinetics; Neutropenia; Cancer; Nausea; Toxicity; Population; Phases of clinical research; Internal medicine; Gastroenterology; Vomiting; Pharmacology","score_opus":0.0318275384668315,"score_gpt":0.3383269827617641,"score_spread":0.3064994442949326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037647430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970878,0.00014415683,0.000012093421,0.0014576219,0.000054900174,0.001062969,0.00001396561,0.000024177882,0.00014233784],"genre_scores_gemma":[0.99757135,0.000041357016,0.0009724619,0.0006632848,0.00011198434,0.00003528538,0.000044377484,0.000019597139,0.00054028124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983518,0.00006947987,0.00059972465,0.00030849184,0.00045659876,0.00021386846],"domain_scores_gemma":[0.9992175,0.00007633528,0.0002088181,0.00014290819,0.00010856733,0.00024588304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018622374,0.0001882517,0.00043336154,0.00028606234,0.000044061202,0.000011038934,0.00007801238,0.000026052148,0.00017923625],"category_scores_gemma":[0.00004804709,0.00014905198,0.000033986853,0.00059093663,0.00015141393,0.00010936261,0.000052374646,0.00017460389,0.0000032544829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009850161,0.0040157414,0.86493146,0.000053394586,0.00038472374,0.000018857701,0.002197079,0.000495788,0.000037051806,0.000035611636,0.0008364373,0.12600884],"study_design_scores_gemma":[0.058909945,0.004528271,0.93356425,0.000118268894,0.0006570813,0.0000036845204,0.00021449244,0.0009194063,0.00008011719,0.00009824716,0.00074347755,0.0001627537],"about_ca_topic_score_codex":0.00080002524,"about_ca_topic_score_gemma":0.0002359531,"teacher_disagreement_score":0.12584609,"about_ca_system_score_codex":0.000071815295,"about_ca_system_score_gemma":0.00025510968,"threshold_uncertainty_score":0.60781634},"labels":[],"label_agreement":null},{"id":"W2040084015","doi":"10.1007/s10637-011-9775-5","title":"A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Regional Cancer Foundation; BC Cancer Agency; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Everolimus; Temozolomide; Regimen; Pharmacokinetics; Pharmacology; Internal medicine; Phases of clinical research; Gastroenterology; Toxicity; Chemotherapy","score_opus":0.03297897731114133,"score_gpt":0.2907754117416299,"score_spread":0.2577964344304886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040084015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970893,0.00009676359,0.000001382086,0.000102895385,0.000043611966,0.0025930814,0.000014285309,0.00003727456,0.000021408117],"genre_scores_gemma":[0.9980887,0.000006098241,0.0014475631,0.00016943092,0.000050864364,0.00016301738,0.000013066448,0.000047017027,0.000014204228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977374,0.00020061983,0.0005744806,0.00062217104,0.0005658457,0.00029946474],"domain_scores_gemma":[0.9984474,0.00030791273,0.00034672974,0.00032513644,0.00018844008,0.00038438258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029905682,0.00032790654,0.0005695045,0.00034573764,0.00011618764,0.00003963044,0.000097522,0.00007189357,0.0000492997],"category_scores_gemma":[0.0003524946,0.00023768906,0.000023996394,0.0004422421,0.00015831686,0.00040385782,0.00007486676,0.00018310832,0.0000019545603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028781127,0.014048887,0.93851995,0.00004238038,0.00024255746,0.00033936033,0.035136253,0.000008412806,0.0002956405,0.000008005664,0.000023556146,0.00845689],"study_design_scores_gemma":[0.04377605,0.017156817,0.9275651,0.0006702386,0.00026786418,0.00002826366,0.0077474006,0.00014128415,0.0023651863,0.000044521574,0.0000017519292,0.00023554354],"about_ca_topic_score_codex":0.001437176,"about_ca_topic_score_gemma":0.0008447969,"teacher_disagreement_score":0.040897936,"about_ca_system_score_codex":0.00007949163,"about_ca_system_score_gemma":0.00023547244,"threshold_uncertainty_score":0.96926785},"labels":[],"label_agreement":null},{"id":"W2042791872","doi":"10.1007/s10637-015-0228-4","title":"Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Concomitant; Glioma; Radiation therapy; Medicine; Chemotherapy; Pharmacology; Cancer research; Internal medicine","score_opus":0.0162601562638525,"score_gpt":0.2394931991475106,"score_spread":0.2232330428836581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042791872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907536,0.00017073263,0.004081314,0.0038498158,0.00017215814,0.0007846497,0.000021423755,0.000047600213,0.00011873468],"genre_scores_gemma":[0.967859,0.0000023024586,0.030359628,0.0014320348,0.00007608765,0.00009987286,0.000012611747,0.00002726679,0.00013117176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976622,0.00024671602,0.0005015253,0.00041561824,0.00086941733,0.00030454702],"domain_scores_gemma":[0.998044,0.0008021103,0.00021963644,0.00031502385,0.00026724246,0.00035195705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012554331,0.00025535416,0.00035215582,0.00015966709,0.000093937444,0.00008347273,0.00025028517,0.00006760377,0.000053157382],"category_scores_gemma":[0.00018288096,0.00018282284,0.000039596278,0.00045629204,0.000388394,0.00028505694,0.000053580414,0.00012610776,0.000027901679],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001063863,0.0000597386,0.0016868638,0.000023884098,0.000015152965,0.000006263544,0.0031071242,0.39527628,0.5954685,0.0005448434,0.002447079,0.0003003703],"study_design_scores_gemma":[0.00472652,0.00047649935,0.0001848033,0.00013525432,0.00002369279,0.000008766499,0.00018813435,0.20867491,0.7843981,0.00085900974,0.00008038443,0.00024393042],"about_ca_topic_score_codex":0.0006281322,"about_ca_topic_score_gemma":0.000065520435,"teacher_disagreement_score":0.18892956,"about_ca_system_score_codex":0.0002337568,"about_ca_system_score_gemma":0.0010806054,"threshold_uncertainty_score":0.74552995},"labels":[],"label_agreement":null},{"id":"W2043276988","doi":"10.1007/s10637-011-9649-x","title":"Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Phytochemicals and Medicinal Plants","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Tubulin; Cell cycle checkpoint; Chemistry; Cell cycle; Pharmacology; Microtubule; Cell; Biology; Biochemistry; Cell biology","score_opus":0.019239528468736885,"score_gpt":0.2366865553387708,"score_spread":0.21744702687003392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043276988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929712,0.00035805092,0.0011007293,0.00077021524,0.00013545695,0.00030629765,0.00030425505,0.000057713398,0.0039961063],"genre_scores_gemma":[0.99243486,0.000033827684,0.0038630813,0.0013097625,0.00023462546,0.000009106788,0.0019713687,0.000026145897,0.00011722663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986788,0.000034672546,0.00039895478,0.00029861307,0.0003979517,0.00019099918],"domain_scores_gemma":[0.9990904,0.000084905325,0.0002622364,0.00017396334,0.00011509814,0.000273416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051831004,0.000187961,0.00030498207,0.0000558631,0.000046474077,0.000007111466,0.00006856121,0.00013128894,0.00014700934],"category_scores_gemma":[0.000055192904,0.00017510334,0.00006317633,0.00024590438,0.00029629387,0.00017435067,0.000023683937,0.00019703565,0.00003158159],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005930326,0.00037307543,0.003087794,0.000041978936,0.00007460377,0.000014691302,0.0032937345,0.0000026443504,0.98369205,0.0003383966,0.008377973,0.00011004505],"study_design_scores_gemma":[0.002427151,0.00025867618,0.010498267,0.00042451994,0.00013101342,0.000009441595,0.00029350448,0.00043966548,0.971233,0.013764685,0.00031836348,0.00020172],"about_ca_topic_score_codex":0.003441406,"about_ca_topic_score_gemma":0.00000857093,"teacher_disagreement_score":0.013426289,"about_ca_system_score_codex":0.000046391113,"about_ca_system_score_gemma":0.0003318379,"threshold_uncertainty_score":0.7140507},"labels":[],"label_agreement":null},{"id":"W2044055451","doi":"10.1023/b:drug.0000036679.12112.4c","title":"Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise; Centre hospitalier universitaire de Québec","funders":"University of Texas MD Anderson Cancer Center","keywords":"Potency; In vivo; Medicine; Pharmacology; Life span; Bioisostere; Cytotoxicity; In vitro; Colorectal cancer; Cancer; Internal medicine; Chemistry; Chemical synthesis; Biology; Biochemistry","score_opus":0.010332806309681109,"score_gpt":0.24072094335159686,"score_spread":0.23038813704191574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044055451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956295,0.0001475446,0.0000875485,0.0028603834,0.00015411885,0.00031237173,0.00000580913,0.00002945527,0.00077327446],"genre_scores_gemma":[0.9958435,0.00000808351,0.002997285,0.00062108744,0.00025153134,0.000013330365,0.000050761715,0.000018019111,0.00019634447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988179,0.000028218323,0.00037943208,0.0002058591,0.0003595302,0.00020906712],"domain_scores_gemma":[0.9992187,0.00015327559,0.00012628891,0.00014753327,0.00012741852,0.00022679321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016291023,0.00015537828,0.00029877757,0.00021519966,0.00003105895,0.0000047754115,0.00007348545,0.00008763504,0.000059361635],"category_scores_gemma":[0.0005842042,0.00014237179,0.00006065325,0.00035780176,0.00019231981,0.000105902065,0.00002683139,0.00018036307,0.000033919692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057855755,0.0004576282,0.7001063,0.0008619378,0.00008189776,0.00046058203,0.010150987,0.0023330688,0.2543441,0.027670724,0.0015210173,0.0014331917],"study_design_scores_gemma":[0.004761052,0.00028060915,0.8242484,0.0004489222,0.00003134707,0.0000691946,0.00013248593,0.00016802624,0.16116701,0.00823815,0.00028049605,0.00017431051],"about_ca_topic_score_codex":0.0005249548,"about_ca_topic_score_gemma":0.00003929559,"teacher_disagreement_score":0.12414209,"about_ca_system_score_codex":0.00008500444,"about_ca_system_score_gemma":0.001037759,"threshold_uncertainty_score":0.5805753},"labels":[],"label_agreement":null},{"id":"W2046295314","doi":"10.1007/s10637-010-9495-2","title":"Sonodynamic and photodynamic mechanisms of action of the novel hypocrellin sonosensitizer, SL017: mitochondrial cell death is attenuated by 11, 12-epoxyeicosatrienoic acid","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Eicosanoids and Hypertension Pharmacology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FuelCell Energy (Canada); Quest University Canada; University of Alberta","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Sonodynamic therapy; Ascorbic acid; Chemistry; Reactive oxygen species; Mitochondrion; Photodynamic therapy; Fragmentation (computing); Programmed cell death; Apoptosis; Epoxyeicosatrienoic acid; Arachidonic acid; Antioxidant; Biochemistry; Pharmacology; Biology","score_opus":0.011147436213922881,"score_gpt":0.23489736729297583,"score_spread":0.22374993107905294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046295314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961401,0.000099755125,0.0014107013,0.0011645273,0.0005963105,0.00026430094,0.0002257654,0.000008834681,0.0000896526],"genre_scores_gemma":[0.99270064,0.00004822468,0.004920537,0.0012954796,0.00015198524,0.000008332183,0.00021401081,0.000025723137,0.00063509366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882764,0.000047827314,0.00034782427,0.0003600391,0.00022489246,0.0001917712],"domain_scores_gemma":[0.999106,0.000036538764,0.0003008092,0.0002653442,0.0001514475,0.0001398942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010722142,0.00019313308,0.00021860105,0.000050803155,0.00010179288,0.000012299676,0.0002012645,0.00026670366,0.000043882326],"category_scores_gemma":[0.00005354297,0.00016209952,0.00011256769,0.00009594405,0.00025858375,0.000009741419,0.00011192547,0.0002023544,0.0000027397634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000620021,0.000073303,0.0002649027,0.000017565115,0.000035506277,3.214928e-7,0.000056020766,0.000022657594,0.99017847,0.0007496579,0.008465994,0.000073585376],"study_design_scores_gemma":[0.0015122442,0.00009596954,0.00092267303,0.00001001037,0.000070573056,0.000027948063,0.00003436857,0.0023813595,0.9892051,0.00287248,0.0026998648,0.00016738212],"about_ca_topic_score_codex":0.00025545465,"about_ca_topic_score_gemma":0.00008978428,"teacher_disagreement_score":0.005766129,"about_ca_system_score_codex":0.0000092770615,"about_ca_system_score_gemma":0.00030967593,"threshold_uncertainty_score":0.66102266},"labels":[],"label_agreement":null},{"id":"W2047528221","doi":"10.1007/s10637-010-9611-3","title":"A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Essar Steel Algoma (Canada); BC Cancer Agency; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; Clinical endpoint; Oncology; Progressive disease; Phases of clinical research; Stage (stratigraphy); Deoxycytidine; Cancer; Chemotherapy; Clinical trial; Gastroenterology","score_opus":0.024561046939553282,"score_gpt":0.3483358976497588,"score_spread":0.3237748507102055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047528221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917998,0.000056747624,0.0000041450935,0.0055679646,0.000092641276,0.001574463,0.000008208947,0.000013257694,0.0008827735],"genre_scores_gemma":[0.9969423,0.000007995916,0.0013219974,0.00031918057,0.0000908994,0.00026526925,0.000021773276,0.000015952673,0.0010146269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833,0.000110659035,0.0004715206,0.00025819428,0.0006091644,0.00022045092],"domain_scores_gemma":[0.9989173,0.00027891237,0.00017822921,0.00028904906,0.00018940374,0.00014711518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042113566,0.00014522865,0.00041449073,0.00021066521,0.00007669297,0.000006377648,0.00014956396,0.00008778912,0.00012478585],"category_scores_gemma":[0.00055696076,0.000098057884,0.000029006227,0.0007636548,0.0002802027,0.00012048458,0.000058672573,0.0005071905,0.0000039444976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007390593,0.0043069646,0.95545787,0.00006173577,0.000052434898,0.000012348901,0.0066421228,0.000064776475,0.027468752,0.0016121247,0.0004190612,0.0031627591],"study_design_scores_gemma":[0.03422645,0.0028003352,0.95393896,0.00040750412,0.000091383255,0.00001424888,0.0010476907,0.0019109945,0.0028142182,0.0023475352,0.0002645405,0.00013614728],"about_ca_topic_score_codex":0.0019508131,"about_ca_topic_score_gemma":0.0037360254,"teacher_disagreement_score":0.03348739,"about_ca_system_score_codex":0.000119045944,"about_ca_system_score_gemma":0.0017859464,"threshold_uncertainty_score":0.39986846},"labels":[],"label_agreement":null},{"id":"W2050197847","doi":"10.1007/s10637-014-0159-5","title":"A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Doxorubicin; Pharmacokinetics; Pantoprazole; Medicine; Pharmacology; Chemotherapy; Internal medicine","score_opus":0.01229624724605933,"score_gpt":0.29589252283165135,"score_spread":0.28359627558559203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050197847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984187,0.000075217096,0.0006184783,0.000060385155,0.000031613134,0.0006863398,0.00002440959,0.0000014295996,0.00008345598],"genre_scores_gemma":[0.9982168,0.000022477974,0.0014407894,0.000039321043,0.00002477771,0.000021611595,0.00021270773,0.000012057252,0.000009429432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986954,0.00010215322,0.0004632214,0.00018678355,0.00045890422,0.00009353448],"domain_scores_gemma":[0.99899936,0.00002846891,0.00046752457,0.00013324012,0.00032777007,0.000043645887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049800123,0.00011282537,0.000240242,0.00012572162,0.000009770573,0.0000030718088,0.00007040311,0.000057881734,0.0000055413047],"category_scores_gemma":[0.00004623285,0.0001028052,0.000017538692,0.00017946934,0.00011684413,0.000015759477,0.0000175113,0.000048224545,4.7754767e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072940825,0.00072137837,0.0022587806,0.00007504634,0.000029167193,5.2273005e-8,0.0007495427,0.003262246,0.9651709,0.0009824497,0.0000065943054,0.019449743],"study_design_scores_gemma":[0.07770293,0.004321359,0.0075177895,0.0001609363,0.000051988936,2.9183454e-7,0.00007698236,0.0026525047,0.9056384,0.0017238758,0.000044648164,0.00010828635],"about_ca_topic_score_codex":0.00015208113,"about_ca_topic_score_gemma":0.00009529979,"teacher_disagreement_score":0.07040885,"about_ca_system_score_codex":0.000020188896,"about_ca_system_score_gemma":0.0002968876,"threshold_uncertainty_score":0.41922745},"labels":[],"label_agreement":null},{"id":"W2052076354","doi":"10.1007/s10637-013-9931-1","title":"A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Tolerability; Internal medicine; Sunitinib; Clinical endpoint; Renal cell carcinoma; Progressive disease; Phases of clinical research; Pazopanib; Oncology; Adverse effect; Gastroenterology; Clinical trial; Surgery; Disease","score_opus":0.03995789522017983,"score_gpt":0.3047918596194014,"score_spread":0.2648339643992216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052076354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897096,0.00018012134,0.000001980197,0.00041392923,0.000104627456,0.009234152,0.00011191206,0.000013969527,0.00022969279],"genre_scores_gemma":[0.99723285,0.000002678239,0.00082594814,0.00007261264,0.00008016168,0.0009115597,0.00014705525,0.000033619785,0.0006935256],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967691,0.0003011908,0.0009703829,0.0004897315,0.0011269973,0.00034259728],"domain_scores_gemma":[0.9977503,0.00027740025,0.0007539676,0.0004532428,0.00042309263,0.00034203773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015078273,0.00038938937,0.0007656681,0.00023667746,0.000101990045,0.000016967084,0.00017999201,0.000057424324,0.00026249883],"category_scores_gemma":[0.00014834017,0.0002092597,0.00014606443,0.0006484302,0.00031112536,0.00016272366,0.00007719239,0.00019147045,0.0000069236544],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34138772,0.36454576,0.17913643,0.0009325231,0.0027623768,0.00044311307,0.06931653,0.00047084285,0.018022146,0.00024031359,0.0046107643,0.018131493],"study_design_scores_gemma":[0.72542536,0.15058485,0.036963757,0.00048241758,0.0014228899,0.000021000747,0.0022992657,0.0003139247,0.08168406,0.00031992237,0.00011449626,0.0003680738],"about_ca_topic_score_codex":0.0014884821,"about_ca_topic_score_gemma":0.0000867904,"teacher_disagreement_score":0.3840376,"about_ca_system_score_codex":0.00037471068,"about_ca_system_score_gemma":0.0016868633,"threshold_uncertainty_score":0.85333633},"labels":[],"label_agreement":null},{"id":"W2052229320","doi":"10.1007/s10637-013-0040-y","title":"Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Androgen receptor; Antiandrogens; Prostate cancer; NF-κB; Androgen Receptor Antagonists; Chemistry; Androgen; Mutant; Cancer research; In vitro; Hedgehog signaling pathway; Signal transduction; Pharmacology; Biology; Medicine; Cancer; Internal medicine; Biochemistry; Gene; Hormone","score_opus":0.015647080231729855,"score_gpt":0.24870473195222512,"score_spread":0.23305765172049525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052229320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894134,0.00010515418,0.0000011467589,0.009926107,0.000032431202,0.00036963163,0.000030876734,0.0000052672794,0.00011599561],"genre_scores_gemma":[0.99898875,0.000032576492,0.00032029487,0.00022362894,0.000047225905,0.000031593216,0.000082955965,0.000007597959,0.00026538016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931043,0.000047018213,0.00019848424,0.00011898733,0.00023925581,0.000085841995],"domain_scores_gemma":[0.9995254,0.00013097479,0.000088121786,0.00008203204,0.000086633525,0.00008683231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010090188,0.00007337816,0.00015194168,0.00009098588,0.000032623127,0.000010162845,0.000030243273,0.000046871042,0.000060430364],"category_scores_gemma":[0.0001021049,0.00005030058,0.000023162806,0.00017390575,0.00029516578,0.000090485955,0.000025897423,0.00006415278,0.0000035949236],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013427246,0.000043252257,0.05344689,0.00007612236,0.000021659811,4.145307e-7,0.0003754393,0.0000010743619,0.94413304,0.00008917144,0.00023485124,0.0014438342],"study_design_scores_gemma":[0.00096770417,0.000038586695,0.12585706,0.00018471963,0.000016004145,0.0000033057756,0.000051563402,0.0001786187,0.87192667,0.000576205,0.0001571022,0.000042490396],"about_ca_topic_score_codex":0.00027044702,"about_ca_topic_score_gemma":0.0000023780071,"teacher_disagreement_score":0.072410166,"about_ca_system_score_codex":0.000036487985,"about_ca_system_score_gemma":0.00036029084,"threshold_uncertainty_score":0.2051198},"labels":[],"label_agreement":null},{"id":"W2052372910","doi":"10.1023/b:drug.0000047107.35764.d9","title":"An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Fluorouracil; Angiogenesis; Pharmacokinetics; Matrix metalloproteinase; Angiogenesis inhibitor; Medicine; Matrix metalloproteinase inhibitor; Pharmacology; Internal medicine; Chemotherapy","score_opus":0.01035810629076799,"score_gpt":0.2652112211502177,"score_spread":0.2548531148594497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052372910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981311,0.0002611091,0.0002741283,0.00038276234,0.000060284456,0.00083809975,0.000014947725,0.000010287565,0.000027262708],"genre_scores_gemma":[0.998331,0.000008425473,0.0011249324,0.00017380291,0.00012956077,0.00007796113,0.00005944062,0.000020499378,0.00007434797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881124,0.00011418096,0.00027023265,0.00032995082,0.00031956035,0.00015481014],"domain_scores_gemma":[0.9993674,0.000008780764,0.00013998573,0.00026210406,0.00008276786,0.00013894854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020338263,0.00017393619,0.00014663578,0.00007880557,0.00007895036,0.000022368806,0.00016917376,0.000076126846,0.000010855894],"category_scores_gemma":[0.000038316073,0.00013517635,0.00004114404,0.00020978309,0.000095523246,0.0000278953,0.000066253604,0.00008322604,0.0000015125638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019030088,0.00081617385,0.0020324779,0.00002016963,0.00004347252,0.000006171426,0.0005089382,0.00094183866,0.99389833,0.0006015848,0.00003798631,0.0009025391],"study_design_scores_gemma":[0.0073517263,0.0015919345,0.0048119673,0.000040379444,0.00005537295,0.000015299573,0.0002845683,0.00010183395,0.9824238,0.0029707572,0.00015551446,0.00019685357],"about_ca_topic_score_codex":0.00032144922,"about_ca_topic_score_gemma":0.00018482535,"teacher_disagreement_score":0.0114745535,"about_ca_system_score_codex":0.00003051937,"about_ca_system_score_gemma":0.0002807009,"threshold_uncertainty_score":0.5512331},"labels":[],"label_agreement":null},{"id":"W2056723407","doi":"10.1007/s10637-008-9143-2","title":"O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma","year":2008,"lang":"fr","type":"article","venue":"Investigational New Drugs","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Mashhad University of Medical Sciences","keywords":"Medicine; Imatinib mesylate; Adverse effect; Phases of clinical research; Clinical trial; Melanoma; Internal medicine; Imatinib; Surgery; Oncology; Gastroenterology","score_opus":0.04069337693991506,"score_gpt":0.3313887372190749,"score_spread":0.2906953602791599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056723407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819058,0.0028389716,0.00003328679,0.009475622,0.0027527183,0.0016957397,0.00037452026,0.00003898699,0.00088431174],"genre_scores_gemma":[0.9728541,0.00021378086,0.013315712,0.0010630327,0.0010006578,0.00011846256,0.0007212272,0.000060423674,0.010652603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99613935,0.00047193852,0.001367217,0.0005956496,0.00074626337,0.00067956245],"domain_scores_gemma":[0.99749064,0.00062138273,0.0005780436,0.0004232242,0.00020687914,0.00067984895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005252209,0.0004901682,0.0010813456,0.00034421711,0.00023494783,0.000011532718,0.00021841169,0.00027642003,0.0010366376],"category_scores_gemma":[0.00068645866,0.00048126452,0.00025802612,0.00054164,0.0009986092,0.00035616042,0.000106351785,0.00050871226,0.0003921689],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3001349,0.11753633,0.15853283,0.0031616043,0.014566319,0.02343001,0.10057397,0.002501862,0.009756983,0.07314406,0.06005787,0.13660327],"study_design_scores_gemma":[0.8785456,0.018483575,0.046058785,0.0019768258,0.002543255,0.00063972187,0.0006138114,0.0046316353,0.01430767,0.011575254,0.01950103,0.001122851],"about_ca_topic_score_codex":0.0054728915,"about_ca_topic_score_gemma":0.0005949424,"teacher_disagreement_score":0.5784107,"about_ca_system_score_codex":0.00043438183,"about_ca_system_score_gemma":0.00345171,"threshold_uncertainty_score":0.99987656},"labels":[],"label_agreement":null},{"id":"W2058272907","doi":"10.1023/b:drug.0000006179.20974.af","title":"Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Cancer Institute","keywords":"Gemcitabine; Medicine; Cisplatin; Internal medicine; Regimen; Neutropenia; Chemotherapy; Oncology; Esophageal cancer; Toxicity; Phases of clinical research; Cancer","score_opus":0.03715668079495866,"score_gpt":0.3237959246812277,"score_spread":0.28663924388626905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058272907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953237,0.00066301296,0.00011021117,0.00078726484,0.00006977237,0.002747297,0.00010718902,0.000026590415,0.00016495073],"genre_scores_gemma":[0.9821125,0.000004375756,0.016085003,0.0003317121,0.00007960271,0.0004187963,0.00027532355,0.000028578306,0.0006640674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835086,0.00011346801,0.00030193463,0.00040042086,0.00051770953,0.00031557935],"domain_scores_gemma":[0.9985745,0.00039273637,0.0001059072,0.00016612849,0.0001935829,0.0005671687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023758296,0.00021538771,0.00035294364,0.00012410262,0.00013906113,0.000026926204,0.000053956315,0.000036241767,0.00011435885],"category_scores_gemma":[0.00032608415,0.00014260427,0.000042518695,0.00022503686,0.00015136313,0.00010391522,0.000023321389,0.00014943302,0.000011723264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00348175,0.0029074317,0.97670937,0.00018328034,0.00043029612,0.00022341606,0.0034494076,0.0000069593693,0.0000077087125,0.0036379637,0.0015564925,0.007405928],"study_design_scores_gemma":[0.039396666,0.023632921,0.93099046,0.00006789803,0.00048154595,0.00005986207,0.0008364889,0.00007869765,0.000091303984,0.0031354716,0.0009980303,0.00023067468],"about_ca_topic_score_codex":0.00020165932,"about_ca_topic_score_gemma":0.0002810618,"teacher_disagreement_score":0.045718923,"about_ca_system_score_codex":0.0002254841,"about_ca_system_score_gemma":0.0010772488,"threshold_uncertainty_score":0.5815233},"labels":[],"label_agreement":null},{"id":"W2058783279","doi":"10.1007/s10637-012-9837-3","title":"Investigational agents in development for the treatment of ovarian cancer","year":2012,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Ovarian cancer; PI3K/AKT/mTOR pathway; Cancer research; Epidermal growth factor receptor; Cancer; Protein kinase B; Receptor tyrosine kinase; Biology; Tyrosine kinase; Medicine; Signal transduction; Pharmacology; Internal medicine; Receptor; Cell biology","score_opus":0.21656059714362874,"score_gpt":0.398267042823047,"score_spread":0.18170644567941824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058783279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012423318,0.993072,0.000019486886,0.0028417513,0.0004595026,0.0030449682,0.00022752263,0.000016171458,0.00019438092],"genre_scores_gemma":[0.0001229668,0.9850487,0.006367621,0.0004399646,0.0010276947,0.0040469053,0.0012089355,0.00006353916,0.0016736635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775183,0.000058353668,0.0009553228,0.0004138411,0.0004909219,0.0003297076],"domain_scores_gemma":[0.99806666,0.00067386683,0.00048361038,0.0003222461,0.0001113305,0.0003423043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020270344,0.00045910478,0.0011917478,0.00022063384,0.00009675659,0.000019059464,0.00015486174,0.00021162757,0.0003426292],"category_scores_gemma":[0.000042348882,0.00028652605,0.0004011815,0.0003789864,0.0001592111,0.00006549694,0.000023400911,0.00012280862,0.000036233945],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020615598,0.0005620996,0.0024754703,0.0028010807,0.0012479819,0.0000033329254,0.0011256472,0.000023079516,2.597744e-7,0.003344608,0.0030324461,0.98536336],"study_design_scores_gemma":[0.0020110335,0.0000997887,0.0070611895,0.0065224012,0.0019946601,0.00001090774,0.0000110811525,0.00001467946,0.00003882807,0.0004923929,0.9815146,0.00022844985],"about_ca_topic_score_codex":0.0005559302,"about_ca_topic_score_gemma":0.00012937619,"teacher_disagreement_score":0.9851349,"about_ca_system_score_codex":0.0014297765,"about_ca_system_score_gemma":0.0067299595,"threshold_uncertainty_score":0.9999587},"labels":[],"label_agreement":null},{"id":"W2059255702","doi":"10.1007/s10637-014-0106-5","title":"A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Docetaxel; Dasatinib; Medicine; Prostate cancer; Oncology; Cancer; Internal medicine; Prostate; Pharmacology; Tyrosine kinase; Receptor","score_opus":0.03335540329604145,"score_gpt":0.3297910892392198,"score_spread":0.2964356859431784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059255702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368966,0.00014274767,0.000005052048,0.001807286,0.000104138184,0.0034485764,0.000047246696,0.000024698225,0.0007306088],"genre_scores_gemma":[0.9980111,0.00004058591,0.00039531634,0.000071278875,0.000063585234,0.0003926691,0.0004480804,0.000028185083,0.0005492102],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971137,0.00033492397,0.00078998524,0.00042189952,0.0010389149,0.00030056955],"domain_scores_gemma":[0.9985064,0.00036200453,0.00032905626,0.00021404879,0.00038899813,0.00019949219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008217006,0.00023987069,0.0006676186,0.0004175951,0.00010094979,0.000023400287,0.00009749405,0.00007570307,0.000037454636],"category_scores_gemma":[0.0004295042,0.00018413879,0.000052486103,0.0007657736,0.0002539108,0.0002435173,0.000032872795,0.00024791167,0.0000021855492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8873422,0.009633924,0.051926292,0.00035524936,0.000367173,0.00005063537,0.03155755,0.0004001931,0.013010154,0.0015908221,0.000498884,0.0032669085],"study_design_scores_gemma":[0.9236452,0.008383076,0.059605904,0.00064616743,0.00016222877,8.2262636e-7,0.00095963734,0.0010942623,0.0038325002,0.0013385,0.00009897174,0.00023271525],"about_ca_topic_score_codex":0.003718333,"about_ca_topic_score_gemma":0.0029945588,"teacher_disagreement_score":0.036302995,"about_ca_system_score_codex":0.0003381139,"about_ca_system_score_gemma":0.00083548645,"threshold_uncertainty_score":0.75089616},"labels":[],"label_agreement":null},{"id":"W2061189534","doi":"10.1007/s10637-009-9236-6","title":"Cyclin-dependent kinase inhibitors as potential targeted anticancer agents","year":2009,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cyclin-dependent kinase; Kinase; Cell cycle; Cyclin; CDK inhibitor; Biology; Cancer research; Drug development; Cell biology; Cell; Drug; Pharmacology; Biochemistry","score_opus":0.03175408200627041,"score_gpt":0.32445668209352097,"score_spread":0.2927026000872506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061189534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027450413,0.9916055,0.00006627442,0.0013871934,0.0016977674,0.0018019052,0.00014195858,0.00021526028,0.0028096242],"genre_scores_gemma":[0.00027988665,0.98394156,0.0015255461,0.0027198982,0.0031193336,0.000088438064,0.002589513,0.00018990035,0.0055459538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521923,0.00018090158,0.0012860164,0.0010310475,0.0016914131,0.00059137057],"domain_scores_gemma":[0.9972381,0.00008105086,0.0006748597,0.0006946446,0.00021618702,0.0010951721],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002664866,0.00081528974,0.0017409566,0.00051750714,0.00013924234,0.00007677976,0.00033297905,0.0007927679,0.00091354427],"category_scores_gemma":[0.000401835,0.00076876744,0.00096394913,0.00074176653,0.0002404835,0.00012394795,0.00012204243,0.0012220638,0.0015522913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052230505,0.00022425444,0.000004581739,0.0032707804,0.0007717841,0.001070848,0.00013860098,0.0000965159,0.00027101493,0.000801952,0.076707415,0.91659003],"study_design_scores_gemma":[0.001548634,0.00015432366,0.00003305895,0.013265823,0.0022255958,0.0005485639,0.000009021115,0.000034806933,0.00037061947,0.0018458654,0.97926176,0.000701939],"about_ca_topic_score_codex":0.00024694513,"about_ca_topic_score_gemma":0.0000059192844,"teacher_disagreement_score":0.9158881,"about_ca_system_score_codex":0.00086630083,"about_ca_system_score_gemma":0.006749128,"threshold_uncertainty_score":0.99999976},"labels":[],"label_agreement":null},{"id":"W2063038645","doi":"10.1007/s10637-009-9246-4","title":"Esophageal ulcer in a patient who received bevacizumab","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Bevacizumab; Irinotecan; Perforation; Esophagus; Esophageal Ulcer; Surgery; Esophageal cancer; Regimen; Endoscopy; Dysphagia; Gastroenterology; Endoscopic mucosal resection; Ileostomy; Internal medicine; Colorectal cancer; Chemotherapy; Cancer","score_opus":0.015227393686470305,"score_gpt":0.2713807269272034,"score_spread":0.2561533332407331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063038645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96584755,0.00073716283,0.0000030793292,0.015858354,0.000082912615,0.00031465007,0.000007822074,0.000038727303,0.01710971],"genre_scores_gemma":[0.98979825,0.000030274474,0.001138743,0.0065556047,0.00015681147,0.0000220068,0.000034007226,0.000007933733,0.0022563771],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990446,0.0000197598,0.00022999616,0.00022305158,0.0003046017,0.00017799308],"domain_scores_gemma":[0.9995651,0.000042777727,0.00005002117,0.000107830216,0.00006210611,0.00017214351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043188,0.00013239429,0.00021920369,0.00009482496,0.000056304107,0.000012535773,0.000038942922,0.00004626293,0.00015148398],"category_scores_gemma":[0.00007737046,0.000110678324,0.000057631078,0.00022564619,0.00005711491,0.00007357468,0.000015749243,0.00011435912,0.000039248876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029675744,0.0015476388,0.14506328,0.0000852394,0.0004619776,0.0010814943,0.04635714,0.0005238952,0.0022968939,0.019459607,0.1456044,0.63455087],"study_design_scores_gemma":[0.004320165,0.0010451861,0.94990605,0.00020777453,0.00005242542,0.000048785005,0.0002493723,0.00024537975,0.0015867188,0.023916358,0.018209385,0.0002123955],"about_ca_topic_score_codex":0.00020474783,"about_ca_topic_score_gemma":0.000057109577,"teacher_disagreement_score":0.80484277,"about_ca_system_score_codex":0.00023287637,"about_ca_system_score_gemma":0.0003066006,"threshold_uncertainty_score":0.4513331},"labels":[],"label_agreement":null},{"id":"W2063432158","doi":"10.1007/s10637-011-9719-0","title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Sorafenib; Medicine; Internal medicine; Gallbladder; Gastroenterology; Oncology; Carcinoma; Hepatocellular carcinoma; Stage (stratigraphy); Chemotherapy; Gallbladder cancer","score_opus":0.04928934074195547,"score_gpt":0.27559561059896975,"score_spread":0.2263062698570143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063432158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701726,0.00040176586,0.00000635416,0.000265319,0.000052640036,0.0011746832,0.000025628493,0.000028532486,0.0010278234],"genre_scores_gemma":[0.9972536,0.00000393447,0.0015159886,0.00036661804,0.00005952253,0.00007606511,0.000048592603,0.00003655688,0.00063911785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801564,0.0000684161,0.00049296144,0.00046059085,0.0006408435,0.0003215578],"domain_scores_gemma":[0.99889225,0.00008556877,0.00017756902,0.00031436502,0.00022970437,0.00030054516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001685451,0.0002907109,0.0005609201,0.00032222774,0.0001150042,0.000015642447,0.00013199767,0.00004808616,0.00017208079],"category_scores_gemma":[0.000096391566,0.00021132763,0.000051421925,0.0005470364,0.00021407848,0.00024450693,0.00012748216,0.00020255057,0.000004610255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027738863,0.0026496288,0.96674055,0.00009850991,0.00029146238,0.00007534537,0.025298625,0.0000032977314,0.00006865727,0.00013098343,0.0010181587,0.0008508767],"study_design_scores_gemma":[0.02863069,0.0076052584,0.9594144,0.00011521402,0.00030397158,0.000014968351,0.002626058,0.000037156555,0.0005756683,0.00036221943,0.00007761538,0.00023678406],"about_ca_topic_score_codex":0.0023593642,"about_ca_topic_score_gemma":0.00060314615,"teacher_disagreement_score":0.025856804,"about_ca_system_score_codex":0.00006807921,"about_ca_system_score_gemma":0.00048398343,"threshold_uncertainty_score":0.8617691},"labels":[],"label_agreement":null},{"id":"W2064256411","doi":"10.1007/s10637-015-0222-x","title":"3,4′,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Resveratrol; Phytoalexin; In vivo; Pharmacology; Polyphenol; Potency; Apoptosis; Angiogenesis; In vitro; Cell growth; Cell cycle; Cancer; Chemistry; Cancer research; Biology; Biochemistry; Biotechnology; Antioxidant; Genetics","score_opus":0.023703673029608102,"score_gpt":0.28568552796131413,"score_spread":0.261981854931706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064256411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737863,0.0020834154,0.003984284,0.01229109,0.00042537865,0.0005147606,0.000017813012,0.00007830507,0.0068186554],"genre_scores_gemma":[0.9666979,0.000036146917,0.027751124,0.0020530818,0.0007591693,0.000011786171,0.000103781524,0.000028290615,0.0025587487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997876,0.000064519976,0.00043317792,0.00033139857,0.0010222307,0.00027267038],"domain_scores_gemma":[0.9982293,0.00012998759,0.0001594282,0.00029899125,0.00057923514,0.00060300773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033114248,0.00022093831,0.00046600425,0.00019453796,0.00004956729,0.000011479247,0.00013277853,0.00010707891,0.000088821864],"category_scores_gemma":[0.00035150518,0.00015114494,0.00009087445,0.00056713744,0.00047195554,0.00012995998,0.00001923054,0.0003334995,0.000010530304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072161714,0.0007115505,0.031726584,0.00051634264,0.0018093894,0.0003307679,0.0118213445,0.0036727204,0.8329203,0.015043167,0.070231825,0.023999805],"study_design_scores_gemma":[0.07863575,0.008798331,0.18091676,0.0050600455,0.0032532946,0.0013387863,0.004885739,0.011173378,0.62283355,0.0373937,0.043129053,0.0025815954],"about_ca_topic_score_codex":0.00055736373,"about_ca_topic_score_gemma":0.000030043726,"teacher_disagreement_score":0.21008676,"about_ca_system_score_codex":0.00008231274,"about_ca_system_score_gemma":0.0019600256,"threshold_uncertainty_score":0.6163512},"labels":[],"label_agreement":null},{"id":"W2066557153","doi":"10.1007/s10637-011-9673-x","title":"A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gemcitabine; Eribulin; Medicine; Internal medicine; Pancreatic cancer; Neutropenia; Gastroenterology; Phases of clinical research; Oncology; Progressive disease; Clinical endpoint; Refractory (planetary science); Adverse effect; Cancer; Metastatic breast cancer; Chemotherapy; Breast cancer; Clinical trial","score_opus":0.04866918016163396,"score_gpt":0.34107250550963053,"score_spread":0.29240332534799657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066557153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952808,0.000608921,0.0000011755252,0.0014254827,0.00021721153,0.0008039499,0.000025313917,0.00002136496,0.0016158023],"genre_scores_gemma":[0.99518096,0.00005497014,0.00033144784,0.00072356215,0.00010532145,0.00015201214,0.000024656916,0.000016964634,0.0034100786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988371,0.000084100975,0.00038441515,0.00024486662,0.00026817244,0.00018136083],"domain_scores_gemma":[0.99929184,0.00006472622,0.00018260913,0.00023040056,0.00007997769,0.00015047623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107758766,0.00015896722,0.00031947278,0.00011453353,0.00006443946,0.0000024140359,0.00012315187,0.000051142266,0.000867384],"category_scores_gemma":[0.000054151726,0.0001153094,0.00006331398,0.00042342854,0.00013418552,0.000090878326,0.000055072916,0.0001883152,0.000006850492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007048501,0.022815514,0.7260762,0.00019150872,0.0012563654,0.00013077064,0.076186344,0.00041102903,0.13232698,0.0016906462,0.009192495,0.02267366],"study_design_scores_gemma":[0.062306453,0.008702003,0.8796339,0.00043944397,0.0009665816,0.00002247334,0.0012242638,0.0003310442,0.03085719,0.0048997793,0.010191292,0.000425544],"about_ca_topic_score_codex":0.004271796,"about_ca_topic_score_gemma":0.0014615989,"teacher_disagreement_score":0.15355773,"about_ca_system_score_codex":0.00015278083,"about_ca_system_score_gemma":0.00056661514,"threshold_uncertainty_score":0.94972473},"labels":[],"label_agreement":null},{"id":"W2067193622","doi":"10.1023/b:drug.0000026252.86842.e2","title":"A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Hamilton Regional Laboratory Medicine Program; BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Neutropenia; Toxicity; Limiting; Maximum tolerated dose; Chemotherapy; Gastroenterology; Internal medicine; Surgery; Pharmacology","score_opus":0.012139141604533549,"score_gpt":0.2486694885995397,"score_spread":0.23653034699500614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067193622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988121,0.000020096337,0.000030790794,0.00026984356,0.00009221457,0.0006635535,0.00003890042,0.00003557486,0.00003697336],"genre_scores_gemma":[0.99833584,0.0000012888136,0.0012224058,0.00030387027,0.00005046583,0.00002762086,0.000029407134,0.000019647126,0.000009451944],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99820185,0.000080552556,0.00040524843,0.00040225117,0.00065041747,0.00025965722],"domain_scores_gemma":[0.9990609,0.00006822759,0.00019808659,0.00025729623,0.00014936228,0.00026609434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002552256,0.00018291804,0.00024695828,0.0001528698,0.00009761378,0.0000469464,0.00020124536,0.000053870262,0.000060111197],"category_scores_gemma":[0.00007467819,0.0001655006,0.000015015435,0.00031223262,0.000250121,0.00058050634,0.00007839802,0.00010905725,0.000021674197],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004459788,0.015598352,0.31010932,0.00013255673,0.000095985175,0.00010650844,0.058461256,0.078381635,0.52155566,0.0022471324,0.00033581452,0.008515959],"study_design_scores_gemma":[0.068640865,0.018482145,0.53569067,0.0006298658,0.00014103022,0.000013154372,0.0028167225,0.0010697107,0.3323939,0.038928397,0.000047275098,0.0011462793],"about_ca_topic_score_codex":0.008389557,"about_ca_topic_score_gemma":0.002008578,"teacher_disagreement_score":0.22558132,"about_ca_system_score_codex":0.00023379458,"about_ca_system_score_gemma":0.0010212217,"threshold_uncertainty_score":0.99821365},"labels":[],"label_agreement":null},{"id":"W2068833931","doi":"10.1007/s10637-008-9184-6","title":"Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Calcitriol; Medicine; Pancreatic cancer; Internal medicine; Oncology; Cancer; Cancer research; Calcium","score_opus":0.04046030513904524,"score_gpt":0.3491620148261989,"score_spread":0.30870170968715366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068833931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961692,0.00017367686,0.00010869936,0.00032292944,0.000028736682,0.0026501194,0.000028751017,0.00003719485,0.00048068882],"genre_scores_gemma":[0.9918618,0.00007859047,0.0040560924,0.00032669146,0.000039911323,0.00030541426,0.000110412955,0.000032805627,0.0031882597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728006,0.00017004236,0.0007553686,0.00043554162,0.00094042835,0.00041856302],"domain_scores_gemma":[0.99814034,0.00034558497,0.0002820714,0.00032548682,0.0004887829,0.00041775443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002130944,0.00028003808,0.0009837517,0.00028188425,0.0001431421,0.0000054341326,0.00015344849,0.00007173894,0.00038602893],"category_scores_gemma":[0.0005125595,0.00019134622,0.000049784125,0.0009298581,0.00038796137,0.00017257892,0.00005114723,0.0002721975,0.000012980409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014813935,0.013687726,0.94509715,0.00027216363,0.0009662712,0.0002008155,0.014246762,0.00070688647,0.0009756032,0.0000679025,0.000703305,0.00826146],"study_design_scores_gemma":[0.15042348,0.0347892,0.80695075,0.0013609922,0.001032471,0.000036845435,0.001175645,0.0014057882,0.0018336175,0.00035904517,0.00013273301,0.00049941876],"about_ca_topic_score_codex":0.0017195565,"about_ca_topic_score_gemma":0.00052370696,"teacher_disagreement_score":0.13814642,"about_ca_system_score_codex":0.00024388138,"about_ca_system_score_gemma":0.0032554138,"threshold_uncertainty_score":0.7802872},"labels":[],"label_agreement":null},{"id":"W2070030853","doi":"10.1007/s10637-012-9856-0","title":"A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Neutropenia; Paclitaxel; Lung cancer; Adverse effect; Internal medicine; Toxicity; Population; Oncology; Pharmacology; Chemotherapy; Gastroenterology","score_opus":0.011286878644105476,"score_gpt":0.31518292024716726,"score_spread":0.3038960416030618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070030853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973052,0.0002272522,0.000057201585,0.00023771686,0.00006198202,0.0015843482,0.000020008289,0.000013940381,0.00049236085],"genre_scores_gemma":[0.9968289,0.0000041283547,0.0023754044,0.0001722476,0.000038149126,0.00022653029,0.00012924413,0.000026001393,0.00019940687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988596,0.000037323553,0.0003007757,0.00020478347,0.0003764385,0.00022110136],"domain_scores_gemma":[0.9993297,0.00005004687,0.00018345773,0.00012781202,0.00013849052,0.00017050463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006968257,0.0001626227,0.00023714165,0.00020672647,0.000037129677,0.000009515885,0.000050533676,0.00003148723,0.00003381235],"category_scores_gemma":[0.000010712184,0.00012583229,0.000016562764,0.00040859738,0.000047961777,0.00029113732,0.000014332305,0.00012753576,0.0000013185345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006120937,0.006741124,0.97341895,0.00012428909,0.000077584235,0.000004323585,0.014030566,0.0016700404,0.00080473645,0.000028103725,0.000103087106,0.002385108],"study_design_scores_gemma":[0.07865162,0.0013437372,0.91429144,0.00071204704,0.00029051583,0.000001011106,0.0012174651,0.00082474394,0.002394967,0.000042301534,0.000051048817,0.00017912524],"about_ca_topic_score_codex":0.0009283752,"about_ca_topic_score_gemma":0.00011873498,"teacher_disagreement_score":0.07803953,"about_ca_system_score_codex":0.00035349632,"about_ca_system_score_gemma":0.0004942712,"threshold_uncertainty_score":0.5131292},"labels":[],"label_agreement":null},{"id":"W2070830789","doi":"10.1023/b:drug.0000011792.13160.b0","title":"Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"University of Toronto","keywords":"Pharmacokinetics; Medicine; Pharmacology; Dosing; Bolus (digestion); Tolerability; Bilirubin; Toxicity; Nausea; Internal medicine; Adverse effect","score_opus":0.020678511874418576,"score_gpt":0.3127480514658571,"score_spread":0.29206953959143855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070830789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967632,0.00027335936,0.0014215556,0.00051219354,0.00009572454,0.00063963566,0.00016998105,0.000006960124,0.00011734577],"genre_scores_gemma":[0.996859,0.000040031093,0.0014114353,0.0009989963,0.0001934563,0.000046092162,0.00023704473,0.00001842124,0.00019552284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999208,0.000027943122,0.00019547377,0.00029344982,0.00013392366,0.00014124993],"domain_scores_gemma":[0.99944293,0.000020548052,0.0001030548,0.00014109287,0.00012110802,0.00017124315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000939978,0.00013072773,0.00013969978,0.00003806143,0.00006988875,0.000016165664,0.00010975096,0.00006200188,0.0000125578645],"category_scores_gemma":[0.00003129942,0.00013711357,0.000033393673,0.00005875307,0.00010769416,0.0000064965016,0.000041174608,0.000051519728,0.0000010648963],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007117561,0.0010463895,0.000028579805,0.000017348264,0.00020568614,0.0000041673543,0.005698893,0.0004898131,0.97479147,0.0047298167,0.0007200631,0.011556049],"study_design_scores_gemma":[0.021309063,0.0088928025,0.00020173195,0.000024775914,0.00013933041,0.000029391305,0.0029008768,0.00016706767,0.9043943,0.05201344,0.009626435,0.00030075383],"about_ca_topic_score_codex":0.00031187365,"about_ca_topic_score_gemma":0.000045524586,"teacher_disagreement_score":0.0703971,"about_ca_system_score_codex":0.000015392563,"about_ca_system_score_gemma":0.00045184666,"threshold_uncertainty_score":0.55913293},"labels":[],"label_agreement":null},{"id":"W2072016597","doi":"10.1007/s10637-011-9700-y","title":"Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Apoptosis; Jurkat cells; Cell culture; Cell growth; Chemistry; Growth inhibition; Cell biology; Kinase; Flow cytometry; Cancer research; Molecular biology; Biology; Biochemistry; Immunology; T cell; Genetics","score_opus":0.023515593660788064,"score_gpt":0.2322449968493194,"score_spread":0.20872940318853134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072016597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728703,0.00038769442,0.0006259031,0.0001838294,0.00008340915,0.00019148878,0.000100395235,0.0000069525377,0.0011332993],"genre_scores_gemma":[0.99548465,0.00009268831,0.0034112583,0.00050405686,0.00009032662,0.000051003808,0.000097422875,0.000025715908,0.00024285978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998663,0.000048287176,0.0005115841,0.00034794846,0.00021329935,0.00021589576],"domain_scores_gemma":[0.99905026,0.000025450441,0.00028351878,0.00032245362,0.00017806567,0.00014024202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015647092,0.0001843528,0.00023190226,0.00013346919,0.000037046244,0.000009008582,0.00024042292,0.00015950367,0.000053420652],"category_scores_gemma":[0.00009530523,0.0001860637,0.00011921814,0.00024341994,0.00016725565,0.0000110635365,0.000088918336,0.000094885545,0.000007141255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022520786,0.000097055985,0.0065930686,0.000035231664,0.00015650233,0.0000020116615,0.0011748571,0.00016704794,0.98735523,0.0010875795,0.001710743,0.0013954757],"study_design_scores_gemma":[0.00092852325,0.00015501106,0.008314678,0.00011634046,0.00005782495,0.000007598241,0.0001787762,0.00021813651,0.98791075,0.0015734261,0.00033465543,0.00020427986],"about_ca_topic_score_codex":0.0009040808,"about_ca_topic_score_gemma":0.00002766714,"teacher_disagreement_score":0.0027853553,"about_ca_system_score_codex":0.00007179008,"about_ca_system_score_gemma":0.0009525543,"threshold_uncertainty_score":0.75874573},"labels":[],"label_agreement":null},{"id":"W2073021016","doi":"10.1007/s10637-005-0793-z","title":"Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Renal cell carcinoma; Medicine; Carcinoma; Internal medicine; Oncology; Phases of clinical research; Chemotherapy","score_opus":0.019725545834419628,"score_gpt":0.2647082686783908,"score_spread":0.24498272284397118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073021016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771047,0.00008036974,0.000009070829,0.000489586,0.000017319904,0.0014844955,0.000019244206,0.0000065196587,0.00018294215],"genre_scores_gemma":[0.9943382,0.0000012524032,0.0050080647,0.00015841705,0.00001844383,0.0000175488,0.000033927907,0.0000172102,0.0004069482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839747,0.00008941016,0.000502183,0.0002481966,0.0006109291,0.00015179932],"domain_scores_gemma":[0.99904406,0.00013294176,0.00023964088,0.00026360535,0.0001526937,0.00016707974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001237202,0.00017851268,0.00035884124,0.00010286408,0.00005200939,0.0000037641335,0.00009525618,0.00002728156,0.000040932173],"category_scores_gemma":[0.00007645502,0.000102446436,0.000035714766,0.00034380495,0.00018728609,0.000094032985,0.00006260504,0.00012985898,0.0000013682793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029161897,0.029962763,0.86508137,0.0003339326,0.000405919,0.000054832046,0.019910362,0.008009199,0.008451198,0.00024061161,0.00053138006,0.037856527],"study_design_scores_gemma":[0.0782453,0.012235528,0.8903963,0.00018116864,0.00028205846,0.0000070536266,0.0003563184,0.00020908662,0.01775473,0.00006159016,0.00013513982,0.00013574013],"about_ca_topic_score_codex":0.00017727469,"about_ca_topic_score_gemma":0.0001330577,"teacher_disagreement_score":0.049083404,"about_ca_system_score_codex":0.00010049733,"about_ca_system_score_gemma":0.00053249934,"threshold_uncertainty_score":0.41776443},"labels":[],"label_agreement":null},{"id":"W2073369621","doi":"10.1007/s10637-005-5862-9","title":"A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Ottawa Regional Cancer Foundation; Cancer Care Ontario","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Adverse effect; Rash; Cancer; Oncology; Nausea; Tolerability; Chemotherapy; Gastroenterology","score_opus":0.026954450114541846,"score_gpt":0.30517916414720736,"score_spread":0.2782247140326655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073369621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945656,0.00026960493,0.0000052181463,0.0031270431,0.00022072908,0.0012163144,0.00039772916,0.000035907924,0.00016183114],"genre_scores_gemma":[0.9950987,0.000023694456,0.002887387,0.00054383226,0.0004471056,0.0001861972,0.0004349463,0.00003566632,0.00034248718],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978165,0.00011130732,0.00057943986,0.0004246012,0.000738771,0.00032938438],"domain_scores_gemma":[0.9988328,0.00011075364,0.00024116636,0.000147251,0.00031531355,0.00035268944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014511739,0.00032420031,0.0006231703,0.00019379724,0.00013564037,0.000018306748,0.000092489485,0.000067182074,0.0005532606],"category_scores_gemma":[0.0001719223,0.00024416848,0.00009567176,0.00034568377,0.00029929154,0.0003908567,0.000058285346,0.00019450708,0.0000072769412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24517155,0.040766377,0.50934637,0.00035688453,0.0021897808,0.0000616448,0.03198411,0.0004207831,0.013854691,0.0015766361,0.015884591,0.13838662],"study_design_scores_gemma":[0.49088874,0.031585544,0.44302836,0.00058205647,0.00065214804,0.000006257829,0.0003557333,0.0005365331,0.0261361,0.0004447028,0.0048770024,0.00090683566],"about_ca_topic_score_codex":0.001658609,"about_ca_topic_score_gemma":0.00092444004,"teacher_disagreement_score":0.2457172,"about_ca_system_score_codex":0.0003818092,"about_ca_system_score_gemma":0.00092900894,"threshold_uncertainty_score":0.9956901},"labels":[],"label_agreement":null},{"id":"W2074077730","doi":"10.1007/s10637-008-9190-8","title":"Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Romidepsin; Medicine; Colorectal cancer; Internal medicine; Chemotherapy; Oncology; Regimen; Performance status; Mucositis; Induction chemotherapy; Cancer; Surgery; Histone deacetylase; Biology; Histone","score_opus":0.0150066062739379,"score_gpt":0.30320357760859734,"score_spread":0.28819697133465944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074077730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732715,0.00019150115,0.000004604804,0.00018723353,0.00009906318,0.001946303,0.00014381623,0.000022582319,0.00007775119],"genre_scores_gemma":[0.99786067,0.00003140991,0.0003245816,0.00006815167,0.00019348382,0.00041458578,0.00076170085,0.000047965557,0.0002974621],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978022,0.00024162282,0.0005182873,0.0005456074,0.00055548106,0.0003367823],"domain_scores_gemma":[0.9988625,0.000054114586,0.00023257459,0.00024977716,0.00023151447,0.0003694887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018295807,0.0002449405,0.00034826863,0.00014892324,0.0001264152,0.0000074373756,0.00021986078,0.0001275963,0.000024623485],"category_scores_gemma":[0.00028139594,0.00022449472,0.000079254525,0.00035105785,0.00042626914,0.000018621451,0.00010744992,0.00017889746,0.0000037949217],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2485002,0.050907265,0.366455,0.00010759299,0.00062032894,0.00023377752,0.010046868,0.0017391513,0.30377775,0.00007742891,0.00812475,0.009409915],"study_design_scores_gemma":[0.583021,0.077523306,0.20701602,0.0002739502,0.00018973438,0.000014924268,0.00041416063,0.00019665268,0.11993065,0.00013267278,0.009888558,0.0013984118],"about_ca_topic_score_codex":0.00094546075,"about_ca_topic_score_gemma":0.0015355537,"teacher_disagreement_score":0.33452076,"about_ca_system_score_codex":0.00018710057,"about_ca_system_score_gemma":0.0018371054,"threshold_uncertainty_score":0.9154629},"labels":[],"label_agreement":null},{"id":"W2075532113","doi":"10.1007/s10637-014-0138-x","title":"Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Irinotecan; Diarrhea; Medicine; Camptothecin; Toxicity; Pharmacology; Pharmacokinetics; Gastroenterology; Colorectal cancer; Internal medicine; Cancer; Biology; Biochemistry","score_opus":0.0234114526948035,"score_gpt":0.2835922386419162,"score_spread":0.2601807859471127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075532113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954336,0.0000811323,0.003790519,0.00033263027,0.00007329896,0.00018424547,0.000009471299,0.0000037986786,0.000091269394],"genre_scores_gemma":[0.9950067,0.000018614961,0.0044807857,0.00023762231,0.00012037799,0.000012386954,0.000018334344,0.00001217385,0.00009304684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998854,0.00008187509,0.00053470593,0.00018203046,0.00020407322,0.00014334563],"domain_scores_gemma":[0.99913585,0.00014465555,0.0002879822,0.00022422914,0.00013394807,0.000073347495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036424946,0.00011179833,0.00021858302,0.000042577125,0.000023064147,0.000004960564,0.00016650958,0.00006699649,0.0000030461858],"category_scores_gemma":[0.00025977212,0.00009243275,0.00010309216,0.00009743653,0.00020456353,0.0000067788487,0.00006654725,0.000082173065,5.03115e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012029977,0.00008812842,0.004434834,0.0000761244,0.000013364789,1.1761817e-7,0.00021469331,0.008410358,0.97335,0.010878696,0.000060938197,0.002352458],"study_design_scores_gemma":[0.0009790764,0.0006350923,0.0036588372,0.00012533969,0.000018461367,0.000003180603,0.000037839618,0.025599629,0.9568089,0.011905636,0.00014325645,0.00008471626],"about_ca_topic_score_codex":0.00010007277,"about_ca_topic_score_gemma":0.000092593305,"teacher_disagreement_score":0.01718927,"about_ca_system_score_codex":0.000009877047,"about_ca_system_score_gemma":0.0002854049,"threshold_uncertainty_score":0.3769298},"labels":[],"label_agreement":null},{"id":"W2076465532","doi":"10.1007/s10637-007-9104-1","title":"A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Doxorubicin; Hepatocellular carcinoma; Medicine; Sodium; Chemistry; Internal medicine; Chemotherapy","score_opus":0.013069935389937452,"score_gpt":0.25746976716384384,"score_spread":0.2443998317739064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076465532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775577,0.00073851336,0.00017400562,0.00018885346,0.00019438521,0.0006764856,0.000012308803,0.000008463234,0.0002512277],"genre_scores_gemma":[0.99791795,0.000028635743,0.0009495453,0.00024715497,0.00026910717,0.000028107295,0.00018571575,0.00002388997,0.00034989172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846476,0.000071239796,0.0004557933,0.00039458886,0.0003366683,0.00027697184],"domain_scores_gemma":[0.99925184,0.000027391525,0.000178596,0.0002585247,0.00012971032,0.0001539626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039989417,0.00019314619,0.00024940146,0.00022345189,0.000051181258,0.000008439873,0.00013910807,0.0001073276,0.000008375115],"category_scores_gemma":[0.000063869644,0.00019498008,0.000043687614,0.00040352673,0.00011279885,0.000016085254,0.000058814683,0.00013450201,0.0000016986943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010217325,0.0021568893,0.056463577,0.000029844738,0.000042323147,0.000021338492,0.0034906403,0.00055627886,0.92881054,0.00044305692,0.0004860409,0.006477716],"study_design_scores_gemma":[0.049674258,0.0052686767,0.1371329,0.0001010234,0.00007287207,0.00002948808,0.00434356,0.0010727289,0.78262365,0.0012616036,0.017630827,0.00078844134],"about_ca_topic_score_codex":0.0012114102,"about_ca_topic_score_gemma":0.0015990523,"teacher_disagreement_score":0.14618693,"about_ca_system_score_codex":0.000047264297,"about_ca_system_score_gemma":0.00044008257,"threshold_uncertainty_score":0.7951057},"labels":[],"label_agreement":null},{"id":"W2078057935","doi":"10.1007/s10637-011-9722-5","title":"A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"Bayer Canada","keywords":"Bicalutamide; Medicine; Sorafenib; Prostate cancer; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Rash; Clinical trial; Cancer; Androgen receptor; Hepatocellular carcinoma","score_opus":0.031659175896759706,"score_gpt":0.30201894918646277,"score_spread":0.27035977328970306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078057935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970444,0.000039303464,0.0000026322534,0.0008689182,0.000013277699,0.0018094847,0.000019631003,0.000012356686,0.00019000728],"genre_scores_gemma":[0.99871373,0.000009412815,0.00055006467,0.00008563096,0.0000130476565,0.00015624495,0.00011799667,0.000017982527,0.00033588693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986956,0.000049405204,0.00029278148,0.0002466382,0.00054030644,0.00017528342],"domain_scores_gemma":[0.99937034,0.000022353335,0.000133828,0.00012372794,0.00023290615,0.00011685576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012423671,0.000134246,0.00021614217,0.00024386468,0.000042936863,0.000006944033,0.000051069102,0.000037574733,0.000049321625],"category_scores_gemma":[0.000016055623,0.00009309586,0.000013147533,0.00054743723,0.00014136334,0.00017658393,0.000013148179,0.00013964693,9.728882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016196856,0.009656559,0.935629,0.00006228638,0.0001030024,0.000031826803,0.032685798,0.00004723925,0.0015687828,0.00019079755,0.000065533306,0.0037623048],"study_design_scores_gemma":[0.06624364,0.012815354,0.9122341,0.00036301918,0.00003458728,7.377312e-7,0.0010394283,0.00009638777,0.0062777447,0.0007607496,0.000015257613,0.00011893709],"about_ca_topic_score_codex":0.0028828003,"about_ca_topic_score_gemma":0.0012779937,"teacher_disagreement_score":0.050046787,"about_ca_system_score_codex":0.00022455331,"about_ca_system_score_gemma":0.00078592484,"threshold_uncertainty_score":0.4357951},"labels":[],"label_agreement":null},{"id":"W2079006697","doi":"10.1007/s10637-013-0018-9","title":"NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; University Health Network; Queen's University","funders":"","keywords":"Medicine; Pharmacokinetics; Neutropenia; Tolerability; Pharmacodynamics; Internal medicine; Febrile neutropenia; Cmax; Gastroenterology; Anemia; Response Evaluation Criteria in Solid Tumors; Toxicity; Pharmacology; Phases of clinical research; Adverse effect","score_opus":0.010791651067732083,"score_gpt":0.25858450297743635,"score_spread":0.24779285190970426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079006697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980728,0.00018609995,0.000063521584,0.00058928144,0.00009894154,0.00058472477,0.000017408434,0.000010414814,0.00037681448],"genre_scores_gemma":[0.9961138,0.000044624026,0.0012826766,0.00062019844,0.00010758277,0.00007496915,0.00017778737,0.000020854424,0.0015575415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879444,0.00006416823,0.00037935484,0.00032874403,0.00022875838,0.00020453283],"domain_scores_gemma":[0.99927723,0.00002189281,0.00016164064,0.00026351906,0.0001393905,0.00013630882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108347,0.00017568043,0.00018939534,0.00010019432,0.00004668841,0.000020234733,0.00021480546,0.00012487051,0.00006760842],"category_scores_gemma":[0.0001281783,0.00017492556,0.000056690813,0.00018306395,0.00008688352,0.000019462004,0.00013195697,0.000097585646,0.000034310357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006428377,0.00048581185,0.0122298505,0.000019966254,0.00003377178,0.0000026592286,0.0012165768,0.00037855215,0.97734445,0.00018230044,0.004843182,0.0031985946],"study_design_scores_gemma":[0.019221857,0.004706681,0.118492864,0.0003503372,0.00008258466,0.00003876507,0.006716235,0.0010185572,0.81061065,0.01386148,0.023571288,0.0013286814],"about_ca_topic_score_codex":0.0007685472,"about_ca_topic_score_gemma":0.00018942282,"teacher_disagreement_score":0.16673379,"about_ca_system_score_codex":0.000024562165,"about_ca_system_score_gemma":0.0003192289,"threshold_uncertainty_score":0.7133257},"labels":[],"label_agreement":null},{"id":"W2081181781","doi":"10.1007/s10637-007-9103-2","title":"A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Toronto; Cancer Care Ontario; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Leukocytopenia; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Phases of clinical research; Cancer; Liver function; Pharmacokinetics; Neutropenia; Toxicity; Oncology; Surgery","score_opus":0.06080585527464875,"score_gpt":0.3347445557224106,"score_spread":0.2739387004477618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081181781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983708,0.00014532373,0.000010212262,0.000056906556,0.00010981437,0.0011610336,0.0001338041,0.0000011763505,0.000010884512],"genre_scores_gemma":[0.9994573,0.000014992541,0.00014359377,0.00015701851,0.000055662727,0.000051055365,0.00006489747,0.000011341472,0.00004414401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978095,0.00034995997,0.00090967584,0.00027818975,0.0005321106,0.000120547404],"domain_scores_gemma":[0.9988701,0.00007078372,0.0005420502,0.0001573442,0.0002648673,0.00009489859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005622382,0.00015327036,0.00041597473,0.0000644108,0.00007008913,0.0000026033742,0.00018031697,0.00004461555,0.000006500899],"category_scores_gemma":[0.00028211804,0.00011390519,0.000050454968,0.00021989267,0.00021413548,0.000010470449,0.0001103659,0.00011164478,3.3518447e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053906493,0.005484859,0.9730406,0.000041304982,0.00037297865,0.0000030170193,0.0014030008,0.00087962725,0.017209213,0.000026420532,0.00075862085,0.00024132879],"study_design_scores_gemma":[0.054626785,0.0055030496,0.9189701,0.00008529993,0.0003984641,0.000005729297,0.00062063406,0.0012817727,0.017565167,0.00011782876,0.00046745018,0.00035769815],"about_ca_topic_score_codex":0.039795678,"about_ca_topic_score_gemma":0.04727831,"teacher_disagreement_score":0.05408772,"about_ca_system_score_codex":0.000034763765,"about_ca_system_score_gemma":0.0018261535,"threshold_uncertainty_score":0.97010636},"labels":[],"label_agreement":null},{"id":"W2081183120","doi":"10.1007/s10637-014-0182-6","title":"Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"China Scholarship Council","keywords":"Homeobox protein NANOG; SOX2; Stem cell; Downregulation and upregulation; Cell biology; Apoptosis; Cancer stem cell; Embryonic stem cell; Cancer cell; Biology; Cancer research; Reactive oxygen species; Chemistry; Induced pluripotent stem cell; Cancer; Biochemistry; Genetics","score_opus":0.020079328103634525,"score_gpt":0.26918912615858676,"score_spread":0.24910979805495223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081183120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945545,0.00020688122,0.000056184537,0.0021955834,0.00054407795,0.0008874762,0.000049589235,0.00003709671,0.001468583],"genre_scores_gemma":[0.9910541,0.000016690607,0.00015892492,0.004921011,0.00034907527,0.00009980999,0.000018475415,0.000040002265,0.0033418913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794924,0.00020085952,0.00037643916,0.0004015509,0.0007680954,0.00030379172],"domain_scores_gemma":[0.99855345,0.0003172805,0.0003073571,0.00030099327,0.00027379254,0.00024713005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020688568,0.00025948754,0.0004406786,0.0000873469,0.00017675616,0.000023698954,0.00017327329,0.00010335734,0.00007456769],"category_scores_gemma":[0.00012170146,0.00018884237,0.00016488764,0.0003848406,0.00028509193,0.00007776296,0.000061752435,0.000316451,0.000015091533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002337687,0.00041092836,0.05351747,0.00032659012,0.000676955,0.00000602696,0.0035348954,0.0012776975,0.91100585,0.0038615311,0.020888133,0.004260155],"study_design_scores_gemma":[0.002823353,0.00032901648,0.17198151,0.0005941498,0.00023295695,0.000002210803,0.00004423431,0.00014773359,0.82126,0.0011356868,0.001248432,0.00020075274],"about_ca_topic_score_codex":0.0016329209,"about_ca_topic_score_gemma":0.00029467855,"teacher_disagreement_score":0.118464045,"about_ca_system_score_codex":0.00039052984,"about_ca_system_score_gemma":0.0008011911,"threshold_uncertainty_score":0.7700768},"labels":[],"label_agreement":null},{"id":"W2081649373","doi":"10.1007/s10637-005-5860-y","title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Cancer; Medicine; Investigational Drugs; Drug; Cancer drugs; Family medicine; Gerontology; Internal medicine; Clinical trial; Pharmacology","score_opus":0.14092656980953736,"score_gpt":0.45770799104479143,"score_spread":0.3167814212352541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081649373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933965,0.000044115826,0.0000016500543,0.004982414,0.0002327543,0.0050602383,0.00020314369,0.00000991382,0.00012611043],"genre_scores_gemma":[0.9973891,0.0000019208674,0.0011374841,0.0005896441,0.00032683427,0.00020177294,0.000053396412,0.000029327834,0.00027054493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99147934,0.0010450002,0.0025727085,0.0004592684,0.004133163,0.0003105111],"domain_scores_gemma":[0.9956384,0.00068586867,0.0015928297,0.00045841007,0.0012416808,0.00038282629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030242517,0.00027710665,0.0010727535,0.00022706528,0.000088447625,0.000013773342,0.000660679,0.000090340174,0.00009407355],"category_scores_gemma":[0.0037621772,0.00017543639,0.00014383033,0.0014185566,0.000923373,0.00023019407,0.00021146037,0.00060486887,6.402267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012732828,0.016917836,0.947262,0.00013574553,0.00054041663,0.0000020008297,0.0070896107,0.0033222968,0.00012176849,0.00031123834,0.016891528,0.006132259],"study_design_scores_gemma":[0.04801336,0.002802613,0.9426417,0.00090892805,0.00019601431,0.0000017440441,0.0011682882,0.0006381269,0.0010380632,0.00086630485,0.001525231,0.00019966948],"about_ca_topic_score_codex":0.21032289,"about_ca_topic_score_gemma":0.30482167,"teacher_disagreement_score":0.0944988,"about_ca_system_score_codex":0.00052462105,"about_ca_system_score_gemma":0.024907338,"threshold_uncertainty_score":0.98062056},"labels":[],"label_agreement":null},{"id":"W2082800072","doi":"10.1007/s10637-013-9936-9","title":"Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"","keywords":"Bevacizumab; Medicine; Colorectal cancer; Chemotherapy; Oncology; Multicenter study; Retrospective cohort study; Internal medicine; First line; Surgery; Cancer; Randomized controlled trial","score_opus":0.022730997414071086,"score_gpt":0.2621809158162232,"score_spread":0.23944991840215213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082800072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208796,0.000085294385,0.000013975219,0.0047584632,0.00010096442,0.0027985154,0.000043112144,0.000035654914,0.000076088305],"genre_scores_gemma":[0.9945117,0.00002025301,0.0017443692,0.001397973,0.00008119849,0.0012201892,0.00005722523,0.000031989788,0.0009350863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839073,0.000034798883,0.00035782869,0.0004120105,0.00053268607,0.00027196776],"domain_scores_gemma":[0.9991072,0.000059631704,0.00014782381,0.00013762827,0.00038798444,0.00015974435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005976745,0.00026371222,0.00039013478,0.00009796778,0.000079243946,0.000036510668,0.00006255027,0.000033192355,0.00049753673],"category_scores_gemma":[0.000090731766,0.00017095434,0.000049098366,0.00038280533,0.000111481284,0.00024333449,0.000032051503,0.00013346842,0.000021622829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040631727,0.0015475372,0.9851701,0.000028289489,0.00028034017,0.000016930926,0.0056026396,0.00005034191,0.000026368758,0.0000081010785,0.0006288596,0.002577296],"study_design_scores_gemma":[0.016476177,0.0026863755,0.97899187,0.0002190064,0.0001104737,0.0000015302843,0.00050652015,0.0003146568,0.00012929775,0.00020488036,0.00017033039,0.00018891171],"about_ca_topic_score_codex":0.001999024,"about_ca_topic_score_gemma":0.005212145,"teacher_disagreement_score":0.0124130035,"about_ca_system_score_codex":0.0010432248,"about_ca_system_score_gemma":0.00024645732,"threshold_uncertainty_score":0.6971316},"labels":[],"label_agreement":null},{"id":"W2083983329","doi":"10.1007/s10637-006-6406-7","title":"A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Nausea; Vomiting; Sarcoma; Soft tissue sarcoma; Internal medicine; Adverse effect; Toxicity; Progressive disease; Surgery; Population; Dosing; Gastroenterology; Phases of clinical research; Chemotherapy; Soft tissue; Pathology","score_opus":0.04329356748062302,"score_gpt":0.3666796670381587,"score_spread":0.32338609955753567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083983329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705696,0.00026782314,0.00032297507,0.00014116617,0.00030389504,0.0016193264,0.00024537227,0.0000071012523,0.000035386915],"genre_scores_gemma":[0.9964613,0.000006290367,0.0018147182,0.00019970647,0.00031717028,0.0001581668,0.0006234774,0.000026218928,0.00039298888],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967023,0.00036636947,0.0014567752,0.00044688172,0.000799359,0.00022828848],"domain_scores_gemma":[0.9981269,0.00020184406,0.0008000607,0.00020811426,0.0005197089,0.0001433436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093082956,0.00024138698,0.00065237476,0.00008873212,0.00006332294,0.000009794207,0.00022025574,0.00009022621,0.000054198543],"category_scores_gemma":[0.0012511862,0.00019264869,0.00006662666,0.00033953166,0.0002188293,0.000022503109,0.00006035447,0.00012433063,2.5210892e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45433843,0.053991966,0.11144261,0.000615247,0.004243481,0.000073651936,0.0017478005,0.1568194,0.09400805,0.00109191,0.044020813,0.077606626],"study_design_scores_gemma":[0.8401645,0.055794712,0.02359534,0.00080945884,0.0007371009,0.000007631925,0.00019429754,0.0011836076,0.043308217,0.0009745695,0.031724244,0.0015063448],"about_ca_topic_score_codex":0.06350055,"about_ca_topic_score_gemma":0.21179973,"teacher_disagreement_score":0.38582602,"about_ca_system_score_codex":0.00014461683,"about_ca_system_score_gemma":0.0067981873,"threshold_uncertainty_score":0.99883235},"labels":[],"label_agreement":null},{"id":"W2086020450","doi":"10.1007/s10637-011-9697-2","title":"Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Gemcitabine; Axitinib; Medicine; Pharmacokinetics; Pancreatic cancer; Adverse effect; Internal medicine; Oncology; Pharmacology; Cancer; Gastroenterology","score_opus":0.03711149899049349,"score_gpt":0.3264996208753025,"score_spread":0.289388121884809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086020450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961684,0.000039899325,0.000019852647,0.00032424057,0.000019649284,0.0015422228,0.000010001344,0.000015419608,0.0018603256],"genre_scores_gemma":[0.996266,0.0000081730095,0.0029666433,0.00015288817,0.000019860207,0.00020725004,0.0000798709,0.000019769092,0.00027951447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836105,0.00009527496,0.00043295376,0.00027457895,0.00059936696,0.00023679293],"domain_scores_gemma":[0.99904084,0.00013572365,0.0001737459,0.00019723555,0.00027325196,0.00017918483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022376332,0.00015878226,0.00048518265,0.0003085701,0.000029852728,0.0000038067235,0.00009206157,0.000058938767,0.00020431289],"category_scores_gemma":[0.00013055003,0.00011852654,0.000016043272,0.0005924728,0.00020602594,0.00016494544,0.000022348384,0.00021218082,0.0000056286026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002905055,0.005652346,0.98292977,0.00005759989,0.000080866776,0.000019965115,0.005852328,0.00002588086,0.000056504054,0.0005221271,0.000045709774,0.0018518238],"study_design_scores_gemma":[0.05189999,0.0067230505,0.93852973,0.00040676404,0.000095059164,0.0000019687582,0.00095100095,0.00027661884,0.00019266382,0.0007893493,0.000013425819,0.00012038294],"about_ca_topic_score_codex":0.0029362687,"about_ca_topic_score_gemma":0.00080914894,"teacher_disagreement_score":0.048994932,"about_ca_system_score_codex":0.00015844141,"about_ca_system_score_gemma":0.0009713313,"threshold_uncertainty_score":0.48333722},"labels":[],"label_agreement":null},{"id":"W2087779901","doi":"10.1007/s10637-014-0091-8","title":"A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Bicalutamide; Medicine; Vandetanib; Prostate cancer; Tolerability; Internal medicine; Urology; Oncology; Adverse effect; Pharmacology; Cancer; Tyrosine kinase; Androgen receptor","score_opus":0.017686455145267975,"score_gpt":0.3041144943748178,"score_spread":0.28642803922954985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087779901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395674,0.000102694234,0.000016401777,0.002347194,0.000028354596,0.0034249183,0.000020749756,0.000017795865,0.000085119194],"genre_scores_gemma":[0.9987682,0.00005069157,0.0005030014,0.000103838,0.000026373425,0.00018853853,0.00016853122,0.000025028035,0.00016577427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979584,0.00019473491,0.00051636365,0.00036535642,0.000729152,0.00023595919],"domain_scores_gemma":[0.99878865,0.00042393958,0.00019459768,0.00016271463,0.00022819471,0.00020192255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004546302,0.0002168143,0.00061189395,0.00025727556,0.0000820765,0.000019574407,0.00005971346,0.00005640123,0.000026387072],"category_scores_gemma":[0.00016063977,0.00014362944,0.000026200958,0.0005518118,0.00036727058,0.00015592553,0.000021429345,0.0001933356,6.7823225e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8316548,0.005960167,0.14125153,0.00010619985,0.000415116,0.00001992864,0.009518619,0.0005324469,0.0011582832,0.00047186672,0.00003470247,0.008876382],"study_design_scores_gemma":[0.66710615,0.004854322,0.32549897,0.00030890387,0.00008931223,6.417138e-7,0.00020695773,0.0008108549,0.000670328,0.00029106686,0.000027780608,0.00013470821],"about_ca_topic_score_codex":0.0012742298,"about_ca_topic_score_gemma":0.000863933,"teacher_disagreement_score":0.18424743,"about_ca_system_score_codex":0.00021909486,"about_ca_system_score_gemma":0.00055585714,"threshold_uncertainty_score":0.58570385},"labels":[],"label_agreement":null},{"id":"W2088460013","doi":"10.1007/s10637-014-0082-9","title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Rash; Internal medicine; Cancer; Adverse effect; Pharmacodynamics; Breast cancer; Oncology; Tolerability; Phases of clinical research; Colorectal cancer; Clinical trial; Gastroenterology; Pharmacokinetics","score_opus":0.009291892874384198,"score_gpt":0.27114006667339163,"score_spread":0.26184817379900743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088460013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99918765,0.000032074684,0.00015060502,0.00006978363,0.00008611647,0.0003972122,0.000016726333,0.000012503987,0.00004730444],"genre_scores_gemma":[0.9980095,0.0000022380586,0.0012347654,0.00019403169,0.00014361062,0.000024579485,0.0003358784,0.000026646463,0.000028739145],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99855304,0.00012015586,0.00036298129,0.00042515493,0.0003613275,0.0001773212],"domain_scores_gemma":[0.9991944,0.000027372638,0.0002039013,0.00025143288,0.0001683247,0.00015459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019979554,0.00018532411,0.00021040686,0.00008207803,0.000055134824,0.000020217672,0.00012205612,0.00009356335,0.0000058129854],"category_scores_gemma":[0.00010342733,0.00017193142,0.000021119267,0.00015582507,0.00013183073,0.00003576273,0.000053878714,0.00010095461,0.0000011969913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018680438,0.0033847867,0.45960754,0.000058061116,0.00008185893,0.0000020753366,0.0022675977,0.008666178,0.48795375,0.000218829,0.00058944226,0.035301823],"study_design_scores_gemma":[0.034570996,0.016804347,0.7259006,0.0002549038,0.00006336079,0.0000030245646,0.0005248601,0.0034776288,0.2150441,0.0016008102,0.00090426876,0.0008511006],"about_ca_topic_score_codex":0.0001302451,"about_ca_topic_score_gemma":0.00014099776,"teacher_disagreement_score":0.27290967,"about_ca_system_score_codex":0.000030418083,"about_ca_system_score_gemma":0.00020382131,"threshold_uncertainty_score":0.70111597},"labels":[],"label_agreement":null},{"id":"W2089379119","doi":"10.1007/s10637-010-9626-9","title":"Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"RAD51; Molecular biology; DNA-PKcs; DNA damage; Irinotecan; Comet assay; Cancer research; DNA repair; DNA; Chemistry; Homologous recombination; DNA ligase; Biology; Colorectal cancer; Cancer; Biochemistry; Genetics","score_opus":0.0160094944983551,"score_gpt":0.2261960770657665,"score_spread":0.2101865825674114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089379119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99868745,0.000331607,0.00006489465,0.00012520078,0.00014225868,0.00010629558,0.000012756638,0.000007639213,0.0005219261],"genre_scores_gemma":[0.9939632,0.00007523028,0.00520932,0.0002509764,0.000109462075,0.000014120847,0.000019703153,0.000014579123,0.00034341778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928904,0.000029079261,0.00020512819,0.00022393842,0.00012317371,0.00012963671],"domain_scores_gemma":[0.9996256,0.000012601826,0.00009122908,0.00011925369,0.00004483157,0.00010648982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010953897,0.00010081059,0.00010526405,0.000051004565,0.00002006574,0.000004797839,0.00008941319,0.000107878644,0.000028255337],"category_scores_gemma":[0.000022760792,0.00010614272,0.000030437392,0.000086392785,0.00011665296,0.0000055947344,0.00006533804,0.000058046277,0.0000022344777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022092883,0.000025238276,0.002277395,0.000016707641,0.000013598095,0.0000014698674,0.00043033774,0.00008938087,0.9945615,0.0009675699,0.0005134288,0.0010812706],"study_design_scores_gemma":[0.00033269307,0.00007677864,0.0015311817,0.000045842142,0.000007453055,0.0000019895372,0.000061693165,0.00011903497,0.9933842,0.0029492013,0.001373365,0.00011655869],"about_ca_topic_score_codex":0.0006411276,"about_ca_topic_score_gemma":0.00014451779,"teacher_disagreement_score":0.0051444257,"about_ca_system_score_codex":0.00001601351,"about_ca_system_score_gemma":0.00021524477,"threshold_uncertainty_score":0.43283746},"labels":[],"label_agreement":null},{"id":"W2091394897","doi":"10.1007/s10637-006-9009-4","title":"A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Bortezomib; Tolerability; Internal medicine; Phases of clinical research; Adverse effect; Metastatic Urothelial Carcinoma; Population; Cancer; Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Oncology; Surgery; Gastroenterology; Multiple myeloma; Urothelial carcinoma; Bladder cancer","score_opus":0.016727054797264086,"score_gpt":0.2777420946554259,"score_spread":0.26101503985816177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091394897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811214,0.00012343512,0.000028120383,0.00030978472,0.00006168286,0.0009692777,0.00030439848,0.0000030213823,0.00008814455],"genre_scores_gemma":[0.999017,0.000018234718,0.000567283,0.000031597272,0.000054074404,0.000012471762,0.000041491432,0.000007707188,0.00025015665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990507,0.00010737052,0.00031332715,0.00022048065,0.00020077766,0.00010735367],"domain_scores_gemma":[0.99934816,0.000028076902,0.00031093188,0.00017109649,0.00008604887,0.00005565642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015446702,0.000113544185,0.00022856401,0.000039088394,0.0000762602,0.0000029703417,0.00017536648,0.000049065853,0.0000319102],"category_scores_gemma":[0.000093240575,0.00009292512,0.00005195853,0.00015565283,0.00029628677,0.000009074052,0.00013338609,0.00007114654,8.673692e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03529912,0.012884249,0.0067846514,0.00018095868,0.0003159323,0.000011493546,0.0062716883,0.0006260492,0.9276514,0.0016286697,0.00066028733,0.007685477],"study_design_scores_gemma":[0.270084,0.022050051,0.0045571188,0.00017528841,0.00021534046,0.000005338789,0.0019003525,0.00028830647,0.6949354,0.0021997215,0.003180298,0.00040882893],"about_ca_topic_score_codex":0.000939948,"about_ca_topic_score_gemma":0.00070205575,"teacher_disagreement_score":0.23478487,"about_ca_system_score_codex":0.000011113577,"about_ca_system_score_gemma":0.0006373364,"threshold_uncertainty_score":0.37893763},"labels":[],"label_agreement":null},{"id":"W2092271538","doi":"10.1007/s10637-015-0221-y","title":"A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Nausea; Vomiting; Pharmacokinetics; Internal medicine; Tolerability; Toxicity; Gastroenterology; Adverse effect; Surgery; Urology","score_opus":0.025287211490589104,"score_gpt":0.28693944945764266,"score_spread":0.26165223796705356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092271538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981214,0.00023475008,0.00004812019,0.00013222329,0.00019868315,0.0007729884,0.000025392681,0.000008855558,0.00045762942],"genre_scores_gemma":[0.9973074,0.0000068050585,0.0013669676,0.00027975903,0.00024717866,0.000050044542,0.00033685387,0.000027281789,0.00037770803],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853766,0.00007567265,0.0004042325,0.0003862859,0.00038965122,0.0002064807],"domain_scores_gemma":[0.99888706,0.0000130330745,0.00024220062,0.00027954465,0.00031761188,0.00026055635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018943708,0.00018589913,0.00027213906,0.00008309523,0.000042157804,0.000031870728,0.00027435904,0.000061129,0.000008841376],"category_scores_gemma":[0.00014760355,0.00017193433,0.000026489055,0.00026842597,0.00011281896,0.000035692578,0.00012857025,0.0000838491,0.0000036511644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0206258,0.07556935,0.31927907,0.00017322785,0.0011449475,0.000015036946,0.027395904,0.05135362,0.3628611,0.0017033727,0.044219658,0.09565893],"study_design_scores_gemma":[0.35029426,0.039100233,0.3044606,0.00047761615,0.000373702,0.00001783119,0.0049776533,0.00080400705,0.19882613,0.0074897273,0.09014801,0.003030239],"about_ca_topic_score_codex":0.00019045427,"about_ca_topic_score_gemma":0.00022114691,"teacher_disagreement_score":0.32966846,"about_ca_system_score_codex":0.000034171007,"about_ca_system_score_gemma":0.0005886855,"threshold_uncertainty_score":0.7011278},"labels":[],"label_agreement":null},{"id":"W2092652143","doi":"10.1007/s10637-013-0010-4","title":"Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hôpital Notre-Dame","funders":"Pfizer","keywords":"Medicine; Carboplatin; Pemetrexed; Neutropenia; Sunitinib; Rash; Leukopenia; Internal medicine; Adverse effect; Pharmacokinetics; Dosing; Oncology; Gastroenterology; Pharmacology; Toxicity; Chemotherapy; Cancer; Cisplatin","score_opus":0.010599644717435757,"score_gpt":0.2852261942459808,"score_spread":0.27462654952854504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092652143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671,0.000016028413,0.000013064422,0.0007334137,0.000022866727,0.0018268237,0.000053434564,0.000022008511,0.0006023597],"genre_scores_gemma":[0.9960212,0.0000011176966,0.0029402887,0.0001484177,0.000018854937,0.00011473432,0.00046724375,0.000017560022,0.00027057185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998863,0.0000322828,0.00033937226,0.00023810244,0.000385893,0.00014137386],"domain_scores_gemma":[0.9990866,0.00009318389,0.00018746433,0.00014932793,0.00031095347,0.00017245034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059954273,0.00015238363,0.0002555408,0.00014663956,0.000046454512,0.000016335247,0.000034132852,0.0000309685,0.000029760318],"category_scores_gemma":[0.00006909965,0.00010835463,0.000014738506,0.0003550652,0.00010666165,0.00022860625,0.000013103408,0.000076124554,0.0000031350514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039727185,0.0037998764,0.9689534,0.000073294555,0.00033734602,0.000011247584,0.010754667,0.00052327954,0.0012743226,0.00033578937,0.0004177804,0.009546287],"study_design_scores_gemma":[0.05846329,0.0043535843,0.9345387,0.00021052553,0.00013458703,0.0000013264627,0.000988509,0.00033055147,0.00058000674,0.00025746034,0.00001898901,0.00012245563],"about_ca_topic_score_codex":0.0008592852,"about_ca_topic_score_gemma":0.00016152607,"teacher_disagreement_score":0.054490574,"about_ca_system_score_codex":0.00007070277,"about_ca_system_score_gemma":0.00035966965,"threshold_uncertainty_score":0.44185737},"labels":[],"label_agreement":null},{"id":"W2093988174","doi":"10.1007/s10637-012-9886-7","title":"The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Abbott Laboratories","keywords":"PARP inhibitor; Irinotecan; Cancer research; Veliparib; Poly ADP ribose polymerase; Olaparib; Oxaliplatin; DNA damage; PARP1; Cancer; Synthetic lethality; DNA repair; Base excision repair; Colorectal cancer; Biology; Medicine; Polymerase; Internal medicine; DNA; Biochemistry","score_opus":0.03616634036575846,"score_gpt":0.31929290745368355,"score_spread":0.2831265670879251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093988174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709805,0.012070838,0.000020652758,0.012476324,0.0008654457,0.00046604118,0.00006534993,0.000060091592,0.002994742],"genre_scores_gemma":[0.98488784,0.0017447348,0.0013098492,0.0012429695,0.0029201582,0.00020360187,0.00005540506,0.0000331516,0.007602289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862176,0.00005588263,0.0003946777,0.00018089436,0.0004484414,0.00029831444],"domain_scores_gemma":[0.9987067,0.00030693843,0.00022043301,0.00025617596,0.00016291068,0.000346835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013674195,0.0001917484,0.00025015988,0.000043394764,0.00014848425,0.000015283624,0.0000855712,0.00008931734,0.0002874398],"category_scores_gemma":[0.000034822966,0.00013127236,0.000117948206,0.00017790445,0.0003259856,0.0001429176,0.000015804317,0.00008003834,0.000042887666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016818421,0.0025285599,0.108032145,0.00032531115,0.00086341123,0.000010494129,0.017086806,0.0007989014,0.543262,0.02298043,0.23985665,0.062573485],"study_design_scores_gemma":[0.0031321314,0.000395622,0.011796855,0.0001578012,0.00011432836,0.000013029314,0.0002571852,0.000094636816,0.68014324,0.0015135335,0.30218613,0.0001955128],"about_ca_topic_score_codex":0.0011859108,"about_ca_topic_score_gemma":0.00010506772,"teacher_disagreement_score":0.13688125,"about_ca_system_score_codex":0.0004252487,"about_ca_system_score_gemma":0.00078492856,"threshold_uncertainty_score":0.5353132},"labels":[],"label_agreement":null},{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","score_opus":0.02381757120153434,"score_gpt":0.3125895757310258,"score_spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149472508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99842745,0.00018604213,0.000027656662,0.00022170936,0.00003795378,0.0010016882,0.000034996592,0.000016560318,0.000045946497],"genre_scores_gemma":[0.99652064,0.0000032587611,0.003044,0.00023208099,0.000038377053,0.000018089575,0.00004956705,0.000028801973,0.00006521206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979231,0.000059397396,0.00073050655,0.00032976677,0.0007341933,0.00022306241],"domain_scores_gemma":[0.99866176,0.00015856882,0.00046899423,0.0001868535,0.00022210837,0.00030171647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002651473,0.00023327688,0.0005150862,0.000320833,0.000044104276,0.000011711831,0.00006114042,0.000043691714,0.000019406725],"category_scores_gemma":[0.0001732399,0.00019140812,0.00002964168,0.00027423547,0.0003147099,0.00026694709,0.000056706274,0.0001594493,8.600413e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042515352,0.03188136,0.5890997,0.00095567445,0.0007533231,0.0003367946,0.05403939,0.00016305072,0.10178633,0.00022555562,0.00005582016,0.17818765],"study_design_scores_gemma":[0.070072934,0.030680021,0.86363727,0.0014752777,0.00028430173,0.000079537116,0.0101579325,0.000052332627,0.021212295,0.0018300643,0.000097437034,0.00042057372],"about_ca_topic_score_codex":0.00046189275,"about_ca_topic_score_gemma":0.00021734372,"teacher_disagreement_score":0.2745376,"about_ca_system_score_codex":0.0001169715,"about_ca_system_score_gemma":0.00039167592,"threshold_uncertainty_score":0.78053963},"labels":[],"label_agreement":null},{"id":"W2150308444","doi":"10.1007/s10637-010-9444-0","title":"A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Académie française","keywords":"Nimotuzumab; Medicine; Toxicity; Epidermal growth factor receptor; Pharmacodynamics; Rash; Pharmacology; Internal medicine; Cetuximab; Pharmacokinetics; Phases of clinical research; Oncology; Monoclonal antibody; Antibody; Cancer; Immunology","score_opus":0.027555083651461375,"score_gpt":0.35338870311606624,"score_spread":0.3258336194646049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150308444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497074,0.000013904952,0.000036020243,0.0028092014,0.0002965807,0.001419421,0.00008349289,0.000035530335,0.00033508535],"genre_scores_gemma":[0.99553436,0.000009862081,0.0027258748,0.0005340096,0.00040583411,0.0000570039,0.0005815571,0.000036386304,0.0001150879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747777,0.00014004404,0.0005594631,0.0003519516,0.0011379139,0.00033288542],"domain_scores_gemma":[0.998332,0.00024383816,0.00023845166,0.00037497163,0.0004798551,0.00033086425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042010657,0.00020443863,0.00033564714,0.00019676119,0.00009331027,0.000030149864,0.00022549248,0.00012467243,0.00017748427],"category_scores_gemma":[0.00090525975,0.00014247515,0.00006344522,0.0004892603,0.00046600137,0.00039121704,0.00004113388,0.00047099957,0.000014867266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050013054,0.0032990307,0.55219626,0.00028026223,0.00015397173,0.000012417131,0.0072256397,0.0002631521,0.33409595,0.0036980733,0.0024568178,0.046305362],"study_design_scores_gemma":[0.14531843,0.0035739096,0.8036984,0.00047247394,0.00003810875,0.0000034433756,0.00020899416,0.0010520916,0.04119474,0.0018613656,0.0021559543,0.00042207036],"about_ca_topic_score_codex":0.00019173836,"about_ca_topic_score_gemma":0.00007036992,"teacher_disagreement_score":0.29290122,"about_ca_system_score_codex":0.00011539959,"about_ca_system_score_gemma":0.0014968251,"threshold_uncertainty_score":0.5809968},"labels":[],"label_agreement":null},{"id":"W2154086425","doi":"10.1007/s10637-009-9251-7","title":"Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Antiandrogens; LNCaP; Chalcone; Antiandrogen; Prostate cancer; Androgen receptor; Pharmacology; Antagonist; Cancer research; Chemistry; Biology; Internal medicine; Endocrinology; Medicine; Cancer; Receptor; Stereochemistry","score_opus":0.022414702491515264,"score_gpt":0.2939460139984815,"score_spread":0.27153131150696624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154086425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929054,0.000119802084,0.00005837798,0.00579059,0.000045006716,0.00079556793,0.00014187815,0.000026118209,0.000117259544],"genre_scores_gemma":[0.9962774,0.0001762122,0.0020714859,0.0008152801,0.000092215734,0.00004192026,0.00041841768,0.000015674352,0.00009141422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986782,0.00006607093,0.0004124637,0.00031179408,0.00033090252,0.00020058491],"domain_scores_gemma":[0.9988985,0.0004544826,0.00015837951,0.00013757136,0.00014288606,0.00020816289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002772265,0.00015614206,0.00034325427,0.00020366009,0.000052080995,0.000014380206,0.000057043657,0.00011237269,0.000023176286],"category_scores_gemma":[0.0007110698,0.00013310502,0.000066709,0.0002897414,0.00017706119,0.00011219883,0.000015756963,0.0001313266,0.00001409999],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019042058,0.00026736775,0.020935059,0.000056292844,0.000055178,0.000012566027,0.00031182144,0.000009589534,0.9596331,0.00004151675,0.0000143376765,0.01675893],"study_design_scores_gemma":[0.004108301,0.00024508665,0.15040968,0.00040701855,0.00003697412,0.000007977246,0.000028702656,0.0017449094,0.8425027,0.00026071208,0.00012478084,0.00012313349],"about_ca_topic_score_codex":0.000034115583,"about_ca_topic_score_gemma":0.0000020854347,"teacher_disagreement_score":0.12947462,"about_ca_system_score_codex":0.00008757895,"about_ca_system_score_gemma":0.0005566679,"threshold_uncertainty_score":0.5427865},"labels":[],"label_agreement":null},{"id":"W2166042057","doi":"10.1007/s10637-011-9660-2","title":"Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Tolerability; Medicine; Pharmacokinetics; Pharmacodynamics; Myeloid leukemia; Refractory (planetary science); Pharmacology; Internal medicine; Adverse effect; Gastroenterology","score_opus":0.038472222433530136,"score_gpt":0.32911549674982593,"score_spread":0.2906432743162958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166042057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956576,0.000020929003,0.000087022636,0.0012839751,0.00008778238,0.002173681,0.00008308518,0.000028482278,0.00057743216],"genre_scores_gemma":[0.9940418,0.000020911479,0.0038136449,0.0015198009,0.00009111222,0.000045778736,0.00009023008,0.000043276683,0.00033341494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742585,0.0001939103,0.00062970206,0.0004659768,0.00093297125,0.0003515939],"domain_scores_gemma":[0.9982737,0.00023712871,0.00017819743,0.00040845992,0.00042171334,0.00048085692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005970275,0.00027483428,0.00040071423,0.00023727657,0.000116792566,0.00001764036,0.00031942336,0.00006191314,0.0001397759],"category_scores_gemma":[0.00016372235,0.00019316669,0.00004457119,0.00052485004,0.00037212283,0.0002231638,0.00035284524,0.00057310006,0.000010024858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01044609,0.0082710935,0.92626023,0.00013094793,0.0007063599,0.000059110203,0.029821713,0.00018041277,0.009009643,0.00018338668,0.0024010038,0.0125300335],"study_design_scores_gemma":[0.04288195,0.005197128,0.9385398,0.00016393926,0.0004085249,0.000007994744,0.0009889134,0.0040943576,0.005920364,0.0002228865,0.001202998,0.0003711582],"about_ca_topic_score_codex":0.00046899318,"about_ca_topic_score_gemma":0.000048791517,"teacher_disagreement_score":0.03243586,"about_ca_system_score_codex":0.0006057854,"about_ca_system_score_gemma":0.0010657144,"threshold_uncertainty_score":0.7877109},"labels":[],"label_agreement":null},{"id":"W2167646022","doi":"10.1023/a:1015694802521","title":"Targeting Anti-Apoptotic Genes Upregulated by Androgen Withdrawal Using Antisense Oligonucleotides to Enhance Androgen- and Chemo-Sensitivity in Prostate Cancer","year":2002,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Ministry of Education, India; Ministry of Earth Sciences","keywords":"Androgen; Clusterin; Prostate cancer; Cancer research; Tumor progression; Biology; Cancer; Prostate; Medicine; Apoptosis; Oncology; Internal medicine; Hormone; Endocrinology; Genetics","score_opus":0.02925980522481499,"score_gpt":0.33273400604123765,"score_spread":0.3034742008164227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167646022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40840203,0.5896492,0.000010086867,0.0002879457,0.00011913139,0.0012343214,0.0002250495,0.000055857145,0.000016367088],"genre_scores_gemma":[0.015713029,0.97653896,0.005224633,0.0007066344,0.00046114865,0.00010436907,0.0006104993,0.00019670631,0.00044401828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996661,0.000248382,0.00097143726,0.0010631486,0.0004536884,0.000602334],"domain_scores_gemma":[0.99816555,0.00019397853,0.00044129754,0.00034584137,0.00015626974,0.0006970708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035198402,0.0006811122,0.0018366838,0.00035167922,0.00012790578,0.00006531205,0.00011263289,0.00029161866,0.00007567149],"category_scores_gemma":[0.00027887,0.0006726669,0.00016739627,0.00077211665,0.0003770247,0.00015181678,0.00021579351,0.00040735322,0.000029143304],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026529914,0.0006387689,0.034539428,0.047417667,0.0013985623,0.0035014567,0.0036128361,0.002858185,0.053977925,0.000041782416,0.011823694,0.8399244],"study_design_scores_gemma":[0.009684091,0.0006129299,0.0069546974,0.20129742,0.009315656,0.015800225,0.00027972515,0.026506297,0.0422702,0.00071563927,0.67622083,0.010342281],"about_ca_topic_score_codex":0.0004480621,"about_ca_topic_score_gemma":0.000023740185,"teacher_disagreement_score":0.8295821,"about_ca_system_score_codex":0.00034677776,"about_ca_system_score_gemma":0.00092258526,"threshold_uncertainty_score":0.99957246},"labels":[],"label_agreement":null},{"id":"W2205041904","doi":"10.1007/s10637-015-0316-5","title":"Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Vandetanib; Capecitabine; Gemcitabine; Medicine; Internal medicine; Pancreatic cancer; Gastroenterology; Tyrosine-kinase inhibitor; Oncology; Neutropenia; Cancer; Chemotherapy; Sorafenib; Hepatocellular carcinoma","score_opus":0.02157323949200639,"score_gpt":0.31281611314657065,"score_spread":0.29124287365456425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205041904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975439,0.00008129441,0.000017456694,0.00034790728,0.000015054305,0.0017320283,0.000009155227,0.00000985914,0.00024338129],"genre_scores_gemma":[0.99606687,0.000021921813,0.0034083216,0.000103119986,0.000026169444,0.00013100247,0.00015644965,0.00001894479,0.00006717446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831516,0.00012358757,0.00043106166,0.00030085412,0.0005730729,0.00025629133],"domain_scores_gemma":[0.9989746,0.0001737016,0.0001511869,0.00014982186,0.00017410165,0.0003765599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005093284,0.00017901596,0.0006619054,0.00034365823,0.00002154365,0.000008264678,0.00004780054,0.000067974426,0.00000816285],"category_scores_gemma":[0.00021097716,0.00012750176,0.00000809977,0.0004909104,0.00041825775,0.00034432078,0.000017527314,0.00020012009,3.0587861e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046364978,0.0010284559,0.9495132,0.000055463865,0.00003885897,0.00002136555,0.0019016445,0.000099840494,0.000058753616,0.00012545484,0.0000115028,0.0007805045],"study_design_scores_gemma":[0.22757313,0.009303651,0.7593366,0.00043391524,0.00005979997,0.000012556981,0.0006857053,0.0017051267,0.00008337068,0.0006713694,0.0000029924697,0.0001318033],"about_ca_topic_score_codex":0.0016060828,"about_ca_topic_score_gemma":0.0016974676,"teacher_disagreement_score":0.19017659,"about_ca_system_score_codex":0.00029479727,"about_ca_system_score_gemma":0.0015706568,"threshold_uncertainty_score":0.5199371},"labels":[],"label_agreement":null},{"id":"W222191070","doi":"10.1023/a:1020694425356","title":"A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study","year":2002,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Université de Montréal; Cancer Care Ontario; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute","keywords":"Medicine; Nausea; myalgia; Adverse effect; Toxicity; Internal medicine; Lethargy; Phases of clinical research; Chemotherapy; Surgery; Clinical endpoint; Randomized controlled trial; Bryostatin 1; Gastroenterology","score_opus":0.05453415470042501,"score_gpt":0.34755567791445957,"score_spread":0.2930215232140346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W222191070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974664,0.00016125229,0.000041012554,0.00007370211,0.00023483181,0.0016590055,0.00025475575,0.0000027389985,0.000106336156],"genre_scores_gemma":[0.9980703,0.000011303565,0.0013562846,0.00008239824,0.000089088026,0.00012238944,0.00015498926,0.000013316616,0.000099902114],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99666566,0.0006585095,0.0014976399,0.00034216422,0.00068252924,0.00015347285],"domain_scores_gemma":[0.9980702,0.00024922803,0.0009423253,0.00019853012,0.0004078767,0.00013183197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015466381,0.00018534152,0.0008593593,0.00009413882,0.000045439163,0.00000391827,0.00018091266,0.000058325804,0.00004047514],"category_scores_gemma":[0.0014237047,0.00014455535,0.000095098636,0.00018928076,0.00020413035,0.000015601767,0.00006954959,0.00008685182,1.8356974e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123186044,0.035638556,0.75629985,0.00021889682,0.0036487395,0.00002360427,0.0061537134,0.008140611,0.045729127,0.0059955595,0.003361975,0.011603339],"study_design_scores_gemma":[0.9170735,0.010294221,0.05209151,0.00022340422,0.00028540983,0.0000012994757,0.000957241,0.0005721626,0.016706385,0.0008726034,0.0004169192,0.0005053542],"about_ca_topic_score_codex":0.024041045,"about_ca_topic_score_gemma":0.066276036,"teacher_disagreement_score":0.79388744,"about_ca_system_score_codex":0.000030916195,"about_ca_system_score_gemma":0.0012272185,"threshold_uncertainty_score":0.98245794},"labels":[],"label_agreement":null},{"id":"W2265121903","doi":"10.1007/s10637-016-0324-0","title":"A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Ontario Clinical Oncology Group; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Hamilton Health Sciences","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Nausea; Internal medicine; Progressive disease; Melanoma; Adverse effect; Gastroenterology; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Oncology; Toxicity; Chemotherapy; Surgery; Cancer research","score_opus":0.024027290171344008,"score_gpt":0.27115774109121094,"score_spread":0.24713045091986693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265121903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99892527,0.000049124763,0.00004371686,0.00008919318,0.000079114325,0.00066861464,0.00008864832,0.000011024395,0.00004530417],"genre_scores_gemma":[0.99827933,0.000005588699,0.0008656528,0.00007953108,0.0000747721,0.00005105305,0.0003071605,0.000022278879,0.00031462996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985287,0.0001474545,0.00039579967,0.0003990553,0.0003053622,0.00022362336],"domain_scores_gemma":[0.9991715,0.000023450159,0.00017765553,0.00027438867,0.00014109953,0.00021193117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015431405,0.0002025806,0.00023643216,0.000088040826,0.000050497107,0.000009888512,0.00016125837,0.000057301662,0.00004107812],"category_scores_gemma":[0.000094447016,0.00012049398,0.000031535124,0.00016930338,0.00008918297,0.000019551862,0.00006872157,0.000047925543,0.0000044505473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011114899,0.029803053,0.27798653,0.00019175532,0.00069239654,0.000118338874,0.011179834,0.00006735307,0.5877476,0.0009891817,0.0050928704,0.07501623],"study_design_scores_gemma":[0.16357972,0.20292503,0.09460555,0.0012720298,0.00048277993,0.000048180354,0.0016240997,0.00016696875,0.52152056,0.0021840045,0.009402692,0.0021884257],"about_ca_topic_score_codex":0.00016257375,"about_ca_topic_score_gemma":0.00060674385,"teacher_disagreement_score":0.18338098,"about_ca_system_score_codex":0.000026345417,"about_ca_system_score_gemma":0.00045537754,"threshold_uncertainty_score":0.49136022},"labels":[],"label_agreement":null},{"id":"W2283246712","doi":"10.1007/s10637-015-0313-8","title":"A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Adverse effect; Pharmacology; Tolerability; Internal medicine; Nausea; Rash; Toxicity; Gastroenterology; Urology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Chemistry","score_opus":0.026928520588647132,"score_gpt":0.31284350585575443,"score_spread":0.2859149852671073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283246712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970665,0.0008376669,0.00007578145,0.00055429776,0.00036089623,0.0003724682,0.000067474626,0.000016153228,0.00064879155],"genre_scores_gemma":[0.9956735,0.000022839757,0.0021367841,0.00048402973,0.0009435471,0.000050705003,0.0001729222,0.000032196018,0.00048349454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835736,0.00008572473,0.00051264965,0.00042577807,0.00036273288,0.000255746],"domain_scores_gemma":[0.9989807,0.000050483424,0.00023749679,0.00025483262,0.0001469332,0.0003295591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034021802,0.0002153082,0.00029644373,0.00010482189,0.000033045733,0.000019852185,0.00017934595,0.00016194835,0.000012141149],"category_scores_gemma":[0.0004817833,0.00022404845,0.000070552305,0.00019214861,0.0002636776,0.00001941613,0.00008384723,0.00013516945,0.000005519363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010811582,0.0005224905,0.0014314083,0.000047574293,0.00007185458,0.000013927196,0.0012530767,0.0012096347,0.96294546,0.0005462834,0.01556524,0.0055814944],"study_design_scores_gemma":[0.12484028,0.0038787602,0.00041301292,0.00020347361,0.000040465522,0.00003303082,0.00036099475,0.0005977941,0.83415437,0.008282389,0.02651532,0.0006800815],"about_ca_topic_score_codex":0.000119930155,"about_ca_topic_score_gemma":0.00003877187,"teacher_disagreement_score":0.12879103,"about_ca_system_score_codex":0.000056529225,"about_ca_system_score_gemma":0.0011070783,"threshold_uncertainty_score":0.91364306},"labels":[],"label_agreement":null},{"id":"W2302509459","doi":"10.1007/s10637-016-0340-0","title":"Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Oxaliplatin; Medicine; Glioma; Toxicity; Radiation therapy; Chemotherapy; Liposome; Pharmacology; Drug delivery; Internal medicine; Colorectal cancer; Cancer; Cancer research; Chemistry","score_opus":0.024651485260664144,"score_gpt":0.23841443219605876,"score_spread":0.2137629469353946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302509459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937136,0.000019337134,0.004005048,0.0011194508,0.0002932844,0.0004459794,0.00016413633,0.000058966525,0.00018015364],"genre_scores_gemma":[0.9924956,0.000003341216,0.0068854503,0.00011145385,0.00010863223,0.000028966268,0.000045970497,0.000031353473,0.0002892389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996766,0.0002260042,0.0010675609,0.0004930573,0.0010069296,0.00044048132],"domain_scores_gemma":[0.99786985,0.00070200214,0.0005254309,0.0003534576,0.0002916586,0.0002576244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010500448,0.00028130252,0.0004538161,0.00031209935,0.0000948546,0.0000331906,0.00033039067,0.00015193583,0.00037103056],"category_scores_gemma":[0.00033292844,0.00025092106,0.00010630451,0.00044063697,0.00030624692,0.00081025425,0.00015349271,0.00011123511,0.00007274263],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020097847,0.00012537262,0.0056327214,0.000044605582,0.000014899291,0.0000039126116,0.0008992643,0.020038718,0.9677826,0.004790523,0.00016400129,0.0003024133],"study_design_scores_gemma":[0.0016317168,0.000087316,0.0020754128,0.00027049176,0.00002225479,0.0000032271162,0.00011934383,0.07389977,0.9072987,0.014320797,0.0000053546096,0.0002656434],"about_ca_topic_score_codex":0.0006847936,"about_ca_topic_score_gemma":0.0006623701,"teacher_disagreement_score":0.060483914,"about_ca_system_score_codex":0.00030313895,"about_ca_system_score_gemma":0.0008102485,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W2308312264","doi":"10.1007/s10637-015-0315-6","title":"Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Isotype; Tubulin; Colchicine; In vivo; Microtubule; Protein subunit; Cancer research; Paclitaxel; Biology; Breast cancer; Cancer; Chemistry; Pharmacology; Antibody; Immunology; Biochemistry; Cell biology; Genetics; Gene","score_opus":0.011244367174109949,"score_gpt":0.25703212659933466,"score_spread":0.2457877594252247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308312264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978733,0.00038421797,0.00022298725,0.0005918802,0.00013795242,0.00020797552,0.00027877712,0.0000048747115,0.00029805748],"genre_scores_gemma":[0.9980799,0.00003076499,0.0004040589,0.0008161936,0.00028474632,0.000009793311,0.00013807292,0.00001819307,0.00021826327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908465,0.00007060969,0.0002552516,0.00021846764,0.00022945162,0.00014158149],"domain_scores_gemma":[0.9992233,0.000060317547,0.00021074379,0.0002509308,0.00013842205,0.00011627966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002552849,0.0001518916,0.00020214138,0.00003841114,0.00003874563,0.000009966937,0.00019476027,0.00008055876,0.0000116038],"category_scores_gemma":[0.00007272698,0.00010896928,0.00007916178,0.00012653314,0.0002014158,0.00000543575,0.000069716654,0.000094076306,0.0000038793673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017400185,0.000048314603,0.0026806032,0.00004123075,0.000054556138,4.1467143e-7,0.00008672823,0.0024505,0.9880285,0.00027810593,0.0057910006,0.0003659926],"study_design_scores_gemma":[0.0013682232,0.00032036373,0.0036605347,0.00015317881,0.000046469282,0.000012936044,0.000024264144,0.001054015,0.99110883,0.000118053336,0.002000359,0.00013278141],"about_ca_topic_score_codex":0.000403016,"about_ca_topic_score_gemma":0.000031865664,"teacher_disagreement_score":0.0037906417,"about_ca_system_score_codex":0.00001844958,"about_ca_system_score_gemma":0.00041236187,"threshold_uncertainty_score":0.44436383},"labels":[],"label_agreement":null},{"id":"W2309983655","doi":"10.1007/s10637-016-0335-x","title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Veliparib; Cyclophosphamide; PARP inhibitor; Medicine; Triple-negative breast cancer; Nitrogen mustard; Internal medicine; Oncology; Breast cancer; Chemotherapy; Metastatic breast cancer; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","score_opus":0.01259685493353731,"score_gpt":0.2914200369288869,"score_spread":0.2788231819953496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309983655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97265893,0.00073961273,0.00007301426,0.02247703,0.0005316421,0.002821297,0.0005315164,0.000031249947,0.00013567678],"genre_scores_gemma":[0.9956955,0.00019905674,0.00086999085,0.0014746967,0.0005489763,0.00051291246,0.00007552395,0.000036109384,0.0005872837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974299,0.00033290728,0.0008252612,0.00040361664,0.0007252316,0.00028307902],"domain_scores_gemma":[0.9976749,0.000911526,0.0005734825,0.0002503595,0.00029891712,0.0002908262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056701625,0.00029827177,0.00087393005,0.000171404,0.000113828355,0.000013849551,0.00011099988,0.000090673304,0.00022428749],"category_scores_gemma":[0.00055320724,0.00016075105,0.00013188143,0.0004303414,0.0015159375,0.00030922613,0.000042942276,0.00020380215,0.000003375177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96259755,0.00058429304,0.0020864664,0.000021645903,0.00020101492,0.0000017666607,0.001449912,0.000004130965,0.0009028901,0.0014103673,0.0013040653,0.029435875],"study_design_scores_gemma":[0.97829515,0.0007816804,0.0049874233,0.00094717456,0.0001324503,0.000004650724,0.00004252095,0.000034169258,0.009729253,0.0044419966,0.00038099455,0.00022256598],"about_ca_topic_score_codex":0.0007425509,"about_ca_topic_score_gemma":0.000042610005,"teacher_disagreement_score":0.02921331,"about_ca_system_score_codex":0.0002033919,"about_ca_system_score_gemma":0.0010721347,"threshold_uncertainty_score":0.6555238},"labels":[],"label_agreement":null},{"id":"W2312359773","doi":"10.1007/s10637-005-1761-3","title":"Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; Ottawa Hospital","funders":"Central China Normal University","keywords":"Medicine; Glioma; Anaplastic astrocytoma; Toxicity; Nitrosourea; Pulmonary toxicity; Internal medicine; Progressive disease; DLCO; Surgery; Gastroenterology; Phases of clinical research; Chemotherapy; Oncology; Astrocytoma; Lung; Cancer research; Diffusing capacity","score_opus":0.025338808346491087,"score_gpt":0.281879103434974,"score_spread":0.2565402950884829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312359773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883064,0.00015105607,0.000024740151,0.009822033,0.000042024792,0.0007440814,0.00005910937,0.000035542733,0.00081500656],"genre_scores_gemma":[0.9924752,0.0000047429667,0.006239041,0.00048165827,0.00033148666,0.000082300336,0.00018600665,0.000021332798,0.00017820038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984037,0.000027271837,0.00047100012,0.00030872267,0.0005544735,0.00023480719],"domain_scores_gemma":[0.9990877,0.000106133484,0.00017357573,0.00022830033,0.000114788876,0.0002895096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012471141,0.00020551316,0.0003776374,0.00027826882,0.000060122737,0.000009968305,0.0000822519,0.000085554995,0.000095290416],"category_scores_gemma":[0.00009991292,0.00015723988,0.00009152474,0.00060195965,0.00016174573,0.00012531951,0.00003598536,0.00012553437,0.0000100590305],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03484266,0.043760847,0.011906596,0.00007238093,0.00040210696,0.0005882207,0.002511005,0.0005826004,0.88518167,0.008880798,0.0032718848,0.007999264],"study_design_scores_gemma":[0.4410664,0.0074144155,0.019349461,0.00078416587,0.000319028,0.0005908972,0.00025784693,0.0025448,0.5219768,0.0021862672,0.0029937644,0.0005161361],"about_ca_topic_score_codex":0.00038501067,"about_ca_topic_score_gemma":0.00008550075,"teacher_disagreement_score":0.40622374,"about_ca_system_score_codex":0.00013922044,"about_ca_system_score_gemma":0.0005972582,"threshold_uncertainty_score":0.6412056},"labels":[],"label_agreement":null},{"id":"W2337001617","doi":"10.1007/s10637-016-0351-x","title":"A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Irinotecan; Medicine; Tolerability; Internal medicine; Regimen; Oncology; Neutropenia; PARP inhibitor; Colorectal cancer; Cancer; Chemotherapy; Adverse effect","score_opus":0.036393349825994216,"score_gpt":0.33026345964885223,"score_spread":0.293870109822858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337001617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454755,0.00016964084,0.0000067751907,0.0034040757,0.00012736922,0.0012639953,0.00035683432,0.000015470247,0.00010826449],"genre_scores_gemma":[0.99845564,0.00003392952,0.00017463703,0.00075298257,0.00017601048,0.0002560842,0.000035709087,0.000023330847,0.000091692185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983245,0.00012898407,0.0005249812,0.0003158844,0.0004660138,0.00023959685],"domain_scores_gemma":[0.99873996,0.00019901356,0.00026576742,0.00013523121,0.00017346328,0.00048656276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033631548,0.00017463682,0.00047920027,0.0003031239,0.00005355698,0.00001140658,0.00007355631,0.00007604884,0.00028488267],"category_scores_gemma":[0.00014637638,0.00012103557,0.000028935425,0.00034716594,0.00022262664,0.00014809507,0.000014135012,0.00012138501,0.0000022989143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016137953,0.0008042946,0.96928036,0.000025872207,0.00017802368,0.0000065664976,0.003229273,0.000015431846,0.003150508,0.0003103803,0.0015396769,0.019845832],"study_design_scores_gemma":[0.080158696,0.0030677537,0.90633535,0.0008763774,0.00011606361,0.000002919999,0.00026802576,0.000014836992,0.0064868033,0.0008607513,0.0015345282,0.00027786498],"about_ca_topic_score_codex":0.1690231,"about_ca_topic_score_gemma":0.20894493,"teacher_disagreement_score":0.07854491,"about_ca_system_score_codex":0.0005828143,"about_ca_system_score_gemma":0.0022822442,"threshold_uncertainty_score":0.8365104},"labels":[],"label_agreement":null},{"id":"W235826207","doi":"10.1007/s10637-015-0252-4","title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Oncology; Circulating tumor cell; Clinical trial; Cancer; Surgery; Metastasis","score_opus":0.08111566582937407,"score_gpt":0.40143433790230904,"score_spread":0.32031867207293496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W235826207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666065,0.00007462776,0.0000018147024,0.0003149862,0.00020811125,0.0026205308,0.000080457816,0.000006795395,0.00003204757],"genre_scores_gemma":[0.99889106,0.0000023544612,0.00010544235,0.00007760611,0.00031519885,0.00017311337,0.0001262435,0.00002379889,0.0002851871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959255,0.0013415754,0.001069732,0.00047529227,0.00097161985,0.00021630386],"domain_scores_gemma":[0.9983929,0.00007929491,0.0004602209,0.00040828186,0.0004091844,0.00025016023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028225458,0.00018840386,0.00036402748,0.00009302223,0.00011294109,0.000024761024,0.00025158052,0.0001081763,0.0000054642987],"category_scores_gemma":[0.0015219365,0.00013278809,0.000068760884,0.0003958686,0.00022117095,0.000018557317,0.00017372388,0.00025684122,0.000002059508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013944618,0.031171119,0.8105518,0.000051353603,0.00044121026,0.00001577097,0.018342538,0.0006422269,0.09898849,0.00004779778,0.019460952,0.0063421144],"study_design_scores_gemma":[0.19962075,0.10283531,0.55896807,0.0004667177,0.00032897768,0.000003905838,0.011231295,0.00015839472,0.118947275,0.0005033707,0.0055878926,0.001348037],"about_ca_topic_score_codex":0.0010013705,"about_ca_topic_score_gemma":0.0027236878,"teacher_disagreement_score":0.25158376,"about_ca_system_score_codex":0.00010838171,"about_ca_system_score_gemma":0.0016722879,"threshold_uncertainty_score":0.5414941},"labels":[],"label_agreement":null},{"id":"W2405943329","doi":"10.1007/s10637-016-0364-5","title":"A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Dental and Craniofacial Research; National Institute on Deafness and Other Communication Disorders; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Docetaxel; Medicine; Oncology; Internal medicine; Clinical endpoint; Head and neck squamous-cell carcinoma; Head and neck cancer; Radiation therapy; Cancer; Clinical trial; Phases of clinical research; Chemotherapy; Surgery","score_opus":0.018481314063655246,"score_gpt":0.2890376702067251,"score_spread":0.27055635614306983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405943329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932132,0.0004390782,0.0027530638,0.0024770293,0.00012580343,0.00090040587,0.000062554864,0.0000034799834,0.000025420579],"genre_scores_gemma":[0.98896897,0.00015513069,0.008059381,0.00017335304,0.000080517515,0.0001818739,0.00008038034,0.000015653733,0.002284732],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991976,0.000051716455,0.00023971873,0.00023449783,0.0001516979,0.0001247678],"domain_scores_gemma":[0.999494,0.000050152612,0.00017514465,0.00013532396,0.0000815692,0.00006377329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001537766,0.00011374742,0.00013895282,0.000038422815,0.00008206065,0.000005911978,0.000080839236,0.000056978224,0.000012280857],"category_scores_gemma":[0.00008407801,0.00006131109,0.000042923995,0.00009540978,0.00015469265,0.00001007961,0.000049776987,0.000029945306,3.006863e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04110833,0.0010546158,0.00027354894,0.00012661773,0.00012499152,0.00000154497,0.00041944202,0.00025962078,0.8262148,0.010424037,0.0014543104,0.118538134],"study_design_scores_gemma":[0.4698807,0.022560284,0.0023607728,0.0010662657,0.00019955213,0.000050792958,0.00009800269,0.0009578999,0.33423617,0.12488406,0.04293846,0.0007670467],"about_ca_topic_score_codex":0.000028628221,"about_ca_topic_score_gemma":0.0003770336,"teacher_disagreement_score":0.49197865,"about_ca_system_score_codex":0.000033165008,"about_ca_system_score_gemma":0.0003100885,"threshold_uncertainty_score":0.25001937},"labels":[],"label_agreement":null},{"id":"W2415636816","doi":"10.1007/s10637-016-0367-2","title":"Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Cisplatin; Epidermal growth factor receptor; Oncology; Medicine; Head and neck; Radiation therapy; Head and neck squamous-cell carcinoma; Internal medicine; Basal cell; Cancer research; Chemotherapy; Carcinoma; Head and neck cancer; Receptor; Surgery","score_opus":0.01778624658383064,"score_gpt":0.2729515223007116,"score_spread":0.25516527571688097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415636816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961561,0.00032252504,0.000010002253,0.0021960107,0.000076139266,0.0010213974,0.00013373734,0.0000084970825,0.00007561313],"genre_scores_gemma":[0.9987841,0.000023068205,0.0005588961,0.00030665254,0.00012370278,0.00003616431,0.000030152203,0.00002223068,0.000115036186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854684,0.000076755554,0.00044947944,0.00029041144,0.0004508997,0.00018560774],"domain_scores_gemma":[0.998929,0.00028063657,0.0002998883,0.00014295682,0.00017873292,0.00016875431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008627361,0.00020969294,0.00047323375,0.0000785691,0.00006212287,0.000005584602,0.00006656011,0.000057065965,0.000028666642],"category_scores_gemma":[0.00008065207,0.00011242943,0.000037873866,0.0001542288,0.00057054055,0.00011601629,0.000029980352,0.00012010771,3.3345142e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023331704,0.0018563889,0.9389158,0.0002704314,0.00007234067,0.0000032304258,0.0031565907,0.0000015904141,0.015387061,0.00064338377,0.001434563,0.014926933],"study_design_scores_gemma":[0.29224706,0.0084536625,0.6859481,0.00072290126,0.000039379327,0.0000032754945,0.000064990185,0.000009129878,0.011638469,0.00014487324,0.0005217142,0.00020647392],"about_ca_topic_score_codex":0.00015432778,"about_ca_topic_score_gemma":0.00006810172,"teacher_disagreement_score":0.26891536,"about_ca_system_score_codex":0.00007456822,"about_ca_system_score_gemma":0.00041094076,"threshold_uncertainty_score":0.45847392},"labels":[],"label_agreement":null},{"id":"W2464912596","doi":"10.1007/s10637-016-0375-2","title":"A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Internal medicine; Myeloid leukemia; Gastroenterology; Refractory (planetary science); Leukemia; Myelodysplastic syndromes; Bone marrow","score_opus":0.02233236206226961,"score_gpt":0.29068264046947645,"score_spread":0.2683502784072068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464912596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919219,0.000050094382,0.0000386347,0.0045756563,0.00033063797,0.0025125367,0.000115811155,0.00007688827,0.00037784135],"genre_scores_gemma":[0.9818884,0.000065800814,0.0013913341,0.0010234345,0.00089002564,0.00017999981,0.00012436122,0.00011663836,0.0143200075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953869,0.00030030345,0.0009992145,0.0007694562,0.0018101372,0.0007340012],"domain_scores_gemma":[0.99652463,0.0008450974,0.00054079265,0.0010334924,0.00041390164,0.0006421003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005782469,0.00049517525,0.0007394551,0.00043336354,0.00014807706,0.00003142122,0.00059400324,0.00033775312,0.0004313013],"category_scores_gemma":[0.0017034297,0.00024281483,0.00018263518,0.0013236171,0.0009997915,0.00050474005,0.00025704023,0.0008227744,0.00010572114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6716919,0.0031603468,0.01358306,0.00070715137,0.0014176434,0.0007123455,0.003712224,0.00013790735,0.122290164,0.001620302,0.084477894,0.09648906],"study_design_scores_gemma":[0.8489461,0.017782,0.03336828,0.003737497,0.0005250278,0.000082480256,0.00014940772,0.0005568749,0.05719195,0.001171112,0.035409283,0.0010799841],"about_ca_topic_score_codex":0.00032412785,"about_ca_topic_score_gemma":0.00013860466,"teacher_disagreement_score":0.1772542,"about_ca_system_score_codex":0.009363422,"about_ca_system_score_gemma":0.034222607,"threshold_uncertainty_score":0.9944395},"labels":[],"label_agreement":null},{"id":"W2492626689","doi":"10.1007/s10637-016-0377-0","title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Dosing; Tolerability; Trametinib; Medicine; Adverse effect; Rash; MEK inhibitor; Pharmacokinetics; Cohort; Internal medicine; Pharmacology; Oncology; Gastroenterology; MAPK/ERK pathway; Biology","score_opus":0.007907842871237351,"score_gpt":0.24819467680905802,"score_spread":0.24028683393782066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492626689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972736,0.000028682129,0.00008754308,0.0013541003,0.00010945398,0.0010705703,0.000027508991,0.0000090089725,0.000039519342],"genre_scores_gemma":[0.9990642,0.0000013721394,0.0002833061,0.00022584725,0.00011885615,0.0001203844,0.00004926307,0.000029447498,0.0001073442],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99824727,0.00018747218,0.00041434114,0.00038454318,0.00055844523,0.00020795265],"domain_scores_gemma":[0.99896103,0.000093703886,0.00033392786,0.00032690153,0.00020752793,0.000076889264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026692296,0.00020515057,0.00019216165,0.00008451389,0.00007030254,0.000017613951,0.00025453736,0.000083110455,0.000008850568],"category_scores_gemma":[0.00016969864,0.000108294225,0.00003738605,0.0003896534,0.00025586804,0.00003239587,0.00005860092,0.0001339158,0.0000017059278],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004910308,0.0060651465,0.47840866,0.00005608032,0.00017099197,0.000003724952,0.006464698,0.0050521307,0.48100093,0.0004050884,0.0017781171,0.015684111],"study_design_scores_gemma":[0.053111095,0.0071192365,0.579546,0.0007140508,0.00005467164,0.0000026213115,0.00092786946,0.00016326635,0.35603377,0.0009201916,0.0007981262,0.00060912466],"about_ca_topic_score_codex":0.000069077614,"about_ca_topic_score_gemma":0.0003489409,"teacher_disagreement_score":0.12496718,"about_ca_system_score_codex":0.00009413906,"about_ca_system_score_gemma":0.0004161275,"threshold_uncertainty_score":0.44161105},"labels":[],"label_agreement":null},{"id":"W2514523591","doi":"10.1007/s10637-016-0383-2","title":"Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Nivolumab; Pembrolizumab; Medicine; Lung cancer; Tyrosine kinase; Erlotinib; EGFR inhibitors; Cancer research; Oncology; Anaplastic lymphoma kinase; Internal medicine; Immunotherapy; Cancer; Epidermal growth factor receptor; Receptor","score_opus":0.01607847236170796,"score_gpt":0.2932689510862317,"score_spread":0.27719047872452374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514523591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615828,0.0026234582,0.000717504,0.03009374,0.0005693976,0.0013367244,0.000055933335,0.00011074836,0.0029097248],"genre_scores_gemma":[0.98291725,0.000077879085,0.0062250113,0.0023421813,0.0013540288,0.00015158603,0.00008336317,0.00006416434,0.006784523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798703,0.00003723732,0.0005928629,0.00051360123,0.00041165936,0.00045759926],"domain_scores_gemma":[0.9986173,0.00013252322,0.00017740345,0.0002099745,0.00013099538,0.00073179585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016982734,0.000312859,0.0003232629,0.00028400304,0.00011175174,0.00005095402,0.00011554285,0.00011527617,0.00026879183],"category_scores_gemma":[0.00008534069,0.00023409989,0.00011409102,0.0005810012,0.00006809304,0.00022864409,0.00005137249,0.00018251548,0.000065535154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026738897,0.00044732526,0.17937346,0.0003281287,0.00034029144,0.000110575944,0.01196271,0.003112093,0.6177031,0.0017622167,0.08862023,0.09597253],"study_design_scores_gemma":[0.030313907,0.0010552048,0.123549074,0.009854873,0.0010828434,0.000039638653,0.002580576,0.0017829828,0.760756,0.0077687106,0.058947988,0.0022681674],"about_ca_topic_score_codex":0.004400869,"about_ca_topic_score_gemma":0.0003256305,"teacher_disagreement_score":0.14305298,"about_ca_system_score_codex":0.0009343074,"about_ca_system_score_gemma":0.0025248795,"threshold_uncertainty_score":0.9546316},"labels":[],"label_agreement":null},{"id":"W2514939920","doi":"10.1007/s10637-016-0386-z","title":"Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Medicine Hat College; BC Cancer Agency","funders":"Canadian Urological Oncology Group; Pfizer","keywords":"Docetaxel; Sunitinib; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Cancer; Surgery; Urology; Clinical trial","score_opus":0.04279131410167663,"score_gpt":0.3346133206473061,"score_spread":0.29182200654562945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514939920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9171023,0.00069340866,0.00002157802,0.08067576,0.000072283,0.0009750188,0.00014198381,0.000033275777,0.0002844216],"genre_scores_gemma":[0.9674995,0.00043613018,0.0018814766,0.0026982415,0.00012083119,0.00061347155,0.000033143544,0.000031504896,0.026685704],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99815977,0.00016374663,0.00035178266,0.00037111287,0.0005494486,0.0004041546],"domain_scores_gemma":[0.9988161,0.00025157662,0.0000716968,0.00022484212,0.0002246906,0.00041113238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051322323,0.00019118503,0.00023120019,0.00026703932,0.000053405514,0.00003425567,0.0000871927,0.00004357808,0.00042418615],"category_scores_gemma":[0.0001822555,0.000117818665,0.00005625778,0.0004681561,0.00017887678,0.00021300258,0.000020163954,0.00012466963,0.00010558535],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07293225,0.00033470843,0.049200263,0.00011369138,0.00022531333,0.0007619585,0.009703634,0.000051176503,0.80893254,0.0014501237,0.0138567155,0.042437617],"study_design_scores_gemma":[0.019977417,0.0010815338,0.7995566,0.0020115436,0.000045841145,0.000043203177,0.00043025432,0.000033914774,0.08751698,0.011076383,0.07770959,0.0005167136],"about_ca_topic_score_codex":0.00058981293,"about_ca_topic_score_gemma":0.00032157428,"teacher_disagreement_score":0.7503564,"about_ca_system_score_codex":0.00045298092,"about_ca_system_score_gemma":0.00218835,"threshold_uncertainty_score":0.48045057},"labels":[],"label_agreement":null},{"id":"W2537645495","doi":"10.1007/s10637-016-0398-8","title":"Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Center, University of Colorado; Takeda Oncology","keywords":"Neddylation; NEDD8; Biology; Cancer research; Melanoma; Cell cycle; XIAP; Programmed cell death; Apoptosis; Gene; Ubiquitin; Biochemistry; Ubiquitin ligase; Caspase","score_opus":0.010605259637856208,"score_gpt":0.22690385579139907,"score_spread":0.21629859615354285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537645495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743057,0.000653099,0.0013962054,0.021668507,0.0001114559,0.00058389636,0.00006412088,0.00002380413,0.0011932364],"genre_scores_gemma":[0.99402195,0.000011246925,0.0007899348,0.0014030264,0.0008389102,0.00015630762,0.00018653655,0.000027444179,0.002564637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853987,0.00022795994,0.00032547567,0.00032588703,0.0003044491,0.00027634762],"domain_scores_gemma":[0.9992819,0.00014144935,0.0001851613,0.00022327634,0.00007356331,0.0000946754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063376786,0.00018305905,0.00010242556,0.00003222838,0.00022806485,0.000055729746,0.0002903435,0.0001087727,0.00005748712],"category_scores_gemma":[0.0007338026,0.00010044959,0.00005525762,0.00014356847,0.00020185728,0.000022747043,0.00012330287,0.00016379716,0.000022147004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030908916,0.000017988528,0.0008630529,0.00000945491,0.000012250193,7.8480457e-7,0.0004498593,0.000023619423,0.9761786,0.0024522555,0.014305258,0.0056559755],"study_design_scores_gemma":[0.00065915164,0.00007836114,0.00067597476,0.000087659355,0.0000037196633,0.0000078515395,0.00020734644,0.00016852123,0.93633676,0.005941168,0.05561267,0.00022084928],"about_ca_topic_score_codex":0.00012700517,"about_ca_topic_score_gemma":0.000024339066,"teacher_disagreement_score":0.04130741,"about_ca_system_score_codex":0.000044559663,"about_ca_system_score_gemma":0.00025460796,"threshold_uncertainty_score":0.40962154},"labels":[],"label_agreement":null},{"id":"W2585936581","doi":"10.1007/s10637-017-0438-z","title":"First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Tolerability; Pharmacokinetics; Internal medicine; Toxicity; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Anemia; Gastroenterology; Hypokalemia; Asymptomatic; Hypophosphatemia; Neutropenia; Phases of clinical research; Pharmacology","score_opus":0.035873276828167516,"score_gpt":0.31157816259131627,"score_spread":0.2757048857631488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585936581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979638,0.000004454456,0.000007003036,0.0005890472,0.0003531634,0.0007553838,0.00002345476,0.000022177665,0.00028153622],"genre_scores_gemma":[0.9992567,0.0000012224898,0.00005279837,0.0001712517,0.00013237317,0.000039343096,0.000011859493,0.000026787198,0.00030771305],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979633,0.00007268408,0.00049774145,0.00049875426,0.0006480988,0.00031942624],"domain_scores_gemma":[0.99892867,0.000083264524,0.000418802,0.00029418105,0.00007699652,0.0001981032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014720792,0.00022295723,0.000321848,0.00023756502,0.00031920412,0.00005452413,0.00043459333,0.00006277249,0.000028191078],"category_scores_gemma":[0.00031627485,0.00018852127,0.000040657975,0.00023643859,0.00031575002,0.0004960103,0.000114666735,0.00022068145,0.000011485928],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040807854,0.045101456,0.5133196,0.00058684853,0.00010457283,0.0003409757,0.1472217,0.105544925,0.16541718,0.006776556,0.006697364,0.004808026],"study_design_scores_gemma":[0.071068645,0.0060633076,0.35515592,0.0013836449,0.000031300377,0.000005031222,0.002546733,0.005308366,0.5455379,0.010995448,0.00034848735,0.0015551893],"about_ca_topic_score_codex":0.0005394027,"about_ca_topic_score_gemma":0.00025573466,"teacher_disagreement_score":0.38012075,"about_ca_system_score_codex":0.00007192917,"about_ca_system_score_gemma":0.00018714702,"threshold_uncertainty_score":0.7687674},"labels":[],"label_agreement":null},{"id":"W2597378792","doi":"10.1007/s10637-017-0450-3","title":"A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"University of Minnesota","keywords":"Carboplatin; Cetuximab; Medicine; Clinical endpoint; Paclitaxel; Internal medicine; Oncology; Adverse effect; Phases of clinical research; Chemotherapy; Lung cancer; Randomized controlled trial; Cancer; Colorectal cancer; Cisplatin","score_opus":0.023675209734914767,"score_gpt":0.34447456835469203,"score_spread":0.32079935861977726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597378792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939195,0.00008256365,0.000033961274,0.002571407,0.000010887322,0.0032285852,0.000016463382,0.000006255398,0.00013041084],"genre_scores_gemma":[0.9971928,0.000024880925,0.0019085016,0.00050836493,0.000018388175,0.00012674657,0.00005418824,0.000018804745,0.00014735122],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99848944,0.00014805209,0.00046353266,0.000336757,0.00040434886,0.00015787756],"domain_scores_gemma":[0.99865025,0.00023605449,0.00049476716,0.00027608397,0.00021690693,0.00012594607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075678236,0.0001907361,0.0005531305,0.0001287703,0.00024395369,0.00006687944,0.00015584877,0.000038526086,0.000020876263],"category_scores_gemma":[0.00015814952,0.00012338563,0.000020704209,0.00017634683,0.00029712904,0.000275574,0.0000976731,0.00017676438,2.4766666e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22742838,0.011581335,0.7100926,0.00020816673,0.00046422207,0.000007714341,0.01645119,0.0002780306,0.006606804,0.00010968742,0.000053287917,0.026718581],"study_design_scores_gemma":[0.73092985,0.00201666,0.251861,0.001111315,0.00018786042,6.1990136e-7,0.00029882984,0.012362619,0.0010390846,0.000045994842,0.0000031390332,0.00014304371],"about_ca_topic_score_codex":0.0012441843,"about_ca_topic_score_gemma":0.0003151624,"teacher_disagreement_score":0.5035015,"about_ca_system_score_codex":0.00007825721,"about_ca_system_score_gemma":0.0003428467,"threshold_uncertainty_score":0.503152},"labels":[],"label_agreement":null},{"id":"W264127248","doi":"10.1023/a:1022976528441","title":"Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada); BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Pharmacokinetics; Pharmacology; Toxicity; Medicine; DNMT1; Hemoglobin; Chemistry; Methyltransferase; Internal medicine; DNA; Biochemistry","score_opus":0.017976582338079132,"score_gpt":0.30679116350208396,"score_spread":0.2888145811640048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W264127248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981965,0.00018424241,0.00002757177,0.00047286125,0.000062754065,0.000518484,0.000019500052,0.000008917714,0.0005091592],"genre_scores_gemma":[0.99753445,0.000043124066,0.00013844673,0.0006204993,0.00007553698,0.00001613574,0.000026826856,0.000015636162,0.001529323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984943,0.00038881905,0.00027602437,0.00031043345,0.00031222656,0.00021814705],"domain_scores_gemma":[0.99930686,0.000065873,0.00009093116,0.00022289272,0.0001039961,0.00020943857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043894444,0.00015690606,0.00017574127,0.00005385904,0.00021275673,0.000027438064,0.0001774418,0.00007818931,0.00005021132],"category_scores_gemma":[0.00030964846,0.00012189344,0.00006883648,0.0001452131,0.000224835,0.000010458713,0.00007941565,0.00013707028,0.0000031660352],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042436095,0.00036710038,0.005617303,0.000009856242,0.00008090595,0.0000094466295,0.0004179122,0.00003923417,0.99053323,0.0003176196,0.0019550826,0.0006098575],"study_design_scores_gemma":[0.005738851,0.0012703288,0.0073949425,0.000028121427,0.00006393769,0.000023738172,0.0005614714,0.00005797658,0.97995585,0.0014748307,0.0032275608,0.00020239681],"about_ca_topic_score_codex":0.00023249256,"about_ca_topic_score_gemma":0.000043221364,"teacher_disagreement_score":0.010577402,"about_ca_system_score_codex":0.000012645441,"about_ca_system_score_gemma":0.00024250119,"threshold_uncertainty_score":0.49706703},"labels":[],"label_agreement":null},{"id":"W2724602822","doi":"10.1007/s10637-017-0486-4","title":"Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai","keywords":"Eribulin; Medicine; Observational study; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.03159839853472978,"score_gpt":0.33611036699038593,"score_spread":0.30451196845565615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724602822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996691,0.000065250904,0.0000026170924,0.0016970937,0.00006034512,0.0012113249,0.00019722854,0.000009447436,0.00006571372],"genre_scores_gemma":[0.9986223,0.000011028379,0.0006796983,0.0002532074,0.000040798957,0.00009840972,0.00013053046,0.000014598477,0.00014945303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988654,0.00015721109,0.00027624072,0.00025299494,0.0003100096,0.00013810516],"domain_scores_gemma":[0.9985608,0.0006209947,0.00022981451,0.00014627431,0.00030158705,0.00014055845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003811712,0.00015026738,0.00034692648,0.000071386865,0.00011260177,0.000014119345,0.00008077784,0.000026535894,0.00011453923],"category_scores_gemma":[0.00025440767,0.0001095237,0.00002286921,0.00011357331,0.00019064096,0.00016526421,0.000043668068,0.000099862154,0.0000011062072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021084297,0.0005989115,0.9722179,0.00020144162,0.00020886936,0.00001760711,0.0008637649,0.00036336068,0.00063194096,0.000038037288,0.000016094018,0.0037577704],"study_design_scores_gemma":[0.018856512,0.000682236,0.97910154,0.00054429437,0.00015477264,0.000010384966,0.00019280954,0.00015575314,0.00010020252,0.000072614486,0.000021077702,0.00010777986],"about_ca_topic_score_codex":0.0018327595,"about_ca_topic_score_gemma":0.0008038004,"teacher_disagreement_score":0.006883657,"about_ca_system_score_codex":0.00013219478,"about_ca_system_score_gemma":0.0008643629,"threshold_uncertainty_score":0.4466247},"labels":[],"label_agreement":null},{"id":"W2738241641","doi":"10.1007/s10637-017-0488-2","title":"Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"BC Cancer Agency; Canadian Cancer Society Research Institute","keywords":"Clioquinol; Plumbagin; Platinum; Carboplatin; Cisplatin; Copper; Chemistry; Denticity; Pharmacology; Cancer research; Chemotherapy; Biochemistry; Medicine; Internal medicine; Biology; Metal; Organic chemistry","score_opus":0.0754335186395352,"score_gpt":0.3180040468573997,"score_spread":0.2425705282178645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738241641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939783,0.0002087022,0.000030247305,0.0026620794,0.00014796326,0.00025129467,0.00017840292,0.000020674841,0.0025223275],"genre_scores_gemma":[0.9960438,0.00008903814,0.0011733478,0.00022763154,0.00017411454,0.0000067392575,0.00002879237,0.000022086591,0.0022344252],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983682,0.00007247807,0.0004100225,0.00027887867,0.0006309757,0.0002394299],"domain_scores_gemma":[0.9982432,0.00015615081,0.00058822945,0.00049582886,0.00028199184,0.00023458395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037766207,0.00019708659,0.0006191439,0.0000912347,0.00028039605,0.00003405494,0.00013253168,0.000073514115,0.00013833502],"category_scores_gemma":[0.00036455313,0.00016003354,0.0001609619,0.00006773885,0.0006660968,0.0002520874,0.00017142427,0.00015567147,0.000008871905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022683856,0.000112482456,0.07000051,0.00020260399,0.00014149206,0.0000036626502,0.000686769,0.00008015225,0.92223984,0.0011548642,0.0018982893,0.0032525223],"study_design_scores_gemma":[0.0007348483,0.00008033384,0.33371994,0.00034174594,0.000066884524,0.000008009127,0.000049263406,0.00041735536,0.6629383,0.0007384691,0.00078694517,0.00011790455],"about_ca_topic_score_codex":0.0045038536,"about_ca_topic_score_gemma":0.00011981327,"teacher_disagreement_score":0.26371944,"about_ca_system_score_codex":0.000044188342,"about_ca_system_score_gemma":0.0004610819,"threshold_uncertainty_score":0.6808509},"labels":[],"label_agreement":null},{"id":"W2754566416","doi":"10.1007/s10637-017-0510-8","title":"Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications","year":2017,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Interquartile range; Adverse effect; Internal medicine; Clinical endpoint; MEDLINE","score_opus":0.9371062626576229,"score_gpt":0.7366516816469256,"score_spread":0.20045458101069724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754566416","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005908707,0.9701888,0.0027321095,0.004092772,0.0033448057,0.010477428,0.0020285642,0.00024489695,0.0062997537],"genre_scores_gemma":[0.000031503532,0.4421112,0.55453575,0.000045207318,0.001740661,0.00025599482,0.0002025971,0.000082203136,0.000994864],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9782745,0.002403813,0.01705474,0.0010026707,0.0009029506,0.0003612791],"domain_scores_gemma":[0.6909024,0.25971347,0.045390002,0.002569205,0.00053942576,0.0008855058],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.02375586,0.0004946809,0.0063820677,0.0003548514,0.00013686184,0.00014850499,0.0007655091,0.0008686631,0.00008619604],"category_scores_gemma":[0.7733957,0.00042475,0.0006360341,0.00043740388,0.0007795555,0.00014872334,0.00028575904,0.001086023,0.000026222828],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019700874,0.00094929204,0.00003543244,0.0070795994,0.00025888078,0.0000069474495,0.00025195032,3.5823456e-7,9.819821e-7,0.099042624,0.01986966,0.8705342],"study_design_scores_gemma":[0.026989898,0.00019859207,0.000011254087,0.009344024,0.00071759394,0.000006371154,0.000016425769,0.000034697903,0.0000049296777,0.64569896,0.3166168,0.00036046843],"about_ca_topic_score_codex":0.000059753373,"about_ca_topic_score_gemma":0.000011568803,"teacher_disagreement_score":0.8701737,"about_ca_system_score_codex":0.00010208337,"about_ca_system_score_gemma":0.0026770313,"threshold_uncertainty_score":0.9998204},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"reporting","study_design":"observational","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"reporting","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2771486844","doi":"10.1007/s10637-017-0549-6","title":"Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database","year":2017,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Database; Internal medicine; Computer science","score_opus":0.9608405442956974,"score_gpt":0.7387906900373383,"score_spread":0.2220498542583591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771486844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014991597,0.9891179,0.00043566644,0.0010692717,0.0016946361,0.0025231722,0.0030241879,0.000006182891,0.0006297889],"genre_scores_gemma":[0.0016728848,0.98084414,0.0054952363,0.00041851008,0.0019174281,0.00020956152,0.002355459,0.00006879954,0.0070179794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.85438454,0.079299435,0.054381974,0.0024658025,0.009135289,0.00033295722],"domain_scores_gemma":[0.6817466,0.11994887,0.1704834,0.02061303,0.0056534773,0.0015546447],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","scholarly_communication","open_science","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.40160692,0.00078438164,0.036739793,0.0015987547,0.00027319428,0.0020517716,0.007208262,0.00056809175,0.007669412],"category_scores_gemma":[0.48338264,0.00032849607,0.012552737,0.004446177,0.001122469,0.0012527519,0.00070233387,0.00074409816,0.00005982751],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021748023,0.00032783326,0.009974969,0.0012728364,0.00845511,5.3951993e-7,0.00023799721,0.000040460665,7.4027423e-7,0.0020812762,0.17095324,0.80663323],"study_design_scores_gemma":[0.0009038318,0.00004472198,0.0007190221,0.0018869872,0.043363016,0.0000011746688,0.00009611853,0.0042991084,0.0000016687619,0.0024181497,0.9459549,0.00031126826],"about_ca_topic_score_codex":0.00033314418,"about_ca_topic_score_gemma":0.00036349669,"teacher_disagreement_score":0.806322,"about_ca_system_score_codex":0.000053968928,"about_ca_system_score_gemma":0.004638763,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W2772605981","doi":"10.1007/s10637-017-0553-x","title":"A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; McMaster University Medical Centre; University of British Columbia","funders":"Terry Fox Research Institute","keywords":"Prednisone; Medicine; Prostate cancer; Internal medicine; Gastroenterology; Adverse effect; Clinical endpoint; Urology; Cancer; Surgery; Randomized controlled trial","score_opus":0.024409912031311976,"score_gpt":0.3215747798365999,"score_spread":0.2971648678052879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772605981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964525,0.00010101914,0.000057145306,0.0002383265,0.00003620221,0.0029115756,0.000099671364,0.000007913276,0.000095624266],"genre_scores_gemma":[0.9958209,0.0000127072035,0.0032724282,0.000015392585,0.000054689517,0.00034481855,0.00026627298,0.000033119486,0.00017972023],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99774915,0.00030879735,0.0004838949,0.00045704877,0.0007089272,0.00029218223],"domain_scores_gemma":[0.99853337,0.00006239689,0.00041892953,0.00043819784,0.0003692592,0.00017784184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057081145,0.00022167726,0.0004262783,0.0001018733,0.00020130513,0.00007592463,0.00022338443,0.000057281,0.000012126429],"category_scores_gemma":[0.00062710606,0.0001717793,0.000039514136,0.0001402768,0.00035309177,0.000039452232,0.00009024233,0.00013510585,0.0000012356999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70034343,0.003497705,0.12338927,0.0003050709,0.0015375285,0.00006328548,0.006456726,0.0035102128,0.15812497,0.00011378469,0.0005084726,0.002149535],"study_design_scores_gemma":[0.8569251,0.0051683625,0.03623374,0.0003214488,0.00020043258,0.0000020171165,0.0007800751,0.00082107564,0.098748535,0.00014038496,0.00011829518,0.0005405783],"about_ca_topic_score_codex":0.0028583768,"about_ca_topic_score_gemma":0.0013955324,"teacher_disagreement_score":0.15658161,"about_ca_system_score_codex":0.000050851842,"about_ca_system_score_gemma":0.0009809306,"threshold_uncertainty_score":0.70049566},"labels":[],"label_agreement":null},{"id":"W2795799317","doi":"10.1007/s10637-018-0591-z","title":"A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pharmacokinetics; Tolerability; Dosing; Pharmacodynamics; Adverse effect; Internal medicine; Gastroenterology; Nausea; Pharmacology","score_opus":0.023426818378666114,"score_gpt":0.3401203968094243,"score_spread":0.3166935784307582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795799317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959791,0.000045425844,0.000053293752,0.0017230822,0.00025927927,0.0016094228,0.00018785532,0.000009223989,0.00013333585],"genre_scores_gemma":[0.99497324,0.000002880631,0.0010772576,0.0032427975,0.0002932766,0.00005411295,0.000065819055,0.000038414106,0.00025221612],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978618,0.00026621748,0.0005419686,0.00055167376,0.00048042307,0.0002978868],"domain_scores_gemma":[0.99864763,0.000055738547,0.00025673842,0.00047464817,0.0003137299,0.0002515109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058624975,0.0002777612,0.00026850827,0.000057951525,0.00018017305,0.00007307207,0.00079810043,0.000050441442,0.000029502535],"category_scores_gemma":[0.0001910452,0.00018891475,0.00002875086,0.00040957995,0.00085788476,0.000026544418,0.00079772423,0.00020777092,0.0000035038329],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004460123,0.0054659965,0.5012798,0.00009019267,0.00047181247,0.000005831549,0.007031977,0.006051674,0.45918408,0.00059500133,0.010659281,0.0047042468],"study_design_scores_gemma":[0.078813605,0.011130769,0.09441389,0.000496969,0.00030222558,0.000010392707,0.0007489061,0.006014662,0.789213,0.0030278438,0.014122812,0.0017049072],"about_ca_topic_score_codex":0.00038967794,"about_ca_topic_score_gemma":0.00044128177,"teacher_disagreement_score":0.4068659,"about_ca_system_score_codex":0.00006617132,"about_ca_system_score_gemma":0.0006443563,"threshold_uncertainty_score":0.770372},"labels":[],"label_agreement":null},{"id":"W2796296273","doi":"10.1007/s10637-018-0595-8","title":"Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institut National de la Recherche Scientifique","funders":"Canadian Institutes of Health Research","keywords":"Autophagy; In vivo; Prostate cancer; Apoptosis; Programmed cell death; Cancer research; Medicine; Cancer; Pharmacology; Prostate; TUNEL assay; Growth inhibition; Internal medicine; Biology; Immunohistochemistry; Biochemistry","score_opus":0.02092564730317531,"score_gpt":0.2962967590629427,"score_spread":0.2753711117597674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796296273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919011,0.0017214812,0.00013611025,0.004939881,0.000094377654,0.000761733,0.000019748268,0.000063206615,0.000362359],"genre_scores_gemma":[0.99289507,0.0001287875,0.001112075,0.004158752,0.0003829784,0.000097830576,0.00004864398,0.000039460585,0.0011363849],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984944,0.00005573347,0.0004491111,0.00031012515,0.00040294026,0.0002876818],"domain_scores_gemma":[0.99903053,0.00011066217,0.00020002437,0.000302658,0.00016689053,0.00018924975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001921155,0.00021520753,0.00031321924,0.00014260951,0.00008013895,0.000017349073,0.00012030284,0.000092719514,0.00012668721],"category_scores_gemma":[0.00006873667,0.00015965034,0.000103624836,0.00042743838,0.0005572409,0.00014387604,0.00003789998,0.00018978809,0.000017596103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013393025,0.0005064304,0.0020804303,0.00016572587,0.0002576614,0.000010299565,0.009751091,0.0011308835,0.9646097,0.0023656357,0.0003825206,0.017400326],"study_design_scores_gemma":[0.007640349,0.00024618162,0.07513829,0.00042160126,0.00011805699,0.000014892054,0.000078977384,0.019438133,0.87263453,0.023845145,0.00019598796,0.00022785335],"about_ca_topic_score_codex":0.00048675083,"about_ca_topic_score_gemma":0.00003888016,"teacher_disagreement_score":0.09197517,"about_ca_system_score_codex":0.00008105708,"about_ca_system_score_gemma":0.0009880316,"threshold_uncertainty_score":0.6510352},"labels":[],"label_agreement":null},{"id":"W2797850256","doi":"10.1007/s10637-018-0597-6","title":"A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Notch signaling pathway; Adverse effect; Dosing; Tolerability; Internal medicine; Toxicity; Pharmacology; Oncology; Gastroenterology","score_opus":0.01184836436950387,"score_gpt":0.291251166487549,"score_spread":0.27940280211804513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797850256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993642,0.0000105621975,0.0000532916,0.00005199084,0.00008384648,0.000379653,0.000013324864,0.000008431003,0.000034719316],"genre_scores_gemma":[0.9879515,4.1201315e-7,0.011141877,0.00014613231,0.00010895675,0.000016211878,0.0005324628,0.00001357587,0.00008883283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898046,0.00007245745,0.0002891184,0.00032322423,0.00017359412,0.00016116105],"domain_scores_gemma":[0.99943966,0.000009307866,0.00014547378,0.00014686196,0.00014904707,0.000109625566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013452476,0.00014222639,0.0001390864,0.0000629231,0.00007035584,0.000008119404,0.0001050162,0.000088476256,0.0000107701435],"category_scores_gemma":[0.000057212208,0.00012768763,0.000018807741,0.00015643604,0.00016993911,0.00002023676,0.0000546082,0.000062732564,0.0000041802205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013815289,0.0031144896,0.59406704,0.000011254789,0.000068543115,0.0000018058191,0.0024428142,0.0006726752,0.382818,0.000015447182,0.00013279678,0.015273578],"study_design_scores_gemma":[0.0113766035,0.0034801047,0.7717125,0.0000350395,0.000012325469,0.0000014473253,0.00036435743,0.00046240233,0.21211489,0.00011111901,0.00009065375,0.00023859378],"about_ca_topic_score_codex":0.000041184412,"about_ca_topic_score_gemma":0.00028914833,"teacher_disagreement_score":0.17764542,"about_ca_system_score_codex":0.000020053643,"about_ca_system_score_gemma":0.0001862843,"threshold_uncertainty_score":0.52069503},"labels":[],"label_agreement":null},{"id":"W2800067592","doi":"10.1007/s10637-018-0599-4","title":"A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Alberta; St. Michael's Hospital","funders":"Sanofi; Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Irinotecan; Capecitabine; Phases of clinical research; Neutropenia; Oxaliplatin; Nausea; Febrile neutropenia; Clinical endpoint; Toxicity; Cancer; Surgery; Clinical trial; Colorectal cancer","score_opus":0.04650012193401043,"score_gpt":0.31679964612210926,"score_spread":0.2702995241880988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800067592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588865,0.00005742212,0.00006950756,0.00093395665,0.000097428725,0.002779066,0.000025828147,0.000025960835,0.00012219878],"genre_scores_gemma":[0.9909522,0.0000074221534,0.0057693063,0.00036787585,0.00014813263,0.00010201666,0.00017221512,0.000030110301,0.0024507178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997925,0.00006217112,0.0006067935,0.00048778014,0.0006069871,0.00031125563],"domain_scores_gemma":[0.99879843,0.000112549664,0.00030096775,0.00027817272,0.00020517838,0.00030467572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014373874,0.00031754028,0.0005357716,0.00037437855,0.00015354806,0.00003875882,0.00013854656,0.000034901528,0.00029193138],"category_scores_gemma":[0.00012951295,0.00022857201,0.000026591166,0.00075146946,0.00016271882,0.00028017262,0.00014891587,0.000112037094,0.000011824869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009500278,0.013840098,0.94804233,0.00010757265,0.00051027635,0.00009118307,0.006568597,0.000110092464,0.00003769584,0.000084138584,0.0012087265,0.019899033],"study_design_scores_gemma":[0.13748994,0.04617886,0.8123605,0.00015482082,0.00067162624,0.000017247954,0.0010248317,0.001385352,0.0001028872,0.00011395965,0.00029541168,0.0002045044],"about_ca_topic_score_codex":0.00340207,"about_ca_topic_score_gemma":0.0023391077,"teacher_disagreement_score":0.13568175,"about_ca_system_score_codex":0.00028329712,"about_ca_system_score_gemma":0.00040357487,"threshold_uncertainty_score":0.9320896},"labels":[],"label_agreement":null},{"id":"W2803611443","doi":"10.1007/s10637-018-0600-2","title":"Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; MEK inhibitor; Adverse effect; Internal medicine; Rash; Cancer; Gastroenterology; Progressive disease; Response Evaluation Criteria in Solid Tumors; KRAS; Population; Pharmacokinetics; Nausea; Oncology; MAPK/ERK pathway; Chemotherapy; Colorectal cancer","score_opus":0.02750770921311321,"score_gpt":0.29886489760506607,"score_spread":0.2713571883919529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803611443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941472,0.00024366437,0.0000065621293,0.0043031783,0.0002224527,0.0007553332,0.00006885711,0.000022686801,0.00023008499],"genre_scores_gemma":[0.99472564,0.00001083976,0.002578693,0.0019193181,0.00023656785,0.000070552764,0.000059262526,0.000025040601,0.00037410116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998399,0.000071968956,0.00043356608,0.00029829005,0.0005949892,0.0002021709],"domain_scores_gemma":[0.9988688,0.00015491527,0.00024731382,0.00024315814,0.00031365643,0.00017215661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014636622,0.00019542892,0.0003194897,0.00013983385,0.00008348904,0.000010336839,0.000115150084,0.000041306343,0.00010333605],"category_scores_gemma":[0.00025063672,0.000114789924,0.000064962376,0.0007700995,0.0006038887,0.0002020505,0.000041153435,0.00016498806,0.00000743135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017312485,0.0008025485,0.9700115,0.00015400293,0.0001799704,0.0000038160247,0.006318233,0.000018742503,0.004029201,0.00015477306,0.006663933,0.009932069],"study_design_scores_gemma":[0.019532913,0.0013503789,0.9449438,0.00067949964,0.00019131026,0.000004236931,0.00025553763,0.00006781416,0.03062821,0.0010065999,0.0011435021,0.0001961948],"about_ca_topic_score_codex":0.00030825773,"about_ca_topic_score_gemma":0.00024832983,"teacher_disagreement_score":0.026599009,"about_ca_system_score_codex":0.00011349882,"about_ca_system_score_gemma":0.0011917587,"threshold_uncertainty_score":0.4680997},"labels":[],"label_agreement":null},{"id":"W2805277822","doi":"10.1007/s10637-018-0618-5","title":"Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Centre for Drug Research and Development","funders":"","keywords":"S1PR1; Carboplatin; Sphingosine; Antibody; Sphingosine-1-phosphate; Cancer research; Sphingosine-1-phosphate receptor; Cytotoxicity; Pharmacology; Monoclonal antibody; Sphingolipid; Cancer cell; Chemistry; Cell growth; Receptor; Cancer; Biology; Medicine; Immunology; Internal medicine; Biochemistry; In vitro; Chemotherapy; Cisplatin","score_opus":0.01269533112936384,"score_gpt":0.3209698053832642,"score_spread":0.30827447425390037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805277822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998051,0.00019627501,0.000026676205,0.00021807826,0.0007749437,0.00046283993,0.00009062816,0.00001153917,0.00016803553],"genre_scores_gemma":[0.9976602,0.000051509498,0.00018590996,0.00029157527,0.0014107822,0.000011481291,0.00009884252,0.000030055602,0.0002596323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981794,0.00021310041,0.0005707182,0.00041359576,0.00039780137,0.00022538396],"domain_scores_gemma":[0.99868345,0.00006196608,0.00041901908,0.0004536818,0.00024496735,0.00013691929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005345872,0.00022652978,0.000347456,0.000049071343,0.00016655175,0.000020830634,0.00045756617,0.000120970086,0.00008399223],"category_scores_gemma":[0.00014503581,0.00015099873,0.00016329519,0.0002509441,0.00047218814,0.000013160696,0.00019608486,0.00013695638,0.0000067875876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011341378,0.0001333649,0.09062224,0.000036442514,0.00010621224,2.9540092e-7,0.000300921,0.00013314464,0.9069542,0.000063948835,0.0012000808,0.0003357344],"study_design_scores_gemma":[0.0016445934,0.0003576706,0.079803504,0.000107792024,0.00006928747,0.000002075822,0.000048018745,0.000048412414,0.91611147,0.000043480726,0.0015886703,0.00017502601],"about_ca_topic_score_codex":0.00056200154,"about_ca_topic_score_gemma":0.000031371164,"teacher_disagreement_score":0.010818733,"about_ca_system_score_codex":0.000010031482,"about_ca_system_score_gemma":0.00027560946,"threshold_uncertainty_score":0.61575496},"labels":[],"label_agreement":null},{"id":"W2810093122","doi":"10.1007/s10637-017-0455-y","title":"Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"erratum","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Calcium channel; TRPV6; Calcium; Medicine; Phase (matter); Pharmacology; Internal medicine; Chemistry; Calcium metabolism","score_opus":0.032401360179402566,"score_gpt":0.31077772977999396,"score_spread":0.2783763696005914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810093122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814909,0.000033992972,0.0000050776766,0.0009458661,0.011656336,0.0025102438,0.00020981938,0.000058453006,0.0030893101],"genre_scores_gemma":[0.9642248,0.0000075159205,0.000045544068,0.00046530773,0.0011105292,0.00016713436,0.00029523103,0.000122022866,0.033561874],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950157,0.0001841464,0.0011420153,0.0013212371,0.001614713,0.000722193],"domain_scores_gemma":[0.99750924,0.00012461074,0.0010128675,0.0006017962,0.0002202106,0.0005312785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025467706,0.0007194415,0.0010530163,0.0009212352,0.00036342136,0.00010810539,0.0010226538,0.00037805503,0.000045746718],"category_scores_gemma":[0.0006624417,0.0006368319,0.000120210105,0.00074012106,0.00038681086,0.0004703583,0.0002770269,0.0012129659,0.000031916672],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009841508,0.009295697,0.00293563,0.00047939387,0.00005728847,0.00016172905,0.028915342,0.009048736,0.0037377747,0.00021786055,0.9436403,0.0005261235],"study_design_scores_gemma":[0.27002013,0.065465376,0.13181949,0.04804507,0.00060286326,0.000052556425,0.011913776,0.0075467248,0.24873199,0.03188071,0.16129301,0.022628289],"about_ca_topic_score_codex":0.000812194,"about_ca_topic_score_gemma":0.00081773347,"teacher_disagreement_score":0.78234726,"about_ca_system_score_codex":0.0002613044,"about_ca_system_score_gemma":0.0011704648,"threshold_uncertainty_score":0.9996083},"labels":[],"label_agreement":null},{"id":"W2885160762","doi":"10.1007/s10637-018-0644-3","title":"The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lanthanide and Transition Metal Complexes","field":"Materials Science","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Canadian Institutes of Health Research","keywords":"Intracellular pH; Chemistry; Quercetin; Monocarboxylate transporter; Intracellular; In vivo; Intraperitoneal injection; Transporter; Tumor microenvironment; Pharmacology; Extracellular; Cancer cell; Cancer; Biochemistry; Medicine; Biology; Internal medicine; Antioxidant","score_opus":0.021182038711754312,"score_gpt":0.23557935971675015,"score_spread":0.21439732100499584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885160762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970821,0.0002963352,0.0018238825,0.00033218638,0.00012871467,0.00024052848,0.000029596653,0.000028893202,0.00003773713],"genre_scores_gemma":[0.99490374,0.000016469874,0.0047804182,0.000087758206,0.00010899853,0.000018496083,0.0000033778124,0.000016098393,0.00006463718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848664,0.0000998146,0.00055641774,0.0002897794,0.00033019617,0.00023716365],"domain_scores_gemma":[0.99940133,0.000074792486,0.0001571153,0.0001809327,0.000114323666,0.00007150902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005148519,0.00014611974,0.00015619787,0.00015723461,0.00013728281,0.000056271358,0.00018323983,0.000059809638,0.00003570759],"category_scores_gemma":[0.000047574547,0.00012370368,0.00003928942,0.0003228829,0.0003662585,0.0004422303,0.000017875605,0.00012402459,0.000012309638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010471228,0.000023431161,0.00047162455,0.000012019681,8.952966e-7,9.2976455e-7,0.0018894182,0.0020720114,0.99348,0.00046344372,0.0000035130818,0.0014779498],"study_design_scores_gemma":[0.0004549136,0.000032303873,0.0019168616,0.0000711403,0.0000059704385,0.0000025715447,0.00013354252,0.13658266,0.8535943,0.0070446488,0.000039122962,0.000121987534],"about_ca_topic_score_codex":0.00077961537,"about_ca_topic_score_gemma":0.0011076217,"teacher_disagreement_score":0.13988577,"about_ca_system_score_codex":0.000069402995,"about_ca_system_score_gemma":0.00017443908,"threshold_uncertainty_score":0.50444895},"labels":[],"label_agreement":null},{"id":"W2885345548","doi":"10.1007/s10637-018-0627-4","title":"Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Rash; Medicine; Pharmacokinetics; Toxicity; Pharmacology; Bioavailability; Adverse effect; In vivo; Mucositis; Population; Internal medicine; Gastroenterology; Biology","score_opus":0.020630088078205332,"score_gpt":0.28804445371272924,"score_spread":0.2674143656345239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885345548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998628,0.00007682932,0.00034405646,0.00025162863,0.00021470226,0.00027975437,0.000068450085,0.000018580447,0.000117964286],"genre_scores_gemma":[0.996139,0.000010332672,0.00095445476,0.0005739321,0.001074285,0.000019904744,0.0004961841,0.000026107175,0.0007057802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881387,0.00007841698,0.00029951276,0.00039993253,0.0002452578,0.0001629902],"domain_scores_gemma":[0.99910015,0.000013491783,0.0001783775,0.00028151064,0.00024769682,0.00017876273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018541244,0.0001595057,0.00014556969,0.0000639598,0.0000940528,0.00003703958,0.00015270757,0.0001101132,0.000059428814],"category_scores_gemma":[0.00008983214,0.00016392751,0.000025098841,0.00015287081,0.00027040267,0.000026174144,0.00007541383,0.00006334379,0.000012069981],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121331475,0.0003001494,0.0038025626,0.0000122277215,0.00003692665,0.0000011576075,0.00063815253,0.0000064598903,0.99069786,0.00010932589,0.001457142,0.002816705],"study_design_scores_gemma":[0.0028662696,0.0028769188,0.005032455,0.00003567571,0.00003584476,0.0000059258837,0.0002095925,0.00033272713,0.9702883,0.00031057192,0.01773229,0.00027343084],"about_ca_topic_score_codex":0.00010924015,"about_ca_topic_score_gemma":0.00005066179,"teacher_disagreement_score":0.020409562,"about_ca_system_score_codex":0.000018356168,"about_ca_system_score_gemma":0.00033247846,"threshold_uncertainty_score":0.668477},"labels":[],"label_agreement":null},{"id":"W2885940270","doi":"10.1007/s10637-018-0643-4","title":"Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Pancreatic cancer; Unfolded protein response; Endoplasmic reticulum; In vivo; Cytotoxic T cell; Apoptosis; Medicine; Endocrinology; Internal medicine; Toxicity; Chemistry; Cancer; Cancer research; In vitro; Biology; Biochemistry","score_opus":0.010324257116953403,"score_gpt":0.25672939573111053,"score_spread":0.24640513861415714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885940270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971419,0.0001824067,0.00070277235,0.00068148033,0.0001253328,0.0002701855,0.00015171249,0.000013162743,0.000731058],"genre_scores_gemma":[0.9949317,0.000024809686,0.0030621914,0.0007264008,0.00022078252,0.000040124414,0.0003592121,0.000025167677,0.0006096219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984806,0.0000704295,0.00039203683,0.0004692255,0.00031720573,0.00027048014],"domain_scores_gemma":[0.9990274,0.000023270943,0.00018173714,0.0002925881,0.00018181269,0.00029322473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009243693,0.00022292744,0.00020060148,0.00010792775,0.00006753977,0.000020699794,0.00020969077,0.00011992355,0.00002580678],"category_scores_gemma":[0.00023770134,0.0002091066,0.00006589681,0.00022051964,0.0002740162,0.000019217749,0.00012632506,0.00011067623,0.000012750419],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019314971,0.00012283043,0.026865974,0.000042598927,0.000020912072,0.0000027575957,0.0006359806,0.0017450035,0.9507269,0.00037739263,0.018584548,0.0006819499],"study_design_scores_gemma":[0.0009375425,0.00023659255,0.0066905706,0.00017055775,0.000013658255,0.000006562668,0.00018526075,0.0014056005,0.98831326,0.0010992776,0.0006934407,0.00024765305],"about_ca_topic_score_codex":0.00010983207,"about_ca_topic_score_gemma":0.00005944626,"teacher_disagreement_score":0.03758638,"about_ca_system_score_codex":0.000029463516,"about_ca_system_score_gemma":0.0002897371,"threshold_uncertainty_score":0.8527119},"labels":[],"label_agreement":null},{"id":"W2896825577","doi":"10.1007/s10637-018-0680-z","title":"Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; University of Toronto; Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Selumetinib; Medicine; Carboplatin; Pemetrexed; Cohort; Internal medicine; Adverse effect; Chemotherapy; Tolerability; Neutropenia; Oncology; Cisplatin; Cancer; Gastroenterology; KRAS","score_opus":0.03154237553643747,"score_gpt":0.3657243787929642,"score_spread":0.33418200325652675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896825577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944368,0.00009012626,0.00002668777,0.0021469402,0.00009821291,0.0025259524,0.0004403805,0.000028232067,0.00020664137],"genre_scores_gemma":[0.99356955,0.000017408365,0.003926186,0.00092700776,0.000112583744,0.00021366423,0.00024855576,0.000046132456,0.00093889545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979449,0.00017653167,0.0006392166,0.0003859962,0.0005569088,0.00029643075],"domain_scores_gemma":[0.9981416,0.0002008292,0.00047842078,0.00025088323,0.0004940277,0.00043425255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033884723,0.00025050572,0.0007614408,0.00035374393,0.000118859345,0.000024838128,0.00008811368,0.000051501724,0.00047287537],"category_scores_gemma":[0.00034620633,0.00017603142,0.000047455494,0.00083457556,0.00012784761,0.00018686896,0.000009955462,0.00011967566,0.0000038730327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016407669,0.0032873214,0.8655604,0.00014892813,0.003198312,0.000069807116,0.04379717,0.00025228853,0.00033197596,0.00015713272,0.0072775776,0.059511416],"study_design_scores_gemma":[0.2033064,0.013249183,0.7624226,0.0034269395,0.0017607866,0.0000060807947,0.0063878316,0.00017710568,0.0024876918,0.00067639526,0.0053966204,0.00070234307],"about_ca_topic_score_codex":0.056197073,"about_ca_topic_score_gemma":0.21428213,"teacher_disagreement_score":0.18689874,"about_ca_system_score_codex":0.0008296452,"about_ca_system_score_gemma":0.0030861918,"threshold_uncertainty_score":0.9500878},"labels":[],"label_agreement":null},{"id":"W2909480139","doi":"10.1007/s10637-019-00726-2","title":"Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta","funders":"","keywords":"Protein kinase B; Doxorubicin; Phosphorylation; Kinase; PI3K/AKT/mTOR pathway; Cell biology; p38 mitogen-activated protein kinases; Chemistry; Cancer research; Cytotoxicity; Sensitization; Signal transduction; Biology; Protein kinase A; Biochemistry; In vitro; Immunology; Chemotherapy","score_opus":0.011290109986856025,"score_gpt":0.24124372220894996,"score_spread":0.22995361222209393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909480139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943988,0.000527593,0.0030075053,0.0006314404,0.000097018805,0.0002403038,0.00009549368,0.000008248123,0.0009936411],"genre_scores_gemma":[0.99586016,0.00002416607,0.0024673187,0.00038112106,0.00019508871,0.00001244263,0.0006722851,0.000016416736,0.00037101994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898225,0.000058313937,0.00032489467,0.0002446993,0.0002678073,0.000122023666],"domain_scores_gemma":[0.9991519,0.00007831008,0.00030932017,0.00020230885,0.00021478767,0.00004339694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012113139,0.00013579929,0.00014470845,0.000024870038,0.00004324234,0.000009838834,0.00013554642,0.00010830939,0.00008145299],"category_scores_gemma":[0.00010190829,0.00011280127,0.000075525146,0.00015301828,0.00017171368,0.000015584272,0.000049020084,0.00007674705,0.0000063786647],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036237194,0.000028729146,0.0010488086,0.000029963101,0.00005016145,1.10586655e-7,0.00039728213,0.012204616,0.9809657,0.0011622752,0.0036074587,0.0004687004],"study_design_scores_gemma":[0.00047867312,0.00014617071,0.0011429643,0.000084915024,0.000017304403,0.0000020024406,0.00011086335,0.00042197236,0.9873247,0.008192934,0.0019504512,0.00012705158],"about_ca_topic_score_codex":0.00017584577,"about_ca_topic_score_gemma":0.000008429685,"teacher_disagreement_score":0.011782644,"about_ca_system_score_codex":0.000023502684,"about_ca_system_score_gemma":0.00021663327,"threshold_uncertainty_score":0.4599902},"labels":[],"label_agreement":null},{"id":"W2936108326","doi":"10.1007/s10637-019-00768-6","title":"A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Antibody-drug conjugate; Internal medicine; Adverse effect; Nausea; Mesothelioma; Oncology; Germ cell tumors; Phases of clinical research; Gastroenterology; Toxicity; Chemotherapy; Antibody; Immunology; Lymphoma; Pathology; Monoclonal antibody","score_opus":0.027656533319971862,"score_gpt":0.3151312772962788,"score_spread":0.28747474397630696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936108326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705815,0.000031542855,9.811614e-7,0.00037526025,0.000051622752,0.0015380868,0.000016287071,0.000014005472,0.0009140834],"genre_scores_gemma":[0.99798447,6.857872e-7,0.0011056382,0.00038680475,0.000029797107,0.00005654614,0.00013116536,0.00001996801,0.00028494766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985547,0.000043459317,0.00038991132,0.0003192994,0.00051654095,0.0001760644],"domain_scores_gemma":[0.99917185,0.00007640082,0.00019572293,0.0002599363,0.00011512496,0.00018094367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010002283,0.00016531107,0.0003894963,0.00012195236,0.00003572425,0.000034772358,0.00013639835,0.000033335975,0.000070163405],"category_scores_gemma":[0.00003952597,0.0001262805,0.000020197376,0.00024868606,0.000055058445,0.00021050747,0.00008420442,0.00007714159,0.000039507217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067314185,0.031685155,0.96056366,0.000036160964,0.00011195478,0.00001926054,0.0023606236,0.00006482222,0.00035205408,0.00025919956,0.0006196229,0.0032543235],"study_design_scores_gemma":[0.15865093,0.004531725,0.83258516,0.0007083884,0.00008537709,0.0000034672046,0.0004386257,0.00030608964,0.002136666,0.000283437,0.000101649035,0.00016847996],"about_ca_topic_score_codex":0.00071262463,"about_ca_topic_score_gemma":0.000023360879,"teacher_disagreement_score":0.15797779,"about_ca_system_score_codex":0.00013452915,"about_ca_system_score_gemma":0.00054705824,"threshold_uncertainty_score":0.51495695},"labels":[],"label_agreement":null},{"id":"W2954170284","doi":"10.1007/s10637-019-00816-1","title":"Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Lethbridge; University of Calgary","funders":"","keywords":"Neuroblastoma; In vivo; Medicine; Cancer research; Pharmacology; Cytotoxicity; MAPK/ERK pathway; Apoptosis; In vitro; Kinase; Biology; Cell culture","score_opus":0.015092318103487405,"score_gpt":0.2386592850916971,"score_spread":0.2235669669882097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954170284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949018,0.00004665934,0.0000015170999,0.003105252,0.0002261318,0.0011534041,0.000025822805,0.000026968159,0.00051244494],"genre_scores_gemma":[0.9985745,0.000009227758,0.00009005828,0.00053914037,0.00018681289,0.00003016614,0.00002169824,0.000020763533,0.00052761944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982481,0.00017276357,0.00034485836,0.0003429078,0.00061734964,0.00027400392],"domain_scores_gemma":[0.9990557,0.00016704772,0.00013984008,0.00023532625,0.00021523541,0.00018685771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016761146,0.00018951166,0.00027833652,0.00016663135,0.00006388994,0.000019000392,0.00011352377,0.000049690567,0.00007397458],"category_scores_gemma":[0.00031314982,0.00012790179,0.00010334846,0.00073510007,0.00016053008,0.00014281351,0.00009883342,0.00029666486,0.00010897491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004072446,0.0005312598,0.80415326,0.0003046041,0.000070995644,0.00003552797,0.00016714775,0.0008275418,0.19156279,0.00029347936,0.0015047716,0.00014136356],"study_design_scores_gemma":[0.0023710472,0.00029228977,0.87496233,0.000124775,0.00004512695,0.00011529933,0.000013073594,0.00031562056,0.12132862,0.000271886,0.00006321647,0.00009669594],"about_ca_topic_score_codex":0.00014452993,"about_ca_topic_score_gemma":0.000033128614,"teacher_disagreement_score":0.070809074,"about_ca_system_score_codex":0.00007749692,"about_ca_system_score_gemma":0.0010259558,"threshold_uncertainty_score":0.52156836},"labels":[],"label_agreement":null},{"id":"W2966036111","doi":"10.1007/s10637-019-00837-w","title":"Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Ibrutinib; Cancer research; Kinome; Downregulation and upregulation; XIAP; Tyrosine kinase; Bruton's tyrosine kinase; Apoptosis; Kinase; Signal transduction; Caspase; Pharmacology; Medicine; Biology; Programmed cell death; Cell biology; Immunology; Leukemia; Chronic lymphocytic leukemia; Biochemistry","score_opus":0.011200263854343957,"score_gpt":0.2952975540714463,"score_spread":0.28409729021710234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966036111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912051,0.0013952634,0.00011128319,0.005632719,0.000082838094,0.0007340178,0.000057907953,0.000017905135,0.00076295],"genre_scores_gemma":[0.99629825,0.000042212178,0.00073931867,0.0008839961,0.00030031952,0.00003667303,0.000038978666,0.000021475185,0.0016387784],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99885464,0.000036472527,0.00020459702,0.00021358444,0.0004884404,0.00020224068],"domain_scores_gemma":[0.99919677,0.00021673761,0.000101158956,0.00018739342,0.00015528892,0.00014266702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001947151,0.00010604104,0.0001631192,0.000048865495,0.00007045022,0.00003337124,0.00009152446,0.000066280154,0.0002449717],"category_scores_gemma":[0.00004213195,0.00007540789,0.00005993317,0.000108497145,0.00021763956,0.00011827372,0.000047499925,0.000110230445,0.0000177045],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032383348,0.00022580921,0.014152732,0.00096725,0.00078103447,0.000007592458,0.007351021,0.0031752638,0.7291119,0.09537771,0.0035455183,0.14206581],"study_design_scores_gemma":[0.057735663,0.00068948185,0.1042764,0.0019563478,0.0005638217,0.0012555979,0.0042139445,0.3964639,0.1186576,0.27811894,0.035275508,0.00079280086],"about_ca_topic_score_codex":0.0019306585,"about_ca_topic_score_gemma":0.0000071147942,"teacher_disagreement_score":0.6104543,"about_ca_system_score_codex":0.00073937123,"about_ca_system_score_gemma":0.0061113914,"threshold_uncertainty_score":0.99952304},"labels":[],"label_agreement":null},{"id":"W2972912130","doi":"10.1007/s10637-019-00814-3","title":"A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; KRAS; Panitumumab; Mucositis; Internal medicine; Colorectal cancer; Gastroenterology; Rash; Cancer; Oncology; Toxicity","score_opus":0.010342299013200922,"score_gpt":0.27251207476366757,"score_spread":0.2621697757504666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972912130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720126,0.000096050804,4.819489e-7,0.00034655197,0.00008730662,0.001989471,0.000018108329,0.000017541493,0.00024320431],"genre_scores_gemma":[0.9992227,0.0000058421037,0.00020385828,0.0001313274,0.000025365338,0.00015301627,0.00008747355,0.000020751384,0.00014968246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860567,0.000039763418,0.00031359683,0.00032008105,0.00053923577,0.0001816824],"domain_scores_gemma":[0.99928254,0.000066867404,0.00016500981,0.00011829071,0.0002645285,0.00010274209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006268906,0.00019501157,0.00039995802,0.00020523599,0.0000333066,0.000008356951,0.000051340885,0.00003939574,0.000048056627],"category_scores_gemma":[0.000040074152,0.00014357879,0.000020329535,0.0006926739,0.00008686445,0.00017587194,0.000027362043,0.00014363322,0.000004184444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008872104,0.0053214203,0.97590625,0.00004665965,0.00012276958,0.000016689459,0.0064230533,0.00026121933,0.00050696183,0.00006098444,0.00006022992,0.002401663],"study_design_scores_gemma":[0.068611376,0.0158042,0.91239333,0.0004218755,0.00007048236,0.0000013898164,0.0012396626,0.000087676664,0.0010489328,0.000100321435,0.000053854343,0.00016688798],"about_ca_topic_score_codex":0.0016979963,"about_ca_topic_score_gemma":0.0032462876,"teacher_disagreement_score":0.06351291,"about_ca_system_score_codex":0.00036355885,"about_ca_system_score_gemma":0.0005999639,"threshold_uncertainty_score":0.58549726},"labels":[],"label_agreement":null},{"id":"W2984708337","doi":"10.1007/s10637-019-00875-4","title":"A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"Terry Fox Research Institute; Canadian Cancer Society","keywords":"Glioblastoma; mTORC1; Cancer research; Medicine; Dual (grammatical number); Oncology; Internal medicine; Biology; Signal transduction; Philosophy; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.010164630321915433,"score_gpt":0.26229846738537765,"score_spread":0.2521338370634622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984708337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500906,0.000023903314,2.4759706e-7,0.00012152622,0.000050864663,0.00465317,0.0000219272,0.00004329146,0.00007598138],"genre_scores_gemma":[0.99934065,5.502329e-7,0.00010178835,0.00008314906,0.00004988859,0.0001718599,0.000091695525,0.000036093472,0.0001243039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770707,0.00008631062,0.00058944884,0.00046386782,0.000885924,0.0002673688],"domain_scores_gemma":[0.99879324,0.00010361021,0.00023052894,0.00036414262,0.00021908277,0.00028938847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013412924,0.0002889137,0.0005274749,0.00032761128,0.000042122916,0.000021109643,0.000082956976,0.00005900944,0.00007108435],"category_scores_gemma":[0.00006999983,0.00021431172,0.000056799658,0.0006439972,0.00005955554,0.00017313397,0.00004815039,0.0001400769,0.00005692865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019078192,0.043234155,0.9447559,0.00003311154,0.00028449128,0.000060280785,0.0079812575,0.00009076289,0.00033969103,0.000017804598,0.00025508236,0.0010396254],"study_design_scores_gemma":[0.09886291,0.028618488,0.8673032,0.0002675024,0.00022974724,0.000004469598,0.0020894085,0.00012546229,0.0022488341,0.000019952698,0.000033575536,0.00019649086],"about_ca_topic_score_codex":0.0011630446,"about_ca_topic_score_gemma":0.00040952227,"teacher_disagreement_score":0.09695508,"about_ca_system_score_codex":0.0001927486,"about_ca_system_score_gemma":0.00035114988,"threshold_uncertainty_score":0.87393785},"labels":[],"label_agreement":null},{"id":"W2986650118","doi":"10.1007/s10637-019-00869-2","title":"A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"F. Hoffmann-La Roche","keywords":"Pharmacokinetics; Medicine; Prodrug; Pharmacology; Nausea; Pharmacodynamics; Dosing; Cmax; Neutropenia; Internal medicine; Gastroenterology; Toxicity","score_opus":0.007137229277251686,"score_gpt":0.25166890298989547,"score_spread":0.24453167371264378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986650118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965252,0.000046500725,0.0000051025177,0.00041471262,0.000105943436,0.0025152848,0.000034411565,0.000023166289,0.00032965437],"genre_scores_gemma":[0.99905676,9.937463e-7,0.00035947154,0.00021063784,0.000022947126,0.00003181103,0.00007719522,0.000034232424,0.00020595473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796504,0.00007534625,0.0006011697,0.0003342469,0.0008256863,0.00019850123],"domain_scores_gemma":[0.99861914,0.000045408233,0.00042346847,0.000470712,0.0003047316,0.00013651635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013978791,0.00019400004,0.0004265074,0.00015840874,0.000033308006,0.000006508032,0.00017340403,0.000060522143,0.000043561064],"category_scores_gemma":[0.000146383,0.00014019465,0.00006621814,0.0007630056,0.00016864667,0.000098275574,0.00006207468,0.00027537622,0.000008333606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005299979,0.011648612,0.8422365,0.00039275552,0.00043504967,0.000024951196,0.017484229,0.009144277,0.1095566,0.00042354694,0.0006800084,0.0026734974],"study_design_scores_gemma":[0.095179625,0.00823762,0.76701367,0.002215491,0.00025277893,0.00001513074,0.0016686489,0.0014166748,0.1226082,0.000643765,0.0002555748,0.0004928204],"about_ca_topic_score_codex":0.00027042165,"about_ca_topic_score_gemma":0.00005476478,"teacher_disagreement_score":0.08987965,"about_ca_system_score_codex":0.00012007726,"about_ca_system_score_gemma":0.0010610105,"threshold_uncertainty_score":0.5716972},"labels":[],"label_agreement":null},{"id":"W2997760522","doi":"10.1007/s10637-020-00892-8","title":"Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Clinical trial; Transcriptome; Medicine; Genome; Precision medicine; Oncology; Bioinformatics; Selection (genetic algorithm); Internal medicine; Gene; Computational biology; Gene expression; Biology; Pathology; Genetics; Computer science","score_opus":0.02847075282832528,"score_gpt":0.2639221654190349,"score_spread":0.23545141259070962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997760522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865799,0.00038935425,0.011062469,0.0014444577,0.00002913275,0.00033254386,0.00011625077,0.000012910185,0.000033015618],"genre_scores_gemma":[0.9374669,0.000033309017,0.058173303,0.0034458213,0.0002218655,0.00003526228,0.0005780542,0.000015720789,0.000029716264],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939114,0.000010340274,0.00015380036,0.00023524281,0.00008887998,0.00012061418],"domain_scores_gemma":[0.9996885,0.0000114428985,0.00005154118,0.000038710972,0.00006440696,0.00014538264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000031831256,0.000098373435,0.00009624588,0.000034984667,0.00008207098,0.00004128692,0.000044487635,0.000057113335,0.0000051071224],"category_scores_gemma":[0.000021042531,0.00010662427,0.00006558265,0.00019078999,0.00004786434,0.000004275705,0.000022136184,0.000034012195,9.2130153e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063082916,0.000034715657,0.0045107068,0.000016919357,0.0004348989,1.9994127e-7,0.0011401693,0.003929249,0.98266083,0.00015536475,0.00037925554,0.0066746296],"study_design_scores_gemma":[0.0025357376,0.0013216865,0.011715048,0.000014389577,0.0010914986,0.000018615754,0.00062744634,0.07083862,0.17056929,0.0018407626,0.73849726,0.00092963804],"about_ca_topic_score_codex":0.000028926668,"about_ca_topic_score_gemma":0.000023745422,"teacher_disagreement_score":0.8120915,"about_ca_system_score_codex":0.000026302128,"about_ca_system_score_gemma":0.00028919682,"threshold_uncertainty_score":0.43480116},"labels":[],"label_agreement":null},{"id":"W3004651543","doi":"10.1007/s10637-020-00903-8","title":"Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nausea and vomiting management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nausea; Medicine; Mirtazapine; Vomiting; Regimen; Aprepitant; Internal medicine; Chemotherapy; Chemotherapy regimen; Anesthesia; Chemotherapy-induced nausea and vomiting; Adverse effect; Clinical endpoint; Randomized controlled trial; Antiemetic; Antidepressant","score_opus":0.0477603290722459,"score_gpt":0.34115165526372804,"score_spread":0.2933913261914821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004651543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96118546,0.00022853546,0.00040700674,0.029490078,0.00033381817,0.0077967066,0.0000398326,0.0001267793,0.00039180226],"genre_scores_gemma":[0.93096745,0.000019956795,0.04680453,0.017301671,0.002171958,0.0006461491,0.0005907186,0.00010495964,0.0013926111],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974126,0.0001877872,0.0008536244,0.00070709875,0.00047756606,0.00036129518],"domain_scores_gemma":[0.99795604,0.00050865987,0.00036054847,0.00029156305,0.00015159513,0.00073156616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010046426,0.00034870236,0.0008872854,0.00009972024,0.00023244461,0.0002464308,0.00031310995,0.000114521994,0.00018766805],"category_scores_gemma":[0.0017735423,0.0003111381,0.00017398504,0.00027223132,0.00013919082,0.00055570866,0.00020132931,0.0002918192,0.000023615088],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.915333,0.00085405813,0.00007262462,0.0003468531,0.0011909967,0.000031961783,0.0028610162,0.000002607906,0.05592859,0.0012703085,0.008227746,0.013880273],"study_design_scores_gemma":[0.96825105,0.003579172,0.000014038455,0.00017998337,0.0006118951,0.0000074454515,0.00024195366,0.0033991768,0.008551161,0.0010564651,0.013727328,0.00038033613],"about_ca_topic_score_codex":0.00019919896,"about_ca_topic_score_gemma":0.000008059155,"teacher_disagreement_score":0.05291808,"about_ca_system_score_codex":0.00008366843,"about_ca_system_score_gemma":0.0006246202,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W3004815730","doi":"10.1007/s10637-020-00907-4","title":"Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Nausea; Pharmacology; Internal medicine; Myeloid leukemia; Gastroenterology; Adverse effect; Leukemia; Prodrug; Vomiting","score_opus":0.021709417867157913,"score_gpt":0.28512605040206335,"score_spread":0.26341663253490544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004815730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871583,0.000014205953,0.000013207247,0.010768721,0.000043200158,0.0012769089,0.000043880005,0.000029878485,0.00065168686],"genre_scores_gemma":[0.9954045,0.0000024651006,0.0007512408,0.0030912773,0.00015063531,0.000027386626,0.00010662875,0.000033685454,0.00043217483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976685,0.0001039803,0.00043367053,0.0003760095,0.0011508357,0.0002670068],"domain_scores_gemma":[0.99878275,0.00009347745,0.00016260662,0.00035486888,0.00021059871,0.00039571707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014333105,0.00019859818,0.00033719707,0.00010006609,0.00008743636,0.000021561531,0.00033155346,0.00006921339,0.000081701735],"category_scores_gemma":[0.00023029027,0.0001322051,0.000056156132,0.00095448364,0.00028098322,0.00014615725,0.000159928,0.00050135824,0.000032825916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040015993,0.0024283526,0.9416279,0.00011538352,0.0005533012,0.000118324046,0.015516504,0.00044206373,0.0071954583,0.000622363,0.02390696,0.0034717708],"study_design_scores_gemma":[0.07250133,0.0051511894,0.9034323,0.00021159717,0.00027435232,0.000016430475,0.0016312514,0.0020720982,0.01088135,0.00045437846,0.002977173,0.0003965448],"about_ca_topic_score_codex":0.00048701602,"about_ca_topic_score_gemma":0.000032444193,"teacher_disagreement_score":0.06849974,"about_ca_system_score_codex":0.00046035915,"about_ca_system_score_gemma":0.0030425242,"threshold_uncertainty_score":0.5397307},"labels":[],"label_agreement":null},{"id":"W3005499534","doi":"10.1007/s10637-020-00904-7","title":"A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Queen's University","funders":"Canadian Cancer Society Research Institute","keywords":"Tremelimumab; Durvalumab; Tolerability; Medicine; Adverse effect; Internal medicine; Cohort; Oncology; Cancer; Nivolumab; Immunotherapy; Ipilimumab","score_opus":0.05438185365786288,"score_gpt":0.32869030911327457,"score_spread":0.2743084554554117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005499534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907533,0.000574701,0.000013577644,0.0053689373,0.00028455057,0.0023640827,0.00047312613,0.00004004055,0.00012768916],"genre_scores_gemma":[0.9962847,0.000090063084,0.0004274702,0.002278126,0.00018977278,0.00014001006,0.00035619794,0.000049980023,0.00018365748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996745,0.0002337969,0.0011584794,0.000545993,0.0008628371,0.0004539295],"domain_scores_gemma":[0.99808645,0.00015260467,0.0005843348,0.00025236345,0.00032181563,0.00060242054],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004356688,0.00036202045,0.0010865744,0.00027937163,0.00012224646,0.0000442563,0.00023800721,0.00010758325,0.00049702276],"category_scores_gemma":[0.0003377993,0.00028332873,0.0001296958,0.0008727173,0.00021123247,0.0003135981,0.000030799987,0.00021207059,0.0000069019634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12465047,0.007400609,0.5692454,0.0018776038,0.0062148464,0.00055827666,0.08089046,0.0075628636,0.0884663,0.00073222,0.030130005,0.08227094],"study_design_scores_gemma":[0.4416655,0.017189162,0.47782037,0.0043744384,0.001614067,0.000028117154,0.008161098,0.0016605488,0.020265436,0.0004371601,0.024484454,0.0022996517],"about_ca_topic_score_codex":0.086986996,"about_ca_topic_score_gemma":0.07634543,"teacher_disagreement_score":0.31701505,"about_ca_system_score_codex":0.00070403796,"about_ca_system_score_gemma":0.006765754,"threshold_uncertainty_score":0.9999619},"labels":[],"label_agreement":null},{"id":"W3006072911","doi":"10.1007/s10637-020-00909-2","title":"Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"University of Saskatchewan","keywords":"Apoptosis; Sphingosine; Cell culture; Triple-negative breast cancer; Cytotoxicity; Paclitaxel; Sphingolipid; Sphingosine-1-phosphate; Cancer research; Cell growth; Biology; Cell; Breast cancer; Docetaxel; Doxorubicin; Cancer; Chemotherapy; Internal medicine; Medicine; Cell biology; In vitro; Receptor; Biochemistry","score_opus":0.03565899534497211,"score_gpt":0.30247943567622537,"score_spread":0.26682044033125324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006072911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951588,0.00028576585,0.0003937015,0.0034515713,0.00016232753,0.0002844656,0.000117783165,0.00001524693,0.0001303604],"genre_scores_gemma":[0.99219996,0.000052625026,0.0019069619,0.00479082,0.0007626521,0.000025403713,0.00006546913,0.000030230962,0.00016588428],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861324,0.00013202529,0.0002715569,0.00041288746,0.00033885756,0.00023144008],"domain_scores_gemma":[0.9990263,0.00005650034,0.00031377192,0.00021978744,0.0001980795,0.0001855886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002734906,0.00021096121,0.00024419892,0.000027786404,0.0001851622,0.000027945129,0.0002797979,0.000083050494,0.00006039497],"category_scores_gemma":[0.00010201894,0.00015649431,0.00008381632,0.0002374728,0.0003361474,0.000017865894,0.000101712234,0.00017555438,0.000004443585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021279561,0.000023386345,0.0011973191,0.000022241113,0.00008611164,0.0000018471642,0.0006014136,0.0069823796,0.9881237,0.00019544986,0.0017726965,0.0007806696],"study_design_scores_gemma":[0.00161111,0.00016280582,0.01107268,0.0000522645,0.00005400543,0.000006381858,0.000098446646,0.00200163,0.98399997,0.0002604159,0.00044568765,0.00023460675],"about_ca_topic_score_codex":0.00056703796,"about_ca_topic_score_gemma":0.000024838657,"teacher_disagreement_score":0.009875361,"about_ca_system_score_codex":0.00001403496,"about_ca_system_score_gemma":0.00055432087,"threshold_uncertainty_score":0.6381653},"labels":[],"label_agreement":null},{"id":"W3024082028","doi":"10.1007/s10637-020-00928-z","title":"A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Cetuximab; Medicine; KRAS; Colorectal cancer; Pharmacodynamics; Internal medicine; Adverse effect; Oncology; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; EGFR inhibitors; Epidermal growth factor receptor; Toxicity; Phases of clinical research; Cancer; Monoclonal antibody; Pharmacology; Antibody; Immunology","score_opus":0.01769703272519022,"score_gpt":0.29630376845401685,"score_spread":0.2786067357288266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024082028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938509,0.000141866,0.0000016649707,0.0025397923,0.00006372836,0.0030888126,0.00015334821,0.000029868634,0.00013002584],"genre_scores_gemma":[0.998436,0.00000380542,0.0004715912,0.00041743656,0.000076105454,0.00034653032,0.00016873745,0.000031319363,0.000048515325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998052,0.000095967574,0.0003942838,0.0004362275,0.00077384064,0.0002477],"domain_scores_gemma":[0.9991069,0.00009498,0.00024884948,0.00013609466,0.00020429952,0.00020889343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054181914,0.00033610797,0.00071239384,0.000076427634,0.00015542979,0.000024421737,0.00009736738,0.00004341243,0.000015064136],"category_scores_gemma":[0.000042378007,0.00018807096,0.000101680664,0.00065208424,0.00018444385,0.00013658275,0.000055966953,0.00014078239,0.0000010915827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064240256,0.009035766,0.95877975,0.000037030186,0.0017921348,0.000049563023,0.021508249,0.00010452781,0.0007393326,0.00003710561,0.00015927017,0.001333265],"study_design_scores_gemma":[0.09942861,0.04201971,0.8422481,0.00043588117,0.00090889755,0.000002134422,0.001970433,0.00024291895,0.012379813,0.000024428191,0.000060692393,0.0002784202],"about_ca_topic_score_codex":0.0012783803,"about_ca_topic_score_gemma":0.00047913374,"teacher_disagreement_score":0.11653167,"about_ca_system_score_codex":0.00033215946,"about_ca_system_score_gemma":0.00080804527,"threshold_uncertainty_score":0.7669311},"labels":[],"label_agreement":null},{"id":"W3041329672","doi":"10.1007/s10637-020-00958-7","title":"Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Moiety; EGFR inhibitors; Quinazoline; Gefitinib; Chemistry; Transfection; Small molecule; Potency; Mechanism of action; Epidermal growth factor receptor; Penetration (warfare); Biophysics; Biochemistry; Phosphorylation; In vitro; Receptor; Biology; Stereochemistry","score_opus":0.0797261951099458,"score_gpt":0.30861932225513944,"score_spread":0.22889312714519364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041329672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90940917,0.00012598097,0.021754079,0.06762002,0.000053788728,0.00076751894,0.00020616545,0.00002288584,0.00004039595],"genre_scores_gemma":[0.98863536,0.000024045958,0.009114805,0.0015711521,0.00022688574,0.000019857289,0.0002941419,0.000015882137,0.00009785253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841756,0.00004321957,0.00035780724,0.000273022,0.00076486217,0.00014352708],"domain_scores_gemma":[0.9988815,0.00008946591,0.00011130743,0.000106921114,0.00030323144,0.00050757476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025341037,0.00012070332,0.00022767001,0.00007323685,0.00004710565,0.000012864791,0.000061352504,0.00007964174,0.00003770391],"category_scores_gemma":[0.00038285973,0.00011937233,0.00003848311,0.00026531875,0.00014511209,0.000092419825,0.0000723112,0.00012784702,0.000003393691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002987695,0.000062572035,0.0013308531,0.00030160078,0.000046002868,0.0000033334459,0.0012012067,0.00004288273,0.9711321,0.020738415,0.0026789245,0.002163344],"study_design_scores_gemma":[0.0025388726,0.0009466962,0.01666018,0.00026485077,0.00007685968,0.000023359624,0.00025784085,0.004973786,0.9673684,0.004234887,0.0024776198,0.00017661219],"about_ca_topic_score_codex":0.00038496358,"about_ca_topic_score_gemma":0.000015192864,"teacher_disagreement_score":0.07922621,"about_ca_system_score_codex":0.00011154182,"about_ca_system_score_gemma":0.0006933131,"threshold_uncertainty_score":0.48678622},"labels":[],"label_agreement":null},{"id":"W3043204261","doi":"10.1007/s10637-020-00971-w","title":"The proportion of North American cancer trials that evaluate novel targets","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Clinical trial; Cancer; Psychological intervention; Internal medicine; Cancer drugs","score_opus":0.05938365011528055,"score_gpt":0.310282317101327,"score_spread":0.2508986669860464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043204261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838736,0.000923754,0.0010828248,0.013381827,0.00016904772,0.00028446864,0.00018509332,0.0000065138324,0.00009286835],"genre_scores_gemma":[0.994256,0.00066942035,0.0011123936,0.002848983,0.00074642216,0.000035633933,0.00020143924,0.000014509379,0.000115166964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904674,0.00004344513,0.00030653723,0.000203473,0.00027487878,0.00012493887],"domain_scores_gemma":[0.9991074,0.000083347666,0.0003686514,0.00013287019,0.00015454117,0.00015317924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027165448,0.00010103254,0.00016750817,0.00001091487,0.00007341298,0.000020103933,0.0001533586,0.000024546187,0.000009880172],"category_scores_gemma":[0.000924403,0.00007575976,0.00008581802,0.00011410551,0.0002121392,0.000003151318,0.000059116002,0.000052759824,0.0000037233558],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007055287,0.00010130664,0.16224949,0.00006317683,0.0005632773,0.0000013880873,0.00089816505,0.015139716,0.60041237,0.0033873795,0.119429804,0.0970484],"study_design_scores_gemma":[0.0015353352,0.00035152282,0.2157116,0.000018755327,0.0001229373,0.0000021062906,0.00007240015,0.0012815807,0.5312011,0.0010732196,0.24827053,0.000358867],"about_ca_topic_score_codex":0.00026863153,"about_ca_topic_score_gemma":0.0003428683,"teacher_disagreement_score":0.12884073,"about_ca_system_score_codex":0.000016139264,"about_ca_system_score_gemma":0.00075850426,"threshold_uncertainty_score":0.30893934},"labels":[],"label_agreement":null},{"id":"W3045633251","doi":"10.1007/s10637-019-00757-9","title":"Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor","year":2019,"lang":"en","type":"erratum","venue":"Investigational New Drugs","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Sunitinib; Medicine; Neuroendocrine tumors; Pancreatic neuroendocrine tumor; Internal medicine; Oncology; General surgery; Cancer","score_opus":0.02647094043585678,"score_gpt":0.3214914689410952,"score_spread":0.2950205285052384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045633251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869857,0.000060388807,0.000001508763,0.0007148836,0.004075601,0.0055487677,0.000187062,0.000091243906,0.0023348348],"genre_scores_gemma":[0.6796149,0.000022338025,0.00027199605,0.0008050481,0.00032681413,0.00033400996,0.0030232153,0.00019679955,0.3154049],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940067,0.0004349631,0.0011935686,0.0010317549,0.0025267338,0.0008062719],"domain_scores_gemma":[0.9960073,0.00076992717,0.0006510573,0.0007873776,0.0010089829,0.00077535346],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001474069,0.0007372204,0.0015500392,0.0013253966,0.00012602119,0.000057292793,0.0004625219,0.00001660012,0.0009545035],"category_scores_gemma":[0.0032611277,0.0005614619,0.00010708741,0.0019219716,0.00018130775,0.00032048443,0.00029997536,0.0014900761,0.0000869704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0132482955,0.013417418,0.027150828,0.0015282956,0.0006071186,0.004316747,0.001632369,0.00064493687,0.00041089696,0.000011072837,0.9366258,0.00040626878],"study_design_scores_gemma":[0.28468093,0.26270464,0.21986641,0.020370895,0.0045765373,0.0035851602,0.014989896,0.006737053,0.008807053,0.00043520748,0.16773048,0.0055157556],"about_ca_topic_score_codex":0.0038565851,"about_ca_topic_score_gemma":0.0019334797,"teacher_disagreement_score":0.76889527,"about_ca_system_score_codex":0.0002410876,"about_ca_system_score_gemma":0.0022372068,"threshold_uncertainty_score":0.99995875},"labels":[],"label_agreement":null},{"id":"W3045754390","doi":"10.1007/s10637-020-00906-5","title":"Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Natural Science Foundation of China","keywords":"Biology; Colorectal cancer; Flow cytometry; Cancer; Microbiology; Apoptosis; Malignancy; Bacteria; Cancer cell; Bacillus (shape); Ovarian cancer; Cancer research; Gut flora; Immunology; Genetics","score_opus":0.028827298862139788,"score_gpt":0.28444923808792727,"score_spread":0.25562193922578746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045754390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311763,0.00081067294,0.00008043378,0.0045898217,0.0000424093,0.00023665531,0.00029203767,0.000007793657,0.0008225642],"genre_scores_gemma":[0.9959493,0.000041162853,0.00041628224,0.0025694987,0.00049620634,0.000020591306,0.00027030188,0.000013034772,0.00022361006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922997,0.000029735978,0.00012112725,0.00023429001,0.0002494042,0.0001354923],"domain_scores_gemma":[0.99954784,0.000040854433,0.000053269312,0.00016356593,0.0000436715,0.00015077286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003551291,0.000107998865,0.00010545991,0.0000110794435,0.00006113593,0.000015281845,0.00016946418,0.000049938946,0.00006109186],"category_scores_gemma":[0.00010045112,0.00008060031,0.000066008506,0.0000786084,0.0001193704,0.0000038485096,0.00005283024,0.00006694789,0.000022575685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081472506,0.00005206162,0.006003687,0.00002329151,0.0001765091,0.0000037878904,0.00036059928,0.000035794696,0.97516483,0.0010844806,0.012593596,0.004419914],"study_design_scores_gemma":[0.004523754,0.0007509895,0.14860174,0.00017348578,0.000064248066,0.0000024274395,0.000047496436,0.00005057374,0.8257161,0.0031594788,0.016614156,0.00029558592],"about_ca_topic_score_codex":0.0009410936,"about_ca_topic_score_gemma":0.000117024836,"teacher_disagreement_score":0.14944875,"about_ca_system_score_codex":0.000014291429,"about_ca_system_score_gemma":0.00023073987,"threshold_uncertainty_score":0.32867852},"labels":[],"label_agreement":null},{"id":"W3118976699","doi":"10.1007/s10637-020-01043-9","title":"The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Cancer Institute; Fondation du cancer des Cèdres; Frank McGraw Memorial Chair in Cancer Research","keywords":"Pembrolizumab; Ovary; Medicine; Clinical trial; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.029754829291786605,"score_gpt":0.29047536963805537,"score_spread":0.2607205403462688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118976699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925253,0.00043778514,0.0000016139046,0.005698724,0.00021267166,0.00076341187,0.0002756554,0.000005036373,0.00007982461],"genre_scores_gemma":[0.99880254,0.00006165283,0.0005509371,0.0002339205,0.00010962281,0.000021878486,0.00015768157,0.000009934243,0.0000518404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837345,0.00019707,0.0006400282,0.00026779863,0.00039647036,0.00012520308],"domain_scores_gemma":[0.99854994,0.0005697549,0.00028459958,0.00029728864,0.00014325338,0.00015517368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018999478,0.0001419829,0.00034205092,0.000027694574,0.00011414887,0.000012418399,0.0000620283,0.000048015852,0.00004081915],"category_scores_gemma":[0.00025875488,0.0000804391,0.000094304734,0.00021677457,0.00034768847,0.000050682724,0.00007387556,0.00014892663,6.282526e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21154156,0.02728388,0.69013035,0.00023118375,0.0010321547,0.0006987948,0.0085007455,0.000084202125,0.0002890185,0.0022177573,0.0064171124,0.05157324],"study_design_scores_gemma":[0.33129847,0.0064250333,0.6505957,0.001008991,0.000549686,0.0000841639,0.0002926353,0.00003911065,0.0044758776,0.001401625,0.0036191093,0.00020954995],"about_ca_topic_score_codex":0.00025955564,"about_ca_topic_score_gemma":0.00017812039,"teacher_disagreement_score":0.119756915,"about_ca_system_score_codex":0.00007156566,"about_ca_system_score_gemma":0.0009865673,"threshold_uncertainty_score":0.32802114},"labels":[],"label_agreement":null},{"id":"W3121695703","doi":"10.1007/s10637-020-01049-3","title":"Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Paraza Pharma (Canada); McGill University Health Centre","funders":"","keywords":"Mucositis; Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Adverse effect; Nausea; Internal medicine; Diarrhea; Gastroenterology; Phases of clinical research; Pharmacokinetics; Vomiting; Toxicity; Oncology; Surgery","score_opus":0.009158176539371862,"score_gpt":0.2681257152139644,"score_spread":0.25896753867459255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121695703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975968,0.00012303649,0.0010533314,0.00028115066,0.00007481471,0.0007304939,0.000076829965,0.000013997106,0.00004957356],"genre_scores_gemma":[0.9869716,0.000026973794,0.0092002265,0.0016065419,0.00010359525,0.000076368735,0.0009964589,0.000048847694,0.0009693667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983463,0.000115547446,0.00044302735,0.00052797684,0.00029778967,0.00026930586],"domain_scores_gemma":[0.99908334,0.000026299882,0.00014154692,0.00033081247,0.00021467463,0.00020332748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012055465,0.00025866137,0.00027164788,0.00007194559,0.000071314265,0.00003603336,0.00015537199,0.00006289552,0.000046742498],"category_scores_gemma":[0.0001243239,0.00022140452,0.000057271372,0.00032333808,0.0000932548,0.000018505707,0.00007349108,0.00012994678,0.0000073013616],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01703419,0.015523233,0.11283312,0.00019681282,0.0011461873,0.000570002,0.004759092,0.011516603,0.7902998,0.0005599503,0.0059955944,0.039565437],"study_design_scores_gemma":[0.18097728,0.016097764,0.10909858,0.000953295,0.00037100387,0.00009061276,0.004068992,0.0028601617,0.6484051,0.0018385766,0.03134869,0.0038899689],"about_ca_topic_score_codex":0.000043424043,"about_ca_topic_score_gemma":0.00039141183,"teacher_disagreement_score":0.1639431,"about_ca_system_score_codex":0.000051307397,"about_ca_system_score_gemma":0.0011989365,"threshold_uncertainty_score":0.9028615},"labels":[],"label_agreement":null},{"id":"W3176158528","doi":"10.1007/s10637-021-01141-2","title":"Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; McGill University; Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Nausea; Vomiting; Pharmacokinetics; Medicine; Dosing; Pharmacodynamics; Adverse effect; Pharmacology; Regimen; Gastroenterology; Antagonist; Internal medicine","score_opus":0.013022656407419012,"score_gpt":0.2603217956643449,"score_spread":0.24729913925692587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176158528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973882,0.00011694854,0.0000071643094,0.0014596148,0.000058514535,0.00067531195,0.00004344943,0.000010377218,0.00024043286],"genre_scores_gemma":[0.99794614,0.0000028739014,0.0012387045,0.00042395966,0.000018869263,0.000013100189,0.00007881085,0.000021434898,0.00025613196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852175,0.00008135925,0.00043868646,0.0002860844,0.00054027454,0.00013182654],"domain_scores_gemma":[0.99894625,0.00005179262,0.00026550874,0.0003451582,0.00024995152,0.00014136413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092076516,0.00014239427,0.0003109923,0.0000781698,0.000038635015,0.000008381344,0.000087280925,0.000045427016,0.000017638715],"category_scores_gemma":[0.00017096156,0.00011097205,0.000037654623,0.00046980442,0.00021698687,0.00006686796,0.00006639685,0.00017359025,8.301707e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066655283,0.014581563,0.7770222,0.00054523937,0.0006503688,0.00028415577,0.023417674,0.0010461534,0.16345733,0.001752207,0.0027147431,0.00786287],"study_design_scores_gemma":[0.069272704,0.005863476,0.8131039,0.0014443086,0.00024515903,0.00003827133,0.0030737603,0.000142651,0.10519046,0.0007288318,0.0005710162,0.0003254261],"about_ca_topic_score_codex":0.00009717691,"about_ca_topic_score_gemma":0.00011379989,"teacher_disagreement_score":0.06260718,"about_ca_system_score_codex":0.00006166588,"about_ca_system_score_gemma":0.0011862668,"threshold_uncertainty_score":0.45253086},"labels":[],"label_agreement":null},{"id":"W3179641925","doi":"10.1007/s10637-021-01146-x","title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Toxicity; Cancer; Radioimmunotherapy; Antibody-drug conjugate; Phases of clinical research; Gastroenterology; Antibody; Oncology; Pharmacology; Monoclonal antibody; Immunology","score_opus":0.017280771592894664,"score_gpt":0.31509242098452545,"score_spread":0.2978116493916308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179641925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833876,0.000094665724,0.000037234826,0.00026395937,0.000056426677,0.00074285065,0.00041484094,0.000011428871,0.000039823015],"genre_scores_gemma":[0.99581397,0.000017581933,0.002300703,0.00014850804,0.000059357953,0.000075111784,0.00083884824,0.000046401678,0.00069951377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773717,0.00020556294,0.0004698228,0.0005885918,0.00065457047,0.00034430475],"domain_scores_gemma":[0.99858886,0.000073775074,0.00019964321,0.00031707305,0.0005627714,0.00025786183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009798034,0.00027105285,0.00033749593,0.00013039028,0.000058087797,0.00003189125,0.00023953896,0.000059867183,0.00031101968],"category_scores_gemma":[0.00035640155,0.00022390658,0.000055754215,0.0005785924,0.00016738987,0.000034905093,0.00014574599,0.00017600635,0.000009608563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028761467,0.0038293018,0.17222923,0.0002644044,0.00041787841,0.000021722883,0.0019401129,0.0004864502,0.814694,0.0000688008,0.0021819312,0.0009900193],"study_design_scores_gemma":[0.04078425,0.006244858,0.17367306,0.00067087193,0.000059373575,0.0000057698476,0.0013127024,0.00009533813,0.77478814,0.0001980079,0.0012822957,0.0008853256],"about_ca_topic_score_codex":0.00033708414,"about_ca_topic_score_gemma":0.0005246661,"teacher_disagreement_score":0.039905865,"about_ca_system_score_codex":0.00005767285,"about_ca_system_score_gemma":0.0014367627,"threshold_uncertainty_score":0.91306454},"labels":[],"label_agreement":null},{"id":"W3216437033","doi":"10.1007/s10637-021-01202-6","title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tolerability; Medicine; Prostate cancer; Nausea; Pharmacokinetics; Adverse effect; Internal medicine; Vomiting; Androgen receptor; Pharmacology; Oncology; Cancer; Gastroenterology","score_opus":0.03486849492790454,"score_gpt":0.34264569075683055,"score_spread":0.307777195828926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216437033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018985,0.0001565267,0.000004784296,0.007273155,0.00007441469,0.0019605507,0.00031061942,0.000006362266,0.000023715613],"genre_scores_gemma":[0.99862736,0.00001727535,0.00052750966,0.00029833516,0.00006268302,0.00009252729,0.000057913378,0.000016751364,0.00029966727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828,0.00023693584,0.0002883475,0.0002969738,0.00069133873,0.00020638574],"domain_scores_gemma":[0.9990627,0.00013240501,0.00013146826,0.00019427743,0.0002859901,0.00019314299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027285772,0.00016249211,0.0002595776,0.00006776986,0.00012884516,0.000038189897,0.000087308086,0.000014247072,0.000055770535],"category_scores_gemma":[0.00007788581,0.00008956546,0.000033701268,0.00052012946,0.00022295238,0.00011419732,0.00008046518,0.00018145671,0.0000013671795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065867775,0.005118528,0.8422191,0.0002776756,0.00058348017,0.0001741182,0.011845245,0.00015924919,0.12553369,0.000098196215,0.001248976,0.0061549516],"study_design_scores_gemma":[0.03004258,0.0014394438,0.7933948,0.0005290647,0.00028393624,0.000016980573,0.0016794284,0.00007772263,0.171279,0.00023221965,0.0007930228,0.00023179752],"about_ca_topic_score_codex":0.00031939856,"about_ca_topic_score_gemma":0.00024360769,"teacher_disagreement_score":0.04882431,"about_ca_system_score_codex":0.00014851414,"about_ca_system_score_gemma":0.0015801877,"threshold_uncertainty_score":0.36523736},"labels":[],"label_agreement":null},{"id":"W4226403841","doi":"10.1007/s10637-022-01227-5","title":"Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA","year":2022,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Orphan drug; Cancer drugs; Food and drug administration; Drug approval; Clinical trial; Confidence interval; Odds ratio; Clinical research; Cancer; Family medicine; Drug; Internal medicine; Environmental health; Pharmacology; Bioinformatics","score_opus":0.148947661525033,"score_gpt":0.3762924999720464,"score_spread":0.2273448384470134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226403841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65971464,0.0051730573,0.00011297297,0.3290957,0.00034437908,0.0006748532,0.004716927,0.000010776348,0.00015669067],"genre_scores_gemma":[0.9191026,0.00014412988,0.0016682452,0.07582864,0.00038631586,0.00018989443,0.0013671941,0.000031816162,0.0012811763],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969241,0.00027795648,0.0018891363,0.00039693085,0.00025006992,0.00026182635],"domain_scores_gemma":[0.9973102,0.00048191566,0.0016296387,0.00020669858,0.000029952776,0.00034158933],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039073075,0.00014685628,0.0004414626,0.00013099753,0.00046119993,0.000034315886,0.00021037014,0.000038558333,0.001042267],"category_scores_gemma":[0.00028028083,0.00017275035,0.000031506872,0.00020680505,0.00014193148,0.00017970978,0.00010986875,0.00020994512,0.000005572974],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013661103,0.000023882632,0.03214046,0.00011612936,0.0000716765,1.2088348e-7,0.010902484,0.0002837965,0.000010980978,0.034090336,0.9210925,0.0012539453],"study_design_scores_gemma":[0.003670936,0.00019686772,0.15644763,0.00007320718,0.000026503001,0.000019609022,0.010801069,0.0053249816,0.000120034165,0.10637594,0.71620274,0.00074049894],"about_ca_topic_score_codex":0.8485156,"about_ca_topic_score_gemma":0.15722756,"teacher_disagreement_score":0.69128805,"about_ca_system_score_codex":0.00073769677,"about_ca_system_score_gemma":0.0042368434,"threshold_uncertainty_score":0.9998709},"labels":[],"label_agreement":null},{"id":"W4283832186","doi":"10.1007/s10637-022-01266-y","title":"Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines","year":2022,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Institute on Minority Health and Health Disparities; National Institute of General Medical Sciences; National Cancer Institute","keywords":"Programmed cell death; Apoptosis; Cancer research; Cell culture; Cytotoxicity; Cytotoxic T cell; Lymphoma; DNA fragmentation; Cell cycle; Cancer cell; Cancer; Chemistry; Biology; Pharmacology; Biochemistry; Immunology; In vitro","score_opus":0.014182906786536206,"score_gpt":0.26274941122646456,"score_spread":0.24856650443992834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283832186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778676,0.00081559445,0.000039541752,0.0007601238,0.00013104058,0.00025117223,0.000039120827,0.000009954075,0.00016671208],"genre_scores_gemma":[0.99610883,0.000117876145,0.00075399346,0.0010626111,0.00032526406,0.000091293965,0.00020882097,0.0000181114,0.0013132233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925154,0.00003853073,0.00012036746,0.00031206693,0.00016016656,0.00011730705],"domain_scores_gemma":[0.9996757,0.000018802572,0.00007500898,0.00009023586,0.000039304938,0.00010097372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007762473,0.00013420287,0.00009703439,0.0000310551,0.00031779407,0.00003112448,0.000051948704,0.00004382751,0.000012073335],"category_scores_gemma":[0.000010815302,0.00012759575,0.000023438966,0.000059303416,0.00006436322,0.0000081013195,0.00011018701,0.000047904843,4.6991963e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003617311,0.000038820082,0.00077433314,0.00002470094,0.000018766963,4.114806e-7,0.00040016067,0.00033894245,0.99221295,0.0019580259,0.00044723353,0.003749486],"study_design_scores_gemma":[0.001682117,0.0002817698,0.0065576867,0.000019750245,0.000018753246,0.000007884016,0.00011902796,0.0003330109,0.98523724,0.0015390175,0.0039974866,0.00020627775],"about_ca_topic_score_codex":0.00027636302,"about_ca_topic_score_gemma":0.00002022382,"teacher_disagreement_score":0.0069757276,"about_ca_system_score_codex":0.0000226665,"about_ca_system_score_gemma":0.00011699305,"threshold_uncertainty_score":0.52032036},"labels":[],"label_agreement":null},{"id":"W4285387375","doi":"10.1007/s10637-022-01282-y","title":"Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes","year":2022,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Survivin; Cancer research; Small interfering RNA; Breast cancer; Delivery system; Medicine; Cancer; Chemistry; Transfection; Pharmacology; Internal medicine; Biochemistry; Gene","score_opus":0.007668571935846592,"score_gpt":0.2147022064033051,"score_spread":0.2070336344674585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285387375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812657,0.00021602708,0.00002946058,0.0007416316,0.00006354877,0.0001393725,0.00053680484,0.0000041688754,0.0001424457],"genre_scores_gemma":[0.99830735,0.00008597384,0.00020713614,0.00056831783,0.000056049936,0.00003842301,0.00037609335,0.000011229442,0.00034941887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921435,0.000070203125,0.0001795127,0.00023999046,0.00017325665,0.00012265627],"domain_scores_gemma":[0.99956715,0.000030746378,0.00011542366,0.00010003094,0.00011892439,0.000067726505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101896185,0.00011007543,0.00012077428,0.000066600216,0.00006671875,0.000011261407,0.00011594225,0.000038218106,0.00009954233],"category_scores_gemma":[0.0000073439364,0.000110245135,0.00002651953,0.00011954173,0.00014182711,0.000011594542,0.00010634947,0.0000919539,8.1952356e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021432541,0.00008313971,0.011772297,0.000014891564,0.000053806678,0.0000010769847,0.00037776405,0.0011122073,0.9807714,0.0003099752,0.0037192055,0.0015698604],"study_design_scores_gemma":[0.0025975618,0.0006453169,0.101881996,0.000073083815,0.00003206068,0.00003519274,0.001120147,0.00243105,0.8875619,0.0014639401,0.001719592,0.0004381536],"about_ca_topic_score_codex":0.0018378985,"about_ca_topic_score_gemma":0.00042421586,"teacher_disagreement_score":0.09320955,"about_ca_system_score_codex":0.00003168712,"about_ca_system_score_gemma":0.00033059184,"threshold_uncertainty_score":0.4495666},"labels":[],"label_agreement":null},{"id":"W4323036146","doi":"10.1007/s10637-023-01342-x","title":"Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Peripheral blood mononuclear cell; Medicine; CD8; Tolerability; Immune system; Antigen; Pharmacodynamics; Immunotherapy; Immunology; Human leukocyte antigen; Pharmacology; Adverse effect; Internal medicine; Pharmacokinetics; Biology","score_opus":0.04542277026582583,"score_gpt":0.3424850493680232,"score_spread":0.2970622791021974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323036146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120146,0.000023074424,0.000059867154,0.0054301666,0.000066487395,0.0026990478,0.000052470026,0.00005942896,0.00040798387],"genre_scores_gemma":[0.9963501,0.000005654946,0.00058834243,0.0006943876,0.00013225837,0.000062016734,0.000093608236,0.00004474048,0.0020288979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971601,0.00017321539,0.00060175586,0.00049209595,0.0011161808,0.00045666288],"domain_scores_gemma":[0.9982651,0.0004113993,0.000119714605,0.00045215254,0.00023976136,0.00051186926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000655505,0.00024517544,0.00048079077,0.0004609641,0.00013485705,0.000038527472,0.00023067424,0.000052195086,0.00014648185],"category_scores_gemma":[0.0003382236,0.00017593603,0.00005055867,0.0012931969,0.00023393468,0.00009381686,0.00022005517,0.00026263474,0.000025404264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015572764,0.0061278977,0.6106052,0.00035269998,0.0007781004,0.0004954622,0.09929199,0.02444713,0.09129136,0.00046198154,0.009926584,0.14064883],"study_design_scores_gemma":[0.016978199,0.0044096815,0.94947124,0.00030178786,0.00008551213,0.000025469808,0.0018809543,0.008083214,0.016231786,0.00055460236,0.0015629157,0.0004146242],"about_ca_topic_score_codex":0.00068927073,"about_ca_topic_score_gemma":0.00017495343,"teacher_disagreement_score":0.33886606,"about_ca_system_score_codex":0.0001375192,"about_ca_system_score_gemma":0.000531893,"threshold_uncertainty_score":0.7174463},"labels":[],"label_agreement":null},{"id":"W4364353540","doi":"10.1007/s10637-022-01326-3","title":"Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Selumetinib; Nausea; Discontinuation; Vomiting; MEK inhibitor; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Population; Cancer; Phases of clinical research; Surgery; Oncology; Chemotherapy; MAPK/ERK pathway; Kinase; Colorectal cancer","score_opus":0.034795656958310404,"score_gpt":0.3114770306345717,"score_spread":0.27668137367626133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364353540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99784964,0.00001549836,0.0000041974404,0.00028559254,0.00013722588,0.0013404074,0.00025479318,0.000009410813,0.00010321464],"genre_scores_gemma":[0.997847,0.0000020725129,0.0008768906,0.00021053446,0.00008691421,0.00008713097,0.00039780466,0.000025892678,0.00046572226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980991,0.00025066623,0.00059004076,0.00038122997,0.00047010777,0.000208847],"domain_scores_gemma":[0.9987298,0.000079286685,0.00039117225,0.00049752963,0.00018470899,0.00011747147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045616098,0.00018932958,0.0002719948,0.00006823256,0.00009886398,0.000023605617,0.00055997644,0.000048909475,0.0000047350673],"category_scores_gemma":[0.00046710184,0.00010788122,0.000027449403,0.00055727497,0.0001904914,0.000024773211,0.0002936637,0.000116732204,0.0000032680693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019759865,0.018060602,0.009852589,0.000286603,0.0007556628,0.00004744045,0.024670076,0.008747662,0.88303554,0.00076410896,0.021080732,0.012939091],"study_design_scores_gemma":[0.12751395,0.019329034,0.05420246,0.00043657387,0.00017820958,0.000008406724,0.0070068548,0.0011087714,0.78574735,0.00135837,0.0022972564,0.0008127438],"about_ca_topic_score_codex":0.00016285201,"about_ca_topic_score_gemma":0.0003220102,"teacher_disagreement_score":0.107754074,"about_ca_system_score_codex":0.000018531438,"about_ca_system_score_gemma":0.00073682296,"threshold_uncertainty_score":0.43992683},"labels":[],"label_agreement":null},{"id":"W4391614640","doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Randomized controlled trial; Pembrolizumab; Medicine; Antagonist; Internal medicine; Cancer; Immunotherapy; Receptor","score_opus":0.012628129560671114,"score_gpt":0.30921781692091993,"score_spread":0.2965896873602488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391614640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867374,0.0010956035,0.00015862673,0.007933629,0.00027672885,0.0020459273,0.000014901451,0.000101221245,0.0016360099],"genre_scores_gemma":[0.99608344,0.00006552525,0.000988243,0.0009345713,0.00022004815,0.00024397857,0.00028729957,0.000032481214,0.0011444173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981795,0.00015074348,0.0006245434,0.00036097923,0.00044167758,0.00024256008],"domain_scores_gemma":[0.9992317,0.00034614588,0.000102965154,0.00013577857,0.00005924534,0.0001241623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067990524,0.00020776369,0.000553653,0.00038918835,0.000042973857,0.000072243245,0.00007845514,0.000083335915,0.000113321476],"category_scores_gemma":[0.00018675352,0.00016645005,0.00011622969,0.00090020045,0.00025744233,0.00024287596,0.000011217571,0.00029408347,0.000014834344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9712556,0.0004260075,0.00009174923,0.00011395617,0.00013073169,0.00013890686,0.0019346777,0.00007730411,0.0110960575,0.004893171,0.0009870504,0.008854807],"study_design_scores_gemma":[0.97563785,0.00090222346,0.00034216882,0.001185005,0.000054949636,0.000092182185,0.000094433526,0.0058513125,0.0058056135,0.007830329,0.001978552,0.00022537293],"about_ca_topic_score_codex":0.00069407525,"about_ca_topic_score_gemma":0.00017499411,"teacher_disagreement_score":0.009346083,"about_ca_system_score_codex":0.00036217616,"about_ca_system_score_gemma":0.0020047287,"threshold_uncertainty_score":0.67876357},"labels":[],"label_agreement":null},{"id":"W4392805481","doi":"10.1007/s10637-024-01428-0","title":"A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Selumetinib; Medicine; Pembrolizumab; Adverse effect; Internal medicine; MEK inhibitor; Gastroenterology; Pharmacology; Urology; Oncology; Cancer; Colorectal cancer; MAPK/ERK pathway; Immunotherapy; Chemistry; Kinase","score_opus":0.02116369759197948,"score_gpt":0.29944718956827593,"score_spread":0.2782834919762964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392805481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654764,0.00012049956,0.0010252318,0.000876195,0.0002565289,0.0009080905,0.00008178551,0.000010673045,0.00017335753],"genre_scores_gemma":[0.99459904,0.0000048249744,0.0034663065,0.00018187225,0.00018603592,0.00017369937,0.00021699216,0.000019579704,0.0011516553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909914,0.000057582463,0.00028609607,0.0002331821,0.00019443825,0.00012956966],"domain_scores_gemma":[0.9995423,0.00008113537,0.00009710593,0.00014323591,0.0000721686,0.00006403722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018898002,0.0001171427,0.0001480902,0.000057882604,0.00003761091,0.000019344621,0.000117944866,0.00004345272,0.0000099659355],"category_scores_gemma":[0.00024740177,0.000075911696,0.00006967024,0.00019383254,0.00009685269,0.000010435936,0.000028159517,0.00006372026,0.0000016741342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035392728,0.0008951553,0.000061624705,0.00044474698,0.00019180213,0.000012438992,0.001358224,0.0007503036,0.9209279,0.019679928,0.008557369,0.011727783],"study_design_scores_gemma":[0.10288482,0.0051197927,0.00009195527,0.00032759176,0.00008042823,0.00003314646,0.00019834617,0.0022369428,0.8596213,0.011137917,0.017979164,0.0002886105],"about_ca_topic_score_codex":0.00001336786,"about_ca_topic_score_gemma":0.000038405902,"teacher_disagreement_score":0.0674921,"about_ca_system_score_codex":0.000017307058,"about_ca_system_score_gemma":0.0009590286,"threshold_uncertainty_score":0.30955893},"labels":[],"label_agreement":null},{"id":"W4398141543","doi":"10.1007/s10637-024-01444-0","title":"Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"erratum","venue":"Investigational New Drugs","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Randomized controlled trial; Antagonist; Internal medicine; Oncology; Immunotherapy; Cancer; Receptor","score_opus":0.010908600771500552,"score_gpt":0.3068487250344997,"score_spread":0.29594012426299915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398141543","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44807178,0.012542725,0.007172761,0.07376157,0.29083735,0.06938866,0.00081842014,0.0020431306,0.0953636],"genre_scores_gemma":[0.30591607,0.0009334654,0.005618087,0.009733814,0.014568781,0.0057245824,0.015319925,0.0007618515,0.6414234],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99650544,0.00021882608,0.0010673751,0.0008384283,0.00094547117,0.00042443885],"domain_scores_gemma":[0.99850065,0.00030148478,0.0003633133,0.00028579516,0.00020632334,0.00034245395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007511006,0.0005456876,0.0015926898,0.0010377638,0.000070847214,0.00012038242,0.00015257993,0.00032969782,0.00017965156],"category_scores_gemma":[0.0005267455,0.00048161647,0.00022367068,0.0013688212,0.00014471861,0.00017827842,0.000034186545,0.0015435568,0.000051685325],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69383484,0.0005877759,0.0000032349892,0.00022221747,0.00016593309,0.00016304146,0.0019490262,0.00024448955,0.0007888625,0.0036906607,0.29376236,0.0045875506],"study_design_scores_gemma":[0.9175545,0.002608855,0.00002462709,0.0056272326,0.0001875244,0.00009604174,0.00010747276,0.009613131,0.0012161083,0.017153993,0.045227505,0.0005830322],"about_ca_topic_score_codex":0.0020426677,"about_ca_topic_score_gemma":0.0018014875,"teacher_disagreement_score":0.5460598,"about_ca_system_score_codex":0.0011228555,"about_ca_system_score_gemma":0.006112507,"threshold_uncertainty_score":0.99976355},"labels":[],"label_agreement":null},{"id":"W4399361197","doi":"10.1007/s10637-024-01448-w","title":"A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Centre Hospitalier de l’Université de Montréal; Crosslight Software (Canada); University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Nausea; Adverse effect; Medicine; Vomiting; Pharmacokinetics; Internal medicine; Pharmacology; Gastroenterology; Refractory (planetary science); Dosing; Tolerability; Toxicity; Biology","score_opus":0.008491999688964535,"score_gpt":0.2465649185336351,"score_spread":0.23807291884467058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399361197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982003,0.00052764453,0.000035610206,0.0001362223,0.00009219107,0.0005454343,0.000093943316,0.000014412194,0.00035421835],"genre_scores_gemma":[0.9984263,0.000029995452,0.00072394847,0.00011970003,0.00010934591,0.000051519823,0.00035517718,0.000030445393,0.0001535558],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866736,0.000063767926,0.00040292053,0.0004081151,0.00024714545,0.00021066285],"domain_scores_gemma":[0.9995284,0.000032842712,0.000074159194,0.000159899,0.000048774396,0.000155941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017138816,0.00019839861,0.00022009226,0.00014126032,0.000045034416,0.000025141797,0.00010011839,0.00011173508,0.0000165565],"category_scores_gemma":[0.000048929698,0.0001874021,0.000049944487,0.00018417226,0.00018137191,0.00002457089,0.00003405839,0.00014531294,0.0000022805239],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06215683,0.006013438,0.030839914,0.0015452532,0.00016692979,0.00016941571,0.008745435,0.0012438737,0.86563,0.003821094,0.003743951,0.015923899],"study_design_scores_gemma":[0.31577626,0.013138701,0.008596138,0.0013729983,0.0000712236,0.000012843016,0.00027708526,0.00051465153,0.6369167,0.0067276172,0.015275129,0.0013206596],"about_ca_topic_score_codex":0.000112371876,"about_ca_topic_score_gemma":0.00011600776,"teacher_disagreement_score":0.25361943,"about_ca_system_score_codex":0.000043242584,"about_ca_system_score_gemma":0.00054939126,"threshold_uncertainty_score":0.76420355},"labels":[],"label_agreement":null},{"id":"W4402538375","doi":"10.1007/s10637-024-01461-z","title":"A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; MAPK/ERK pathway; Internal medicine; Pharmacology; Chemistry; Kinase; Immunotherapy; Cancer","score_opus":0.010907936607217268,"score_gpt":0.2797415372715782,"score_spread":0.2688336006643609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402538375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967935,0.00027565044,0.0000029895732,0.0013588599,0.0002486617,0.0009554428,0.000024476501,0.000034780664,0.00030563903],"genre_scores_gemma":[0.9985539,0.0000031456696,0.00013008495,0.00056516123,0.000119096665,0.00004262715,0.000033471737,0.00002412573,0.0005284102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985721,0.000044152475,0.0003799486,0.0002570318,0.0005879686,0.000158781],"domain_scores_gemma":[0.99944913,0.000052424697,0.000096946715,0.00022277854,0.0000812841,0.00009743266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109195695,0.00015381697,0.0002334903,0.00013369987,0.000047889655,0.00001969794,0.000110199784,0.00003922433,0.00004466946],"category_scores_gemma":[0.000045289456,0.00009822514,0.00006430607,0.00062492373,0.0001638509,0.00012671167,0.00003178002,0.00018809666,0.0000057413617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08954956,0.03971073,0.36529216,0.0024434465,0.0038239516,0.00034963895,0.16911326,0.003439579,0.0848235,0.0037812665,0.04626213,0.19141077],"study_design_scores_gemma":[0.20837918,0.010405254,0.74108815,0.005062025,0.00032201307,0.00003710401,0.0036214131,0.0012324449,0.021946304,0.0022134855,0.0049394243,0.0007532263],"about_ca_topic_score_codex":0.00024381292,"about_ca_topic_score_gemma":0.00006906859,"teacher_disagreement_score":0.37579596,"about_ca_system_score_codex":0.00020973178,"about_ca_system_score_gemma":0.0010960349,"threshold_uncertainty_score":0.40055048},"labels":[],"label_agreement":null},{"id":"W4408246183","doi":"10.1007/s10637-025-01518-7","title":"First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Medicine; Cmax; Pharmacodynamics; Pharmacokinetics; Adverse effect; Maculopapular rash; Rash; Internal medicine; Gastroenterology; Area under the curve; Lymphoma; Pharmacology; Toxicity","score_opus":0.012745993595768064,"score_gpt":0.30562469083016436,"score_spread":0.2928786972343963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408246183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960232,0.00005860557,0.000011678168,0.0006373078,0.000025018706,0.0027754349,0.000006973285,0.000024052842,0.00043776786],"genre_scores_gemma":[0.9976623,0.000004787844,0.0005776581,0.00017039094,0.000030148041,0.0001581717,0.00009711495,0.000022739767,0.0012767098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979962,0.00009949584,0.000537063,0.0004083334,0.00071748416,0.00024143692],"domain_scores_gemma":[0.99909216,0.00011258883,0.00015911783,0.0002632561,0.0002035361,0.00016932386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025441975,0.00019466474,0.00039044698,0.0005036395,0.00007660097,0.00001813707,0.0000990263,0.000062506864,0.00014330797],"category_scores_gemma":[0.00016484273,0.0001745344,0.00002879583,0.00094243744,0.00018132299,0.00017888646,0.00007254416,0.00017030157,0.0000033461974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071113366,0.0070532802,0.857108,0.0004106667,0.00011069853,0.000041794643,0.006547451,0.0010847833,0.04223701,0.0003148047,0.00017418663,0.07780599],"study_design_scores_gemma":[0.04165766,0.0028754368,0.9474066,0.00096136297,0.000024895206,0.0000018849322,0.0004977352,0.001497122,0.0034824114,0.0011886526,0.0002294,0.00017684253],"about_ca_topic_score_codex":0.0006383174,"about_ca_topic_score_gemma":0.00027533024,"teacher_disagreement_score":0.0902986,"about_ca_system_score_codex":0.0002405996,"about_ca_system_score_gemma":0.0004943268,"threshold_uncertainty_score":0.71173066},"labels":[],"label_agreement":null},{"id":"W4409868775","doi":"10.1007/s10637-025-01537-4","title":"Does anamorelin have beneficial effects in advanced cancer patients with systemic inflammation in the real world?","year":2025,"lang":"en","type":"letter","venue":"Investigational New Drugs","topic":"Adipokines, Inflammation, and Metabolic Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Systemic inflammation; Medicine; Inflammation; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.0064073090568764505,"score_gpt":0.24453849045297707,"score_spread":0.23813118139610062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409868775","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79283345,0.0003571601,0.000013004309,0.20145914,0.0007600403,0.0030543536,0.00016291157,0.00006665499,0.0012933029],"genre_scores_gemma":[0.44823724,0.0005186991,0.001514656,0.48486584,0.022195153,0.0034956513,0.020423539,0.00022285683,0.018526347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970738,0.00021933521,0.0007780358,0.0005083456,0.0010587116,0.00036171745],"domain_scores_gemma":[0.99830335,0.00052570965,0.00042441944,0.00036348216,0.0002748579,0.00010815832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021677332,0.0004258342,0.00061789376,0.0007644674,0.000076581004,0.000049856717,0.00024986223,0.000303794,0.00003461681],"category_scores_gemma":[0.00030327163,0.00024431586,0.000096688214,0.0007305352,0.00013523379,0.0002303703,0.000029530554,0.0008404374,0.000008933285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007138849,0.00016138678,0.7572474,0.0046824366,0.00024255081,0.00022212519,0.0049508745,0.0045008515,0.000059881757,0.0022141712,0.2077317,0.017272776],"study_design_scores_gemma":[0.0059487815,0.000070402704,0.87349373,0.007788563,0.00043469438,0.0000023752734,0.00011212316,0.0002616783,0.00012443379,0.0034269018,0.10781464,0.00052164815],"about_ca_topic_score_codex":0.0029309664,"about_ca_topic_score_gemma":0.004268422,"teacher_disagreement_score":0.34459618,"about_ca_system_score_codex":0.00037111907,"about_ca_system_score_gemma":0.0019710572,"threshold_uncertainty_score":0.99629116},"labels":[],"label_agreement":null},{"id":"W4412543666","doi":"10.1007/s10637-025-01566-z","title":"Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Isotretinoin; Medicine; Drug development; Drug; Dermatology; Intensive care medicine; Pediatrics; Pharmacology; Acne","score_opus":0.08752378600377417,"score_gpt":0.3623963156119547,"score_spread":0.27487252960818054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412543666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937739,0.0005640913,0.0000058771348,0.0040582726,0.000044731656,0.0013489586,0.000015768896,0.000018527724,0.00016987883],"genre_scores_gemma":[0.9978607,0.0000102175645,0.0005117365,0.00023603186,0.00008382385,0.00024649227,0.000028888706,0.000010935785,0.0010111565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988401,0.000074440155,0.00031301787,0.00023473562,0.00034822678,0.00018947016],"domain_scores_gemma":[0.9989894,0.0005015079,0.00007355262,0.00016913938,0.00010584461,0.00016054684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012998696,0.00012285965,0.00019101822,0.0002371577,0.00013258644,0.000016306385,0.000089505855,0.000023362176,0.00001545197],"category_scores_gemma":[0.00027830634,0.00008748559,0.000046112145,0.0003920174,0.00006216513,0.000058117872,0.00006508719,0.0001150581,0.000003857511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009786501,0.006376555,0.89609516,0.0013909537,0.00047885117,0.0022269234,0.037232194,0.00016795231,0.00015105141,0.0013586981,0.01917809,0.03436493],"study_design_scores_gemma":[0.029177237,0.0011428453,0.9289457,0.00093215687,0.0005968369,0.00027452226,0.026663892,0.0009271635,0.00271776,0.0061449166,0.0020368372,0.0004401281],"about_ca_topic_score_codex":0.00027377854,"about_ca_topic_score_gemma":0.00028549065,"teacher_disagreement_score":0.033924803,"about_ca_system_score_codex":0.000078453755,"about_ca_system_score_gemma":0.0013033272,"threshold_uncertainty_score":0.35675588},"labels":[],"label_agreement":null},{"id":"W4413318599","doi":"10.1007/s10637-025-01573-0","title":"Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Colorectal cancer; Triple-negative breast cancer; Internal medicine; Oncology; Breast cancer; Metastatic breast cancer; Open label; Cancer; Cancer research; Immunotherapy; Clinical trial","score_opus":0.05132265043575454,"score_gpt":0.3734473502891841,"score_spread":0.3221246998534295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413318599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934637,0.00046085866,0.000003948171,0.0015317494,0.0002071719,0.003478736,0.00073534425,0.000021351074,0.00009716587],"genre_scores_gemma":[0.99577457,0.00018209688,0.0014360795,0.0001937181,0.000044596283,0.0013483156,0.00016960052,0.000024880865,0.0008261531],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978592,0.00010870691,0.00073382637,0.0005342115,0.0003835125,0.00038057187],"domain_scores_gemma":[0.99891335,0.00017510769,0.00031589103,0.00013058243,0.0002528371,0.00021221027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018863508,0.0003346349,0.00083702616,0.00020986912,0.00016119883,0.00006392427,0.00011900922,0.000039825816,0.00019187396],"category_scores_gemma":[0.00009292954,0.00025116434,0.000028206845,0.000811852,0.0002667015,0.00036540162,0.00012976416,0.00015741351,7.716186e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43369353,0.03288449,0.22865613,0.0015479198,0.006564808,0.0003947441,0.09631226,0.0015545896,0.10545788,0.0005962175,0.0035346895,0.08880274],"study_design_scores_gemma":[0.57736623,0.015075998,0.26075545,0.002732331,0.0017857911,0.000046717574,0.019477757,0.0020549363,0.11879082,0.00085729384,0.00024237894,0.00081431714],"about_ca_topic_score_codex":0.021666346,"about_ca_topic_score_gemma":0.029370498,"teacher_disagreement_score":0.14367267,"about_ca_system_score_codex":0.0007117807,"about_ca_system_score_gemma":0.0030170444,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W45844253","doi":"10.1023/a:1020625423524","title":"Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group","year":2002,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Hôpital Notre-Dame; Hamilton Regional Laboratory Medicine Program; Princess Margaret Cancer Centre; Nova Scotia Cancer Centre; Ottawa Regional Cancer Foundation; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Melanoma; Cancer; Biopsy; Internal medicine; Gastroenterology; Fibrosis; Clinical trial; Necrosis; Matrix metalloproteinase; Pathology; Oncology; Cancer research","score_opus":0.1056938063737493,"score_gpt":0.37627511406933667,"score_spread":0.27058130769558736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W45844253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807775,0.00020056915,0.0000073890865,0.0003570916,0.0003695903,0.00080613274,0.00011902909,0.0000016977539,0.000060761024],"genre_scores_gemma":[0.99900556,0.000018807805,0.00020726585,0.0003182312,0.00026558002,0.000043858337,0.00001731015,0.000008931674,0.00011447442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970191,0.0005734649,0.0014525385,0.00033090718,0.000497325,0.00012665831],"domain_scores_gemma":[0.99875575,0.00012604916,0.0006307594,0.00019078098,0.00017067883,0.00012596771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017831989,0.0001377133,0.00045116348,0.000047662452,0.00005943429,0.000004761438,0.00020861928,0.00008020414,0.000029807185],"category_scores_gemma":[0.0011977032,0.00010328482,0.0000879656,0.0001618722,0.00022370198,0.000011185472,0.00017962126,0.00012988514,1.375378e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021873303,0.033455804,0.42403808,0.00014120161,0.0015233137,0.00004034627,0.0030707386,0.00048904394,0.49284652,0.0036330377,0.02974865,0.008825944],"study_design_scores_gemma":[0.16217004,0.044396766,0.31122738,0.00091580604,0.00092410203,0.00007934892,0.005954042,0.0038961826,0.44215357,0.012956002,0.013316183,0.0020105902],"about_ca_topic_score_codex":0.030061342,"about_ca_topic_score_gemma":0.049289048,"teacher_disagreement_score":0.15998271,"about_ca_system_score_codex":0.000020245163,"about_ca_system_score_gemma":0.0010146133,"threshold_uncertainty_score":0.9763976},"labels":[],"label_agreement":null}]}